[go: up one dir, main page]

WO2018218226A1 - Analyse de cellule unique de chromatine accessible par transposase - Google Patents

Analyse de cellule unique de chromatine accessible par transposase Download PDF

Info

Publication number
WO2018218226A1
WO2018218226A1 PCT/US2018/034774 US2018034774W WO2018218226A1 WO 2018218226 A1 WO2018218226 A1 WO 2018218226A1 US 2018034774 W US2018034774 W US 2018034774W WO 2018218226 A1 WO2018218226 A1 WO 2018218226A1
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
bead
molecules
sequence
barcode
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/034774
Other languages
English (en)
Inventor
Kamila BELHOCINE
Geoffrey MCDERMOTT
Francesca MESCHI
Xinying ZHENG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
10X Genomics Inc
Original Assignee
10X Genomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/842,687 external-priority patent/US10400235B2/en
Priority to SG11201901822QA priority Critical patent/SG11201901822QA/en
Priority to EP18799660.8A priority patent/EP3445876B1/fr
Priority to CN201880002912.9A priority patent/CN109526228B/zh
Priority to EP23168994.4A priority patent/EP4230746A3/fr
Priority to CN202211385845.8A priority patent/CN116064732A/zh
Application filed by 10X Genomics Inc filed Critical 10X Genomics Inc
Publication of WO2018218226A1 publication Critical patent/WO2018218226A1/fr
Priority to US16/419,630 priority patent/US10927370B2/en
Anticipated expiration legal-status Critical
Priority to US16/841,411 priority patent/US11155810B2/en
Priority to US17/492,536 priority patent/US11773389B2/en
Priority to US18/355,946 priority patent/US20240084292A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

Definitions

  • Samples may be processed for various purposes, such as identification of a type of sample of moiety within the sample.
  • the sample may be a biological sample.
  • the biological samples may be processed for various purposes, such as detection of a disease (e.g., cancer) or identification of a particular species.
  • PCR polymerase chain reaction
  • Biological samples may be processed within various reaction environments, such as partitions.
  • Partitions may be wells or droplets.
  • Droplets or wells may be employed to process biological samples in a manner that enables the biological samples to be partitioned and processed separately.
  • droplets may be fiuidically isolated from other droplets, enabling accurate control of respective environments in the droplets.
  • Biological samples in partitions may be subjected to various processes, such as chemical processes or physical processes. Samples in partitions may be subjected to heating or cooling, or chemical reactions, such as to yield species that may be qualitatively or quantitatively processed.
  • Certain applications may benefit from the amplification or sequencing of species obtained from single cells obtained from a much larger population.
  • the single cells of interest may be quite rare.
  • the present disclosure provides sample preparation techniques that allow sequencing of nucleic acids from single cells of interest.
  • chromatin In eukaryotic genomes, chromosomal DNA winds itself around histone proteins (i.e., "nucleosomes"), thereby forming a complex known as chromatin.
  • the tight or loose packaging of chromatin contributes to the control of gene expression.
  • Tightly packed chromatin (“closed chromatin”) is usually not permissive for gene expression while more loosely packaged, accessible regions of chromatin (“open chromatin”) is associated with the active transcription of gene products.
  • ATAC-seq Transposase Accessible Chromatin with high- throughput sequencing
  • sequencing reads can be used to infer regions of increased chromatin accessibility.
  • scATAC-seq single cell ATAC-seq
  • scATAC-seq methods that utilize sample pooling, cell indexing, and cell sorting (see, e.g., Cusanovich, et al, Science, 2015 May 22;348(6237):910-14) result in high variability and a low number of reads associated with any single cell.
  • scATAC-seq methods that utilize a programmable microfluidic device to isolate single cells and perform scATAC-seq in nanoliter reaction chambers (see, e.g., Buenrostro, et al, Nature, 2015 Jul 23;523(7561):486-90) are limited by the throughput of the assay and may not generate personal epigenomic profiles on a timescale compatible with clinical decision-making.
  • the present disclosure provides a method for nucleic acid processing, comprising: (a) generating a partition comprising: (i) a biological particle comprising chromatin comprising a template nucleic acid molecule; (ii) a plurality of nucleic acid barcode molecules comprising a common barcode sequence; (iii) a plurality of transposon end nucleic acid molecules comprising a transposon end sequence; and (iv) a plurality of transposase molecules; (b) generating a plurality of template nucleic acid fragments with the aid of a transposase- nucleic acid complex comprising a transposase molecule of the plurality of transposase molecules and a transposon end oligonucleotide molecule of the plurality of transposon end oligonucleotide molecules; and (c) generating a barcoded nucleic acid fragment using a nucleic acid barcode molecule of the plurality of
  • the barcoded nucleic acid fragment is generated by ligation of the nucleic acid barcode molecule with the template nucleic acid fragment, or a derivative thereof. [0012] In some embodiments, the barcoded nucleic acid fragment is generated by amplification of the template nucleic acid fragment, or a derivative thereof, using the nucleic acid barcode molecule as a primer.
  • the transposase-nucleic acid complex is generated in the partition using transposase molecules of the plurality of transposase molecules and transposon end nucleic acid molecules of the plurality of transposon end nucleic acid molecules.
  • the transposase-nucleic acid complex is partitioned into the partition.
  • the plurality of nucleic acid barcode molecules are attached to a bead and wherein the partition further comprises the bead.
  • the nucleic acid barcode molecules are releasably attached to the bead.
  • the method further comprises releasing the plurality of nucleic acid barcode molecules from the bead.
  • the bead is a gel bead.
  • the gel bead is a degradable gel bead.
  • the degradable gel bead is degradable upon application of a stimulus.
  • the stimulus is a chemical stimulus.
  • the stimulus is a reducing agent.
  • the partition further comprises the chemical stimulus.
  • the template nucleic acid molecule prior to (b), is released from the biological particle. In some embodiments, subsequent to (b), the plurality of template nucleic acid fragments is released from the biological particle.
  • the biological particle is a cell. In some embodiments, the biological particle is a nucleus.
  • the partition is an aqueous droplet in an emulsion. In some embodiments, the partition is a well.
  • the method further comprises releasing or removing the barcoded nucleic acid fragment or a derivative thereof from the partition.
  • the method further comprises sequencing the barcoded nucleic acid fragment, or a derivative thereof.
  • the plurality of transposon end nucleic acid molecules further comprise a sequence complementary to a sequence of the plurality of nucleic acid barcode molecules.
  • the partition further comprises a plurality of second nucleic acid molecules comprising a transposon end sequence and a primer sequence, and wherein the transposase-nucleic acid complex comprises: (i) transposase molecules of the plurality of transposase molecules; (ii) a transposon end oligonucleotide molecule of the plurality of transposon end oligonucleotide molecules; and (iii) a second nucleic acid molecule of the plurality of second nucleic acid molecules.
  • the plurality of nucleic acid barcode molecules are partially double-stranded and comprise (i) a first strand comprising the common barcode sequence and a sequence complementary to a sequence of the plurality of first nucleic acid molecules; and (ii) a second strand comprising a sequence complementary to the common barcode sequence.
  • the plurality of nucleic acid barcode molecules are single-stranded and comprise the common barcode sequence and a sequence complementary to a sequence in the plurality of transposon end nucleic acid molecules.
  • the biological particle further comprises a template ribonucleic acid (RNA) molecule
  • the method further comprises generating a barcoded complementary deoxyribonucleic acid (cDNA) molecule from the template RNA molecule or a derivative thereof.
  • the barcoded cDNA molecule is generated in the partition.
  • the partition comprises a second plurality of nucleic acid barcode molecules comprising the common barcode sequence and a capture sequence.
  • the capture sequence is a poly-T sequence.
  • the capture sequence is a template switching oligo sequence and wherein the barcoded cDNA molecule is generated using a template switching reaction.
  • the plurality of nucleic acid barcode molecules are attached to a first bead
  • the second plurality of nucleic acid barcode molecules are attached to a second bead
  • the partition comprises the first bead and the second bead.
  • the first bead or the second bead is a magnetic bead.
  • the first bead is a gel bead and the second bead is a magnetic bead.
  • the gel bead comprises the magnetic bead.
  • the method further comprises degrading the gel bead.
  • the first bead is a magnetic bead and the second bead is a gel bead.
  • the gel bead comprises the magnetic bead. In some embodiments, the method further comprises degrading the gel bead. In some embodiments, the plurality of nucleic acid barcode molecules and the second plurality of nucleic acid barcode molecules are attached to a bead, and wherein the partition further comprises the bead. In some embodiments, the barcoded nucleic acid fragment and the barcoded cDNA molecule is released from the partition. In some embodiments, the method further comprises sequencing the barcoded nucleic acid fragment or a derivative thereof and the barcoded cDNA molecule or a derivative thereof.
  • the method further comprises cleaving one or more mitochondrial nucleic acid fragments, or derivatives thereof, using (i) one or more guide ribonucleic acid molecules (gRNAs) targeted to the one or more mitochondrial nucleic acid fragments; and (ii) a clustered regularly interspaced short palindromic (CRISPR) associated (Cas) nuclease.
  • the partition further comprises the one or more gRNAs and the Cas nuclease.
  • the Cas nuclease is Cas9.
  • the present disclosure provides a method of generating barcoded nucleic acid fragments, comprising: (a) providing: (i) a plurality of biological particles, an individual biological particle of the plurality of biological particles comprising chromatin comprising a template nucleic acid; (ii) a plurality of transposon end nucleic acid molecules comprising a transposon end sequence; and (iii) a plurality of transposase molecules; (b) generating a plurality of template nucleic acid fragments in a biological particle of the plurality of biological particles with the aid of a transposase-nucleic acid complex comprising a transposase molecule of the plurality of transposase molecules and a transposon end nucleic acid molecule of the plurality of transposon end nucleic acid molecules; (c) generating a partition comprising the biological particle comprising the plurality of template nucleic acid fragments and a plurality of nucleic acid barcode molecules
  • the barcoded nucleic acid fragment is generated by ligation of the nucleic acid barcode molecule with the template nucleic acid fragment, or a derivative thereof.
  • the barcoded nucleic acid fragment is generated by nucleic acid amplification of the template nucleic acid fragment, or a derivative thereof, using the nucleic acid barcode molecule as a primer.
  • the plurality of nucleic acid barcode molecules are attached to a bead and wherein the partition further comprises the bead.
  • the nucleic acid barcode molecules are releasably attached to the bead.
  • the method further comprises releasing the plurality of nucleic acid barcode molecules from the bead.
  • the bead is a gel bead.
  • the gel bead is a degradable gel bead.
  • the degradable gel bead is degradable upon application of a stimulus.
  • the stimulus is a chemical stimulus.
  • the stimulus is a reducing agent.
  • the partition further comprises the chemical stimulus.
  • the template nucleic acid fragments are released from the biological particle.
  • the biological particle is a cell. In some embodiments, the cell is a permeabilized cell. [0030] In some embodiments, the biological particle is a nucleus. In some embodiments, the nucleus is a permeabilized nucleus.
  • the partition is an aqueous droplet in an emulsion. In some embodiments, the partition is a well.
  • the method further comprises releasing or removing the barcoded nucleic acid fragment or a derivative thereof from the partition.
  • the method further comprises sequencing the barcoded nucleic acid fragment, or a derivative thereof.
  • the plurality of transposon end nucleic acid molecules comprise a plurality of first nucleic acid molecules comprising a transposon end sequence and a sequence complementary to a sequence of the plurality of nucleic acid barcode molecules. In some embodiments, the plurality of transposon end nucleic acid molecules further comprise a plurality of second nucleic acid molecules comprising a transposon end sequence and a primer sequence. In some embodiments, the plurality of nucleic acid barcode molecules are partially double-stranded and comprise a first strand comprising the common barcode sequence and a sequence complementary to a sequence of the plurality of first nucleic acid molecules; and a second strand comprising a sequence complementary to the common barcode sequence. In some embodiments, the plurality of nucleic acid barcode molecules are single-stranded and comprise the common barcode sequence and a sequence complementary to a sequence of the plurality of first nucleic acid molecules.
  • the biological particle further comprises a template RNA molecule
  • the method further comprises generating a barcoded cDNA molecule from the template RNA molecule or a derivative thereof.
  • the barcoded cDNA molecule is generated in the partition.
  • the partition comprises a second plurality of nucleic acid barcode molecules comprising the common barcode sequence and a capture sequence.
  • the capture sequence is a poly-T sequence.
  • the capture sequence is a template switching oligo sequence and wherein the barcoded cDNA molecule is generated using a template switching reaction.
  • the plurality of nucleic acid barcode molecules are attached to a first bead
  • the second plurality of nucleic acid barcode molecules are attached to a second bead
  • the partition comprises the first bead and the second bead.
  • the first bead or the second bead is a magnetic bead.
  • the first bead is a gel bead and the second bead is a magnetic bead.
  • the gel bead comprises the magnetic bead.
  • the method further comprises degrading the gel bead.
  • the first bead is a magnetic bead and the second bead is a gel bead.
  • the gel bead comprises the magnetic bead. In some embodiments, the method further comprises degrading the gel bead. In some embodiments, the plurality of nucleic acid barcode molecules and the second plurality of nucleic acid barcode molecules are attached to a bead, and wherein the partition further comprises the bead. In some embodiments, the barcoded nucleic acid fragment and the barcoded cDNA molecule is released from the partition. In some embodiments, the method further comprises sequencing the barcoded nucleic acid fragment or a derivative thereof and the barcoded cDNA molecule or a derivative thereof.
  • the method further comprises (a) lysing a plurality of cells in the presence of a cell lysis agent and a blocking agent; and (b) separating a plurality of nuclei from the plurality of lysed cells to generate the plurality of biological particles, wherein the blocking agent reduces the fraction of sequencing reads corresponding to a mitochondrial genome compared to sequencing reads obtained in the absence of the blocking agent.
  • the blocking agent is bovine serum albumin (BSA).
  • the method further comprises cleaving one or more mitochondrial nucleic acid molecules or derivatives thereof, using (i) one or more guide ribonucleic acid molecules (gRNAs) targeted to the one or more mitochondrial nucleic acid fragments; and (ii) a clustered regularly interspaced short palindromic (CRISPR) associated (Cas) nuclease.
  • the Cas nuclease is Cas9.
  • the mitochondrial nucleic acid molecules are cleaved prior to (c).
  • the mitochondrial nucleic acid molecules are cleaved in the partition.
  • the partition comprises the Cas nuclease.
  • the partition further comprises the one or more gRNAs.
  • the mitochondrial nucleic acid molecules are cleaved subsequent to (d).
  • FIG. 1 shows an example of a microfluidic channel structure for partitioning individual biological particles.
  • FIG. 2 shows an example of a microfluidic channel structure for delivering barcode carrying beads to droplets.
  • FIG. 3 shows an example of a microfluidic channel structure for co-partitioning biological particles and reagents.
  • FIG. 4 shows an example of a microfluidic channel structure for the controlled partitioning of beads into discrete droplets.
  • FIG. 5 shows an example of a microfluidic channel structure for increased droplet generation throughput.
  • FIG. 6 shows another example of a microfluidic channel structure for increased droplet generation throughput.
  • FIG. 7A shows a cross-section view of another example of a microfluidic channel structure with a geometric feature for controlled partitioning.
  • FIG. 7B shows a perspective view of the channel structure of FIG. 7 A.
  • FIG. 8 illustrates an example of a barcode carrying bead.
  • FIG. 9 shows a computer system that is programmed or otherwise configured to implement methods provided herein.
  • FIG. 10 illustrates an exemplary method to produce droplets wherein at least some of the droplets formed will comprise transposase molecules, a single cell, and a single gel bead comprising a forked adaptor.
  • FIGs. 11A-11B illustrate an exemplary method to produce forked adaptor flanked double-stranded template nucleic acid fragments.
  • FIG. 11A illustrates an exemplary method for the in-partition transposition of sequencing adaptors into native chromatin while FIG. 11B illustrates an exemplary method for the in-bulk production of a next-generation sequencing compatible library from the fragments produced in FIG. 11 A.
  • FIGs. 12A-12B illustrate exemplary forked adaptors.
  • FIG. 13 illustrates an exemplary method to produce droplets wherein at least some of the droplets formed will comprise transposase-nucleic acid complexes, a single cell, and a single gel bead comprising a forked adaptor.
  • FIGs. 14A-14B illustrate an alternative exemplary method to produce forked adaptor flanked double-stranded template nucleic acid fragments.
  • FIG. 14A illustrates an exemplary method for the in-partition ligation of forked adaptors onto fragments of native chromatin generated by an in-partition transposition reaction.
  • FIG. 14B illustrates an exemplary method for the in-bulk production of a next-generation sequencing compatible library from the fragments produced in FIG. 14 A.
  • FIGs. 15A-15B illustrate additional exemplary forked adaptors and transposon end sequence containing oligonucleotides.
  • FIG. 16 illustrates an exemplary method to produce droplets wherein at least some of the droplets formed will comprise transposase molecules, a single cell, and a single gel bead comprising a T7-containing adaptor.
  • FIG. 17 illustrates an exemplary method to produce T7-containing adaptor flanked double-stranded template nucleic acid fragments.
  • FIG. 18 illustrates an exemplary T7-containing barcoded adaptor.
  • FIG. 19 illustrates an exemplary method to produce droplets wherein at least some of the droplets formed will comprise transposase molecules, a single cell, and a single gel bead comprising a barcoded adaptor.
  • FIG. 20 illustrates an exemplary scheme for producing barcoded, adapter-flanked nucleic acid fragments.
  • FIG. 21 illustrates an exemplary partially double-stranded barcode oligonucleotide releasably attached to a gel bead.
  • FIG. 22 illustrates a random priming extension reaction scheme
  • FIG. 23 illustrates an exemplary method of inserting barcodes into a template nucleic acid.
  • FIGs. 24A-24B illustrate an exemplary transposase-nucleic acid complex showing a transposase, a first partially double-stranded oligonucleotide releasably attached to a gel bead, the first partially double-stranded oligonucleotide comprising a transposon end sequence, a barcode sequence, and a first primer sequence and a second partially double-stranded oligonucleotide comprising a transposon end sequence and a second primer sequence.
  • the first and the second primer sequence are the same.
  • FIGs. 25A-25B illustrates an exemplary barcode oligonucleotides.
  • FIG. 25A illustrates a partially double-stranded oligonucleotide releasably attached to a gel bead, the first strand comprising a transposon end sequence, a barcode sequence, and a first primer sequence and a second strand comprising a sequence complementary to the transposon end sequence.
  • FIG. 25B illustrates a partially double-stranded oligonucleotide releasably attached to a gel bead, the first strand comprising a transposon end sequence and a barcode sequence and the second strand comprising a sequence complementary to the transposon end sequence
  • FIG. 26 illustrates an exemplary transposase-nucleic acid complex showing a transposase, a first double-stranded oligonucleotide comprising a barcode sequence and a transposon end sequence releasably attached to a first gel bead and a second double-stranded oligonucleotide comprising a transposon end sequence releasably attached to a second gel bead.
  • FIG. 27 illustrates an exemplary method to produce barcoded nucleic acid fragments suitable for next generation sequencing.
  • FIGs. 28A-28B illustrate an exemplary transposase-nucleic acid complex and an exemplary barcoded adaptor releasably attached to a gel bead.
  • FIG. 28A illustrates an exemplary transposase-nucleic acid complex showing a transposase, a first double-stranded oligonucleotide comprising a transposon end sequence and a second double-stranded
  • FIG. 28B illustrates an exemplary barcoded adaptor comprising a transposon end sequence, a barcode sequence, and a primer sequence releasably attached to a gel bead.
  • FIGs. 29A-29D illustrate an exemplary transposase-nucleic acid complex and an exemplary barcoded adaptor, which can be releasably attached to a gel bead.
  • FIG. 28B illustrates an exemplary barcoded adaptor comprising an adapter sequence, a barcode sequence, and a sequence complementary to the first primer sequence.
  • FIGS. 28C-D illustrates an exemplary barcoding scheme.
  • FIGs. 30A-30B illustrate an exemplary barcode oligonucleotide and combination bulk/in-partition barcoding scheme.
  • FIG. 31 illustrates an exemplary in-partition transposition and barcoding scheme.
  • FIGs. 32A-32C illustrate an exemplary barcoding scheme.
  • FIG. 32A illustrates an exemplary barcode oligonucleotide
  • FIG. 32B illustrates an exemplary combination of bulk/in- partition barcoding scheme using CRISPR/Cas-9 mediated cleavage
  • FIG. 32C illustrates an exemplary in-partition barcoding scheme using CRISPR/Cas-9 mediated cleavage.
  • FIGs. 33A-33C illustrate an exemplary barcoding scheme.
  • FIG. 33A illustrates an exemplary forked barcode oligonucleotide
  • FIG. 33B illustrates an exemplary combination of bulk/in-partition barcoding scheme using CRISPR/Cas-9 mediated cleavage
  • FIG. 33C illustrates an exemplary in-partition barcoding scheme using CRISPR/Cas-9 mediated cleavage.
  • FIG. 34 illustrates barcoded magnetic beads which can be embedded within a gel bead comprising a barcoded oligonucleotide.
  • FIG. 35 illustrates exemplary gel bead architectures for single cell ATAC-seq (sc- ATAC-seq) plus single cell RNA-seq (scRNA-seq) analyses.
  • BC barcode.
  • FIGS. 36A-36B illustrates an exemplary scATAC-seq protocol.
  • FIG. 36A provides a schematic of the nuclei preparation of the scATAC-seq protocol.
  • FIG. 36B illustrates approximate time required for steps in the scATAC-seq protocol.
  • FIG. 37 illustrates three exemplary partially-double stranded barcode molecules suitable for use with a ligation-mediated ATAC-seq scheme as described in Example 9 and 18.
  • a shorter Rl sequence (middle), as well as replacement of one nucleic acid in the Rl sequence with a uracil (bottom).
  • FIGs. 38A-38C illustrate exemplary barnyard plots of mixed human and mouse nuclei demonstrating sequencing reads assembled from scATAC-seq experiments using the barcode molecules in FIG. 37.
  • FIG. 38A illustrates a barnyard plot using original Rl barcode molecules ("control”).
  • FIG. 38B illustrates a barnyard plot using shorter Rl barcode molecules ("7b”).
  • FIG. 38C illustrates a barnyard plot using the U-containing barcode molecules ("U40").
  • barnyard plots represent separation between the mouse (light grey dots in the upper left quadrant) and human nucleic acid sequence reads (medium grey dots in the lower right quadrant) from noise (black dots in the lower left quadrant) and doublets (dark grey dots in the upper right quadrant).
  • FIG. 39 illustrates an exemplary single stranded barcode molecule suitable for use with a linear amplification-mediated ATAC-seq scheme as described in Example 11. Primers were utilized at either 75 nM, 150nM, or 250 nM concentrations in the droplet.
  • FIG. 40 shows a table comparing sequencing metrics generated from different replicate sample libraries ("A" and "B") generated using either linear amplification or ligation.
  • "A" replicates represent reactions done in the same conditions, but using a different user, while “B” replicates represent reactions done in the same conditions by the same user.
  • FIGs. 41A-41B illustrate exemplary amounts of detected mouse or human cells and the inferred doublet rate observed from the analysis of sequencing reads (FIG. 40) from a linear amplification ATAC-seq library (using 75 nM, 150nM, or 250 nM of barcode primer) or ligation-based ATAC-seq library (using the barcode molecules of FIG. 37).
  • FIG. 40 shows a table comparing sequencing metrics generated from different replicate sample libraries (“A” and "B”) generated using either linear amplification or ligation.
  • “A” replicates represent reactions done in the same conditions, but using a different user
  • “B” replicates represent reactions done in the same conditions by the same user
  • FIG. 41A illustrates differences in the number of mouse or human cells detected using either a linear amplification or ligation-based ATAC-seq method.
  • FIG. 41B illustrate differences in inferred doublet rate detected using either a linear amplification or ligation-based ATAC-seq method.
  • FIG. 42 illustrates a comparison of the sensitivity of sequencing reads obtained from various ATAC-seq libraries as measured by the median fragments per cell barcode.
  • the sensitivity of the linear amplification and ligation methods of library preparation (36k reads/cell) as compared to the methods described in Buenrostro, et al., Nature, 2015 Jul 23;523(7561):486- 90 using a programmable microfluidics platform (Fluidigm).
  • FIG. 43 illustrates a library prepared by ligation sequenced to increased depth (30M reads and 800M reads) compared to FIGs. 40-42 demonstrate a significant increase in the sensitivity (as measured by median fragments per cell barcode) and reduced noise (as measured by fraction of non-duplicate wasted reads).
  • FIG. 44 illustrates an exemplary comparison of the total noise (non-duplicate wasted reads (Non-dups”) and mitochondrial-based reads ("Mito”)) in libraries prepared using linear amplification or ligation-based ATAC-seq methods.
  • FIGs. 45A-45B provide an exemplary illustration of the breakdown sequencing reads generated by different library preparation methods.
  • FIG. 45A shows an illustration of the breakdown of reads generated by a linear amplification ATAC-seq library.
  • FIG. 45B shows an illustration of the breakdown of reads generated by a ligation-based ATAC-seq library.
  • FIGs. 46A-46B illustrate an exemplary comparison of read pairs showing the periodicity of nucleosomes generated from ATAC-seq libraries prepared using either a linear amplification or ligation-based scheme. Nucleosome free fragments are typically observed below 200bp in length, fragments indicative of a nucleosome periodicity of one are approximately 200bp in length, fragments indicative of a nucleosome periodicity of two are approximately 400bp in length, , fragments indicative of a nucleosome periodicity of two are 600bp in length, and so forth.
  • FIG. 46A illustrates insert lengths of fragments from a library prepared by linear amplification.
  • FIG. 46B illustrates insert lengths of fragments from a library prepared by ligation.
  • FIGs. 47A-47B illustrate an exemplary enrichment of transcription start sites (TSS) or analysis of CTCF (CCCTC-binding factor) sites observed in ATAC-seq libraries prepared by linear amplification or ligation-based methodologies vs. a traditional bulk ATAC-seq library preparation using 50,000 nuclei.
  • FIG. 47A illustrates exemplary enrichment of TSS data.
  • FIG. 48 shows a table comparing exemplary sequencing metrics obtained from linear amplification-based ATAC-seq libraries prepared using different polymerases: a Phusion ® DNA polymerase, a KAPA HiFi DNA polymerase (in combination with betaine), a Deep Vent ® DNA polymerase, as well as a library prepared by ligation.
  • FIG. 49 shows a table providing exemplary parameters of - 1,000 pL droplets vs. smaller ⁇ 400 pL droplets.
  • the benefits of using a smaller droplet size include ⁇ 2-fold decrease in Poisson derived cell doublet rate and an ⁇ 2-fold increase in cell throughput.
  • FIG. 50 illustrates protocols for ATAC-seq as described herein compared to data from (1) typical high quality traditional bulk ATAC-seq protocols; (2) Cusanovich, et al, Science, 2015 May 22;348(6237):910-14; (3) Buenrostro, et al., Nature, 2015 Jul
  • FIGs. 51A-51B shows the results of scRNA-seq and scATAC-seq analysis of nucleic acids in a peripheral blood mononuclear cell (PBMC) sample.
  • FIG. 51A shows an exemplary scatterplot produced using t-Distributed Stochastic Neighbor Embedding (tSNE), allowing visualization of RNA transcripts of different subpopulations cell types in a peripheral blood mononuclear cell (PBMC) sample.
  • tSNE t-Distributed Stochastic Neighbor Embedding
  • 51B shows an exemplary scatterplot produced using t-Distributed Stochastic Neighbor Embedding (tSNE), allowing visualization of ATAC-seq data of different subpopulations cell types in a peripheral blood mononuclear cell (PBMC) sample.
  • tSNE t-Distributed Stochastic Neighbor Embedding
  • barcode generally refers to a label, or identifier, that conveys or is capable of conveying information about an analyte.
  • a barcode can be part of an analyte.
  • a barcode can be independent of an analyte.
  • a barcode can be a tag attached to an analyte (e.g., nucleic acid molecule) or a combination of the tag in addition to an endogenous characteristic of the analyte (e.g., size of the analyte or end sequence(s)).
  • a barcode may be unique. Barcodes can have a variety of different formats.
  • barcodes can include: polynucleotide barcodes; random nucleic acid and/or amino acid sequences; and synthetic nucleic acid and/or amino acid sequences.
  • a barcode can be attached to an analyte in a reversible or irreversible manner.
  • a barcode can be added to, for example, a fragment of a deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sample before, during, and/or after sequencing of the sample. Barcodes can allow for identification and/or quantification of individual sequencing-reads.
  • real time can refer to a response time of less than about 1 second, a tenth of a second, a hundredth of a second, a millisecond, or less.
  • the response time may be greater than 1 second.
  • real time can refer to simultaneous or substantially simultaneous processing, detection or identification.
  • the term "subject,” as used herein, generally refers to an animal, such as a mammal (e.g., human) or avian (e.g., bird), or other organism, such as a plant.
  • the subject can be a vertebrate, a mammal, a rodent (e.g., a mouse), a primate, a simian or a human.
  • Animals may include, but are not limited to, farm animals, sport animals, and pets.
  • a subject can be a healthy or asymptomatic individual, an individual that has or is suspected of having a disease (e.g., cancer) or a pre-disposition to the disease, and/or an individual that is in need of therapy or suspected of needing therapy.
  • a subject can be a patient.
  • a subject can be a microorganism or microbe (e.g., bacteria, fungi, archaea, viruses).
  • genomic information generally refers to genomic information from a subject, which may be, for example, at least a portion or an entirety of a subject's hereditary information.
  • a genome can be encoded either in DNA or in RNA.
  • a genome can comprise coding regions (e.g., that code for proteins) as well as non-coding regions.
  • a genome can include the sequence of all chromosomes together in an organism.
  • the human genome ordinarily has a total of 46 chromosomes. The sequence of all of these together may constitute a human genome.
  • adaptor(s) can be used synonymously.
  • An adaptor or tag can be coupled to a polynucleotide sequence to be “tagged” by any approach, including ligation, hybridization, or other approaches.
  • the term "sequencing,” as used herein, generally refers to methods and technologies for determining the sequence of nucleotide bases in one or more polynucleotides.
  • the polynucleotides can be, for example, nucleic acid molecules such as deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), including variants or derivatives thereof (e.g., single stranded
  • Sequencing can be performed by various systems currently available, such as, without limitation, a sequencing system by Illumina®, Pacific Biosciences (PacBio®), Oxford
  • sequencing may be performed using nucleic acid amplification, polymerase chain reaction (PCR) (e.g., digital PCR, quantitative PCR, or real time PCR), or isothermal amplification.
  • PCR polymerase chain reaction
  • Such systems may provide a plurality of raw genetic data corresponding to the genetic information of a subject (e.g., human), as generated by the systems from a sample provided by the subject.
  • PCR reads also "reads" herein.
  • a read may include a string of nucleic acid bases corresponding to a sequence of a nucleic acid molecule that has been sequenced.
  • systems and methods provided herein may be used with proteomic information.
  • the term "bead,” as used herein, generally refers to a particle.
  • the bead may be a solid or semi-solid particle.
  • the bead may be a gel bead.
  • the gel bead may include a polymer matrix (e.g., matrix formed by polymerization or cross-linking).
  • the polymer matrix may include one or more polymers (e.g., polymers having different functional groups or repeat units). Polymers in the polymer matrix may be randomly arranged, such as in random copolymers, and/or have ordered structures, such as in block copolymers. Cross-linking can be via covalent, ionic, or inductive, interactions, or physical entanglement.
  • the bead may be a macromolecule.
  • the bead may be formed of nucleic acid molecules bound together.
  • the bead may be formed via covalent or non-covalent assembly of molecules (e.g., macromolecules), such as monomers or polymers.
  • Such polymers or monomers may be natural or synthetic.
  • Such polymers or monomers may be or include, for example, nucleic acid molecules (e.g., DNA or RNA).
  • the bead may be formed of a polymeric material.
  • the bead may be magnetic or non-magnetic.
  • the bead may be rigid.
  • the bead may be flexible and/or compressible.
  • the bead may be disruptable or dissolvable.
  • the bead may be a solid particle (e.g., a metal-based particle including but not limited to iron oxide, gold or silver) covered with a coating comprising one or more polymers. Such coating may be disruptable or dissolvable.
  • sample generally refers to a biological sample of a subject.
  • the biological sample may comprise any number of macromolecules, for example, cellular macromolecules.
  • the sample may be a cell sample.
  • the sample may be a cell line or cell culture sample.
  • the sample can include one or more cells.
  • the sample can include one or more microbes.
  • the biological sample may be a nucleic acid sample or protein sample.
  • the biological sample may also be a carbohydrate sample or a lipid sample.
  • the biological sample may be derived from another sample.
  • the sample may be a tissue sample, such as a biopsy, core biopsy, needle aspirate, or fine needle aspirate.
  • the sample may be a fluid sample, such as a blood sample, urine sample, or saliva sample.
  • the sample may be a skin sample.
  • the sample may be a cheek swab.
  • the sample may be a plasma or serum sample.
  • the sample may be a cell- free or cell free sample.
  • a cell-free sample may include extracellular polynucleotides.
  • Extracellular polynucleotides may be isolated from a bodily sample that may be selected from the group consisting of blood, plasma, serum, urine, saliva, mucosal excretions, sputum, stool and tears.
  • biological particle generally refers to a discrete biological system derived from a biological sample.
  • the biological particle may be a
  • the biological particle may be a small molecule.
  • the biological particle may be a virus.
  • the biological particle may be a cell or derivative of a cell.
  • the biological particle may be an organelle.
  • the biological particle may be a rare cell from a population of cells.
  • the biological particle may be any type of cell, including without limitation prokaryotic cells, eukaryotic cells, bacterial, fungal, plant, mammalian, or other animal cell type, mycoplasmas, normal tissue cells, tumor cells, or any other cell type, whether derived from single cell or multicellular organisms.
  • the biological particle may be a constituent of a cell.
  • the biological particle may be or may include DNA, RNA, organelles, proteins, or any combination thereof.
  • the biological particle may be or include a chromosome or other portion of a genome.
  • the biological particle may be or may include a matrix (e.g., a gel or polymer matrix) comprising a cell or one or more constituents from a cell (e.g., cell bead), such as DNA, RNA, organelles, proteins, or any combination thereof, from the cell.
  • the biological particle may be obtained from a tissue of a subject.
  • the biological particle may be a hardened cell. Such hardened cell may or may not include a cell wall or cell membrane.
  • the biological particle may include one or more constituents of a cell, but may not include other constituents of the cell. An example of such constituents is a nucleus or an organelle.
  • a cell may be a live cell.
  • the live cell may be capable of being cultured, for example, being cultured when enclosed in a gel or polymer matrix, or cultured when comprising a gel or polymer matrix.
  • the term "macromolecular constituent,” as used herein, generally refers to a macromolecule contained within or from a biological particle.
  • the macromolecular constituent may comprise a nucleic acid.
  • the biological particle may be a macromolecule.
  • the macromolecular constituent may comprise DNA.
  • the macromolecular constituent may comprise RNA.
  • the RNA may be coding or non-coding.
  • the RNA may be messenger RNA (mRNA), ribosomal RNA (rRNA) or transfer RNA (tRNA), for example.
  • the RNA may be a transcript.
  • the RNA may be small RNA that are less than 200 nucleic acid bases in length, or large RNA that are greater than 200 nucleic acid bases in length.
  • Small RNAs may include 5.8S ribosomal RNA (rRNA), 5S rRNA, transfer RNA (tRNA), microRNA (miRNA), small interfering RNA (siRNA), small nucleolar RNA (snoRNAs), Piwi-interacting RNA (piRNA), tRNA-derived small RNA (tsRNA) and small rDNA-derived RNA (srRNA).
  • the RNA may be double-stranded RNA or single-stranded RNA.
  • the RNA may be circular RNA.
  • the macromolecular constituent may comprise a protein.
  • the macromolecular constituent may comprise a peptide.
  • the macromolecular constituent may comprise a polypeptide.
  • the term "molecular tag,” as used herein, generally refers to a molecule capable of binding to a macromolecular constituent.
  • the molecular tag may bind to the macromolecular constituent with high affinity.
  • the molecular tag may bind to the macromolecular constituent with high specificity.
  • the molecular tag may comprise a nucleotide sequence.
  • the molecular tag may comprise a nucleic acid sequence.
  • the nucleic acid sequence may be at least a portion or an entirety of the molecular tag.
  • the molecular tag may be a nucleic acid molecule or may be part of a nucleic acid molecule.
  • the molecular tag may be an oligonucleotide or a polypeptide.
  • the molecular tag may comprise a DNA aptamer.
  • the molecular tag may be or comprise a primer.
  • the molecular tag may be, or comprise, a protein.
  • the molecular tag may comprise a polypeptide.
  • the molecular tag may be a barcode.
  • partition refers to a space or volume that may be suitable to contain one or more species or conduct one or more reactions.
  • a partition may be a physical compartment, such as a droplet or well. The partition may isolate space or volume from another space or volume.
  • the droplet may be a first phase (e.g., aqueous phase) in a second phase (e.g., oil) immiscible with the first phase.
  • the droplet may be a first phase in a second phase that does not phase separate from the first phase, such as, for example, a capsule or liposome in an aqueous phase.
  • a partition may comprise one or more other (inner) partitions.
  • a partition may be a virtual compartment that can be defined and identified by an index (e.g., indexed libraries) across multiple and/or remote physical compartments.
  • a physical compartment may comprise a plurality of virtual compartments.
  • a method for nucleic acid processing may comprise generating a partition (e.g., a droplet or well) comprising: (i) a biological particle (e.g., a cell or nucleus) comprising chromatin comprising a template nucleic acid molecule; (ii) a plurality of nucleic acid barcode molecules comprising a common barcode sequence; (iii) a plurality of transposon end nucleic acid molecules comprising a transposon end sequence; and (iv) a plurality of transposase molecules.
  • a partition e.g., a droplet or well
  • a biological particle e.g., a cell or nucleus
  • chromatin comprising a template nucleic acid molecule
  • a plurality of nucleic acid barcode molecules comprising a common barcode sequence
  • transposon end nucleic acid molecules comprising a transposon end sequence
  • a plurality of template nucleic acid fragments may then be generated with the aid of a transposase-nucleic acid complex comprising a transposase molecule of the plurality of transposase molecules and a transposon end oligonucleotide molecule of the plurality of transposon end oligonucleotide molecules.
  • a barcoded nucleic acid fragment may then be generated using a nucleic acid barcode molecule of the plurality of nucleic acid barcode molecules and a template nucleic acid fragment of the plurality of template nucleic acid fragments.
  • the present disclosure also discloses a method of generating barcoded nucleic acid fragments, comprising providing: (i) a plurality of biological particles (e.g., cells or nuclei), an individual biological particle of the plurality of biological particles comprising chromatin comprising a template nucleic acid; (ii) a plurality of transposon end nucleic acid molecules comprising a transposon end sequence; and (iii) a plurality of transposase molecules.
  • a plurality of biological particles e.g., cells or nuclei
  • an individual biological particle of the plurality of biological particles comprising chromatin comprising a template nucleic acid
  • a plurality of transposon end nucleic acid molecules comprising a transposon end sequence
  • a plurality of transposase molecules e.g., transposase molecules
  • a plurality of template nucleic acid fragments may then be generated in a biological particle of the plurality of biological particles with the aid of a transposase-nucleic acid complex comprising a transposase molecule of the plurality of transposase molecules and a transposon end nucleic acid molecule of the plurality of transposon end nucleic acid molecules.
  • a partition may then be generated, where the partition comprises the biological particle comprising the plurality of template nucleic acid fragments and a plurality of nucleic acid barcode molecules comprising a common barcode sequence.
  • a barcoded nucleic acid fragment may then be generated using a nucleic acid barcode molecule of the plurality of nucleic acid barcode molecules and a template nucleic acid fragment of the plurality of template nucleic acid fragments.
  • the transposase is a Tn5 transposase. In some embodiments, the transposase is a mutated, hyperactive Tn5 transposase. In some embodiments, the transposase is a Mu transposase. In some embodiments, the partitions disclosed in (a) further comprise cell lysis reagents; and/or (b) reagent and buffers necessary to carry out one or more reactions.
  • a partition (e.g., a droplet or well) comprises a single cell and is processed according to the methods described herein.
  • a partition comprises a single cell and/or a single nucleus.
  • the single cell and/or the single nucleus may be partitioned and processed according to the methods described herein.
  • the single nucleus may be a component of a cell.
  • a partition comprises chromatin from a single cell or single nucleus (e.g., a single chromosome or other portion of the genome) and is partitioned and processed according to the methods described herein.
  • the transposition reactions and methods described herein are performed in bulk and biological particles (e.g., nuclei/cells/chromatin from single cells) are then partitioned such that a plurality of partitions is singly occupied by a biological particle (e.g., a cell, cell nucleus, chromatin, or cell bead).
  • biological particles e.g., nuclei/cells/chromatin from single cells
  • a biological particle e.g., a cell, cell nucleus, chromatin, or cell bead.
  • a plurality of biological particles may be partitioned into a plurality of partitions such that partitions of the plurality of partitions comprise a single biological particle.
  • the oligonucleotides described herein comprise a transposon end sequence.
  • the transposon end sequence is a Tn5 or modified Tn5 transposon end sequence.
  • the transposon end sequence is a Mu transposon end sequence.
  • the transposon end sequence has a sequence of:
  • the oligonucleotides described herein comprise an Rl sequencing priming region.
  • the Rl sequencing primer region has a sequence of
  • the Rl sequencing primer region has a sequence of
  • the oligonucleotides described herein comprise a partial Rl sequence.
  • the partial Rl sequence is
  • the oligonucleotides described herein comprise an R2 sequencing priming region.
  • the R2 sequencing primer region has a sequence of
  • the R2 sequencing primer region has a sequence of
  • the oligonucleotides described herein comprise a T7 promoter sequence.
  • the T7 promoter sequence is
  • the oligonucleotides described herein comprise a region at least 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NO: 1-7.
  • the oligonucleotides described herein comprise a P5 sequence.
  • the oligonucleotides described herein comprise a P7 sequence.
  • the oligonucleotides described herein comprise a sample index sequence.
  • the oligonucleotides described herein are attached to a solid support (e.g., a solid or semi-solid particle such as a bead). In some embodiments, the oligonucleotides described herein are attached to a bead. In some embodiments, the bead is a gel bead. In some embodiments, the oligonucleotides described herein are releasably attached to a bead (e.g., a gel bead). In some embodiments, the oligonucleotides described herein are single- stranded and the first strand attached to a bead.
  • the oligonucleotides described herein are double-stranded or partially double-stranded molecules and the first strand is releasably attached to a bead. In some embodiments, the oligonucleotides described herein are double-stranded or partially double-stranded molecules and the second strand is releasably attached to a bead. In some embodiments, the oligonucleotides described herein are double- stranded or partially double-stranded molecules and both the first and the second strand are releasably attached to a bead or a collection of beads.
  • the solid support (e.g., bead, such as a gel bead) comprises a plurality of first oligonucleotides and a plurality of second oligonucleotides.
  • the first oligonucleotides, the second oligonucleotides, or the combination thereof are releasably attached to a bead.
  • the first oligonucleotides, the second oligonucleotides, or the combination thereof are double-stranded or partially double-stranded molecules and the first strand is releasably attached to a bead.
  • the first oligonucleotides, the second oligonucleotides, or the combination thereof are double-stranded or partially double-stranded molecules and the second strand is releasably attached to abead.
  • the first oligonucleotides, the second oligonucleotides, or the combination thereof are double-stranded or partially double-stranded molecules and the first strand and the second strand are releasably attached to abead.
  • the oligonucleotides, the first oligonucleotides, the second oligonucleotides, or a combination there of are bound to a magnetic particle.
  • the magnetic particle is embedded in a solid support (e.g., a bead, such as a gel bead).
  • the first oligonucleotides are capable of coupling (e.g., by nucleic acid hybridization) to DNA molecules and the second oligonucleotides are capable of coupling (e.g., by nucleic acid hybridization) to RNA molecules (e.g., mRNA molecules).
  • the first oligonucleotide comprises a P5 adaptor sequence, a barcode sequence, and an Rl sequence or partial Rl primer sequence.
  • the second oligonucleotide comprises a Rl sequence or partial Rl primer sequence, a barcode sequence, a unique molecular identifier (UMI) sequence, and a poly(dT) sequence.
  • the second oligonucleotide comprises a Rl sequence or partial Rl primer sequence, a barcode sequence, a unique molecular identifier (UMI) sequence, and a switch oligo.
  • the first oligonucleotide comprises a P5 adaptor sequence, a barcode sequence, and an Rl sequence or partial Rl primer sequence and is partially double- stranded
  • the second oligonucleotide comprises a Rl or partial Rl primer sequence, a barcode sequence, a unique molecular identifier (UMI) sequence, and a poly(dT) sequence.
  • UMI unique molecular identifier
  • the first oligonucleotide comprises a P5 adaptor sequence, a barcode sequence, and an Rl or partial Rl primer sequence and is single-stranded
  • the second oligonucleotide comprises a Rl or partial Rl sequence, a barcode sequence, a unique molecular identifier (UMI) sequence, and a template switching oligo sequence.
  • UMI unique molecular identifier
  • partitions discrete compartments or partitions (referred to interchangeably herein as partitions), where each partition maintains separation of its own contents from the contents of other partitions.
  • the partition can be, for example, a well or a droplet in an emulsion.
  • a partition may comprise one or more other partitions.
  • a partition may include one or more particles.
  • a partition may include one or more types of particles.
  • a partition of the present disclosure may comprise one or more biological particles and/or macromolecular constituents thereof.
  • a partition may comprise one or more cells, nuclei, chromatins, and/or cell beads.
  • a partition may comprise one or more cell beads.
  • a cell bead can be a biological particle and/or one or more of its macromolecular constituents encased inside of a gel or polymer matrix, such as via polymerization of a droplet containing the biological particle and precursors capable of being polymerized or gelled.
  • a partition may comprise one or more solid or semi-solid particles.
  • a partition may comprise one or more beads, such as one or more gel beads.
  • a partition may include a single gel bead, a single cell bead, or both a single cell bead and single gel bead.
  • a partition may include one or more reagents (e.g., as described herein).
  • Unique identifiers such as barcodes
  • the barcodes may comprise nucleic acid sequences.
  • Such nucleic acid barcode sequences may be components of nucleic acid barcode molecules, which may be coupled (e.g., releasably coupled) to a solid or semi-solid particle such as a bead.
  • a partition may be unoccupied.
  • a partition may not comprise a bead or a biological particle.
  • Microfluidic devices comprising one or more channels (e.g., microfluidic channel networks of a chip) can be utilized to generate partitions as described herein. For example, a first fluid and a second fluid that is immiscible with the first fluid may be flowed to a droplet generation junction, and a droplet of the first fluid may be generated within the second fluid.
  • Alternative mechanisms may also be employed in the partitioning of individual biological particles, including porous membranes through which aqueous mixtures of cells are extruded into non-aqueous fluids.
  • the partitions can be flowable within fluid streams.
  • the partitions may comprise, for example, micro-vesicles that have an outer barrier surrounding an inner fluid center or core.
  • the partitions may comprise a porous matrix that is capable of entraining and/or retaining materials within its matrix.
  • the partitions can be droplets of a first phase within a second phase, wherein the first and second phases are immiscible.
  • the partitions can be droplets of aqueous fluid within a non-aqueous continuous phase (e.g., oil phase).
  • the partitions can be droplets of a non-aqueous fluid within an aqueous phase.
  • the partitions may be provided in a water-in-oil emulsion or oil-in-water emulsion.
  • a variety of different vessels are described in, for example, U.S. Patent Application Publication No. 2014/0155295, which is entirely incorporated herein by reference for all purposes.
  • Emulsion systems for creating stable droplets in non-aqueous or oil continuous phases are described in, for example, U.S. Patent Application Publication No. 2010/0105112, which is entirely incorporated herein by reference for all purposes.
  • allocating individual particles to discrete partitions may in one non-limiting example be accomplished by introducing a flowing stream of particles in an aqueous fluid into a flowing stream of a non-aqueous fluid, such that droplets are generated at the junction of the two streams.
  • Fluid properties e.g., fluid flow rates, fluid viscosities, etc.
  • particle properties e.g., volume fraction, particle size, particle concentration, etc.
  • microfluidic architectures e.g., channel geometry, etc.
  • other parameters may be adjusted to control the occupancy of the resulting partitions (e.g., number of biological particles per partition, number of beads per partition, etc.).
  • partition occupancy can be controlled by providing the aqueous stream at a certain concentration and/or flow rate of particles.
  • the relative flow rates of the immiscible fluids can be selected such that, on average, the partitions may contain less than one biological particle per partition in order to ensure that those partitions that are occupied are primarily singly occupied.
  • partitions among a plurality of partitions may contain at most one biological particle (e.g., cell bead, chromatin, DNA, cell, cell nucleus, or other cellular material).
  • the various parameters may be selected or adjusted such that a majority of partitions are occupied, for example, allowing for only a small percentage of unoccupied partitions.
  • the flows and channel architectures can be controlled as to ensure a given number of singly occupied partitions, less than a certain level of unoccupied partitions and/or less than a certain level of multiply occupied partitions.
  • FIG. 1 shows an example of a microfluidic channel structure 100 for partitioning individual biological particles (e.g., as described herein).
  • the channel structure 100 can include channel segments 102, 104, 106 and 108 communicating at a channel junction 110.
  • a first aqueous fluid 112 that includes suspended biological particles (or cells) 114 may be transported along channel segment 102 into junction 110, while a second fluid 116 that is immiscible with the aqueous fluid 112 is delivered to the junction 110 from each of channel segments 104 and 106 to create discrete droplets 118, 120 of the first aqueous fluid 112 flowing into channel segment 108, and flowing away from junction 110.
  • the channel segment 108 may be fluidically coupled to an outlet reservoir where the discrete droplets can be stored and/or harvested.
  • a discrete droplet generated may include an individual biological particle 114 (such as droplets 118).
  • a discrete droplet generated may include more than one individual biological particle 114 (not shown in FIG. 1).
  • a discrete droplet may contain no biological particle 114 (such as droplet 120).
  • Each discrete partition may maintain separation of its own contents (e.g., individual biological particle 114) from the contents of other partitions.
  • the second fluid 116 can comprise an oil, such as a fluorinated oil, that includes a fluorosurfactant for stabilizing the resulting droplets, for example, inhibiting subsequent coalescence of the resulting droplets 118, 120.
  • an oil such as a fluorinated oil
  • fluorosurfactant for stabilizing the resulting droplets, for example, inhibiting subsequent coalescence of the resulting droplets 118, 120.
  • the channel segments described herein may be coupled to any of a variety of different fluid sources or receiving components, including reservoirs, tubing, manifolds, or fluidic components of other systems.
  • the microfluidic channel structure 100 may have other geometries.
  • a microfluidic channel structure can have more than one channel junction.
  • a microfluidic channel structure can have 2, 3, 4, or 5 channel segments each carrying particles (e.g., biological particles, cell beads, and/or solid or semi-solid particles such as gel beads) that meet at a channel junction.
  • Fluid may be directed to flow along one or more channels or reservoirs via one or more fluid flow units.
  • a fluid flow unit can comprise compressors (e.g., providing positive pressure), pumps (e.g., providing negative pressure), actuators, and the like to control flow of the fluid. Fluid may also or otherwise be controlled via applied pressure differentials, centrifugal force, electrokinetic pumping, vacuum, capillary or gravity flow, or the like.
  • the generated droplets may comprise two subsets of droplets: (1) occupied droplets 118, containing one or more biological particles 114, and (2) unoccupied droplets 120, not containing any biological particles 114.
  • Occupied droplets 118 may comprise singly occupied droplets (having one biological particle) and multiply occupied droplets (having more than one biological particle).
  • the majority of occupied partitions can include no more than one biological particle per occupied partition and some of the generated partitions can be unoccupied (of any biological particle). In some cases, though, some of the occupied partitions may include more than one biological particle. In some cases, the partitioning process may be controlled such that fewer than about 25% of the occupied partitions contain more than one biological particle, and in many cases, fewer than about 20% of the occupied partitions have more than one biological particle, while in some cases, fewer than about 10%) or even fewer than about 5% of the occupied partitions include more than one biological particle per partition.
  • the Poissonian distribution may expectedly increase the number of partitions that include multiple biological particles. As such, where singly occupied partitions are to be obtained, at most about 95%, 90%, 85%, 80%, 75%, 70%, 65%, 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5% or less of the generated partitions can be unoccupied.
  • the flow of one or more of the biological particles (e.g., in channel segment 102), or other fluids directed into the partitioning junction (e.g., in channel segments 104, 106) can be controlled such that, in many cases, no more than about 50% of the generated partitions, no more than about 25% of the generated partitions, or no more than about 10% of the generated partitions are unoccupied.
  • These flows can be controlled so as to present a non- Poissonian distribution of singly-occupied partitions while providing lower levels of unoccupied partitions.
  • the above noted ranges of unoccupied partitions can be achieved while still providing any of the single occupancy rates described above.
  • the use of the systems and methods described herein may result in partitions that have multiple occupancy rates of less than about 25%, less than about 20%, less than about 15%, less than about 10%), and in many cases, less than about 5%, while having unoccupied partitions of less than about 50%, less than about 40%, less than about 30%, less than about 20%, less than about 10%), less than about 5%, or less.
  • the above-described occupancy rates are also applicable to partitions that include both biological particles and additional reagents, including, but not limited to, microcapsules or beads (e.g., gel beads) carrying barcoded nucleic acid molecules (e.g., oligonucleotides) (described in relation to FIG. 2).
  • the occupied partitions (e.g., at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 99% of the occupied partitions) can include both a microcapsule (e.g., bead) comprising barcoded nucleic acid molecules and a biological particle.
  • a microcapsule e.g., bead
  • biological particles in addition to or as an alternative to droplet based partitioning, biological particles (e.g., as described herein) may be encapsulated within a microcapsule that comprises an outer shell, layer or porous matrix in which is entrained one or more individual biological particles or small groups of biological particles.
  • the microcapsule may include other reagents. Encapsulation of biological particles may be performed by a variety of processes. Such processes may combine an aqueous fluid containing the biological particles with a polymeric precursor material that may be capable of being formed into a gel or other solid or semi-solid matrix upon application of a particular stimulus to the polymer precursor.
  • Such stimuli can include, for example, thermal stimuli (e.g., either heating or cooling), photo-stimuli (e.g., through photo-curing), chemical stimuli (e.g., through crosslinking, polymerization initiation of the precursor (e.g., through added initiators)), mechanical stimuli, or a combination thereof.
  • thermal stimuli e.g., either heating or cooling
  • photo-stimuli e.g., through photo-curing
  • chemical stimuli e.g., through crosslinking, polymerization initiation of the precursor (e.g., through added initiators)
  • mechanical stimuli e.g., mechanical stimuli, or a combination thereof.
  • microcapsules comprising biological particles may be performed by a variety of methods.
  • air knife droplet or aerosol generators may be used to dispense droplets of precursor fluids into gelling solutions in order to form microcapsules that include individual biological particles or small groups of biological particles.
  • membrane based encapsulation systems may be used to generate microcapsules comprising encapsulated biological particles as described herein.
  • Microfluidic systems of the present disclosure such as that shown in FIG. 1, may be readily used in encapsulating cells as described herein. In particular, and with reference to FIG.
  • non-aqueous fluid 116 may also include an initiator (not shown) to cause polymerization and/or crosslinking of the polymer precursor to form the microcapsule that includes the entrained biological particles. Examples of polymer
  • precursor/initiator pairs include those described in U.S. Patent Application Publication No. 2014/0378345, which is entirely incorporated herein by reference for all purposes.
  • the activation agent may comprise a cross-linking agent, or a chemical that activates a cross-linking agent within the formed droplets.
  • the activation agent may comprise a polymerization initiator.
  • the polymer precursor comprises a mixture of acrylamide monomer with a ⁇ , ⁇ '- bis-(acryloyl)cystamine (BAC) comonomer
  • an agent such as tetraethylmethylenediamine (TEMED) may be provided within the second fluid streams 116 in channel segments 104 and 106, which can initiate the copolymerization of the acrylamide and BAC into a cross-linked polymer network, or hydrogel.
  • TEMED tetraethylmethylenediamine
  • the TEMED may diffuse from the second fluid 116 into the aqueous fluid 112 comprising the linear poly acrylamide, which will activate the crosslinking of the polyacrylamide within the droplets 118, 120, resulting in the formation of gel (e.g., hydrogel) microcapsules, as solid or semi-solid beads or particles entraining the biological particles (e.g., cells) 114.
  • gel e.g., hydrogel
  • biological particles e.g., cells
  • alginate droplets followed by exposure to divalent metal ions (e.g., Ca 2+ ions), can be used as an encapsulation process using the described processes.
  • divalent metal ions e.g., Ca 2+ ions
  • agarose droplets may also be transformed into capsules through temperature based gelling (e.g., upon cooling, etc.).
  • encapsulated biological particles can be selectively releasable from the microcapsule, such as through passage of time or upon application of a particular stimulus, that degrades the microcapsule sufficiently to allow the biological particles (e.g., cell), or its other contents to be released from the microcapsule, such as into a partition (e.g., droplet).
  • a partition e.g., droplet
  • degradation of the microcapsule may be accomplished through the introduction of an appropriate reducing agent, such as dithiothreitol (DTT) or the like, to cleave disulfide bonds that cross-link the polymer matrix.
  • DTT dithiothreitol
  • the biological particle can be subjected to other conditions sufficient to polymerize or gel the precursors.
  • the conditions sufficient to polymerize or gel the precursors may comprise exposure to heating, cooling, electromagnetic radiation, and/or light.
  • the conditions sufficient to polymerize or gel the precursors may comprise any conditions sufficient to polymerize or gel the precursors.
  • a polymer or gel may be formed around and/or within the biological particle.
  • the polymer or gel may be diffusively permeable to chemical or biochemical reagents.
  • the polymer or gel may be diffusively impermeable to macromolecular constituents of the biological particle.
  • the polymer or gel may act to allow the biological particle to be subjected to chemical or biochemical operations while spatially confining the macromolecular constituents to a region of the droplet defined by the polymer or gel.
  • the polymer or gel may include one or more of disulfide cross-linked polyacrylamide, agarose, alginate, polyvinyl alcohol, polyethylene glycol (PEG)-diacrylate, PEG-acrylate, PEG-thiol, PEG-azide, PEG-alkyne, other acrylates, chitosan, hyaluronic acid, collagen, fibrin, gelatin, or elastin.
  • the polymer or gel may comprise any other polymer or gel.
  • a cell comprising a polymer or gel matrix may be referred to as a "cell bead.”
  • the polymer or gel may be functionalized to bind to targeted analytes, such as nucleic acids, proteins, carbohydrates, lipids or other analytes.
  • the polymer or gel may be polymerized or gelled via a passive mechanism. For example, polymerization or gelling may be brought about by a change in salinity, pH, temperature, or pressure.
  • the polymer or gel may be stable in alkaline conditions or at elevated temperature.
  • the polymer or gel may have mechanical properties similar to the mechanical properties of the bead. For instance, a polymer or gel matrix may be of a similar size to the bead.
  • the polymer or gel may have a mechanical strength (e.g. tensile strength) similar to that of the bead.
  • the polymer or gel may be of a lower density than an oil.
  • the polymer or gel may be of a density that is roughly similar to that of a buffer.
  • the polymer or gel may have a tunable pore size.
  • the pore size may be chosen to, for instance, retain denatured nucleic acids.
  • the pore size may be chosen to maintain diffusive permeability to exogenous chemicals such as sodium hydroxide (NaOH) and/or endogenous chemicals such as inhibitors.
  • the polymer or gel may be biocompatible.
  • the polymer or gel may maintain or enhance cell viability.
  • the polymer or gel may be biochemically compatible.
  • the polymer or gel may be polymerized and/or depolymerized thermally, chemically, enzymatically, and/or optically.
  • the polymer or gel may comprise poly(acrylamide-co-acrylic acid) crosslinked with disulfide linkages.
  • the preparation of the polymer or gel may comprise a two-step reaction.
  • poly(acrylamide-co-acrylic acid) may be exposed to an acylating agent to convert carboxylic acids to esters.
  • the poly(aciylamide-co-acrylic acid) may be exposed to 4-(4,6-dimethoxy-l,3,5-triazin-2-yl)-4-methylmo holinium chloride (DMTMM).
  • the polyacrylamide-co-acrylic acid may be exposed to other salts of 4-(4,6-dimethoxy-l,3,5- triazin-2-yl)-4-methylmo holinium.
  • the ester formed in the first step may be exposed to a disulfide crosslinking agent.
  • the ester may be exposed to cystamine (2,2'-dithiobis(ethylamine)).
  • the biological particle may be surrounded by polyacrylamide strands linked together by disulfide bridges.
  • the biological particle may be encased inside of or comprise a gel or matrix (e.g., polymer matrix) to form a "cell bead.”
  • a cell bead can contain biological particles (e.g., a cell) or macromolecular constituents (e.g., RNA, DNA, proteins, etc.) of biological particles.
  • a cell bead may include a single cell or multiple cells, or a derivative of the single cell or multiple cells. For example after lysing and washing the cells, inhibitory components from cell lysates can be washed away and the macromolecular constituents can be bound as cell beads.
  • Systems and methods disclosed herein can be applicable to both cell beads (and/or droplets or other partitions) containing biological particles and cell beads (and/or droplets or other partitions) containing macromolecular constituents of biological particles.
  • Encapsulated biological particles can provide certain potential advantages of being more storable and more portable than droplet-based partitioned biological particles.
  • encapsulation may allow for longer incubation than partitioning in emulsion droplets, although in some cases, droplet partitioned biological particles may also be incubated for different periods of time, e.g., at least 10 seconds, at least 30 seconds, at least 1 minute, at least 5 minutes, at least 10 minutes, at least 30 minutes, at least 1 hour, at least 2 hours, at least 5 hours, or at least 10 hours or more.
  • the encapsulation of biological particles may constitute the partitioning of the biological particles into which other reagents are co-partitioned.
  • encapsulated biological particles may be readily deposited into other partitions (e.g., droplets) as described above.
  • a partition may comprise one or more unique identifiers, such as one or more barcodes. Barcodes may be previously, subsequently, or concurrently delivered to the partitions that hold the compartmentalized or partitioned biological particle. For example, barcodes may be injected into droplets previous to, subsequent to, or concurrently with droplet generation. The delivery of the barcodes to a particular partition allows for the later attribution of the
  • Barcodes may be delivered, for example, as components of a nucleic acid molecule (e.g., an oligonucleotide). Barcodes may be delivered to a partition via any suitable mechanism. For example, barcoded nucleic acid molecules can be delivered to a partition such as a droplet or well via a
  • microcapsule or bead can comprise a bead. Beads are described in further detail below.
  • barcoded nucleic acid molecules can be initially associated with the microcapsule or bead and then released from the microcapsule or bead.
  • a bead may comprise a plurality of nucleic acid barcode molecules releasably coupled thereto. Release of the barcoded nucleic acid molecules can be passive (e.g., by diffusion out of the microcapsule or bead).
  • release from the microcapsule or bead can be upon application of a stimulus which allows the barcoded nucleic acid nucleic acid molecules to dissociate or to be released from the microcapsule or bead.
  • a stimulus which allows the barcoded nucleic acid nucleic acid molecules to dissociate or to be released from the microcapsule or bead.
  • Such stimulus may disrupt the microcapsule or bead, an interaction that couples the barcoded nucleic acid molecules to or within the microcapsule or bead, or both.
  • Such stimulus can include, for example, a thermal stimulus, photo-stimulus, chemical stimulus (e.g., change in pH or use of a reducing agent(s)), a mechanical stimulus, a radiation stimulus; a biological stimulus (e.g., enzyme), or any combination thereof.
  • FIG. 2 shows an example of a microfluidic channel structure 200 for delivering barcode carrying beads to droplets.
  • the channel structure 200 can include channel segments 201, 202, 204, 206 and 208 communicating at a channel junction 210.
  • the channel segment 201 may transport an aqueous fluid 212 that includes a plurality of beads 214 (e.g., beads comprising nucleic acid barcode molecules, oligonucleotides, or molecular tags) along the channel segment 201 into junction 210.
  • the plurality of beads 214 may be sourced from a suspension of beads.
  • the channel segment 201 may be connected to a reservoir comprising an aqueous suspension of beads 214.
  • the channel segment 202 may transport the aqueous fluid 212 that includes a plurality of biological particles 216 along the channel segment 202 into junction 210.
  • the plurality of biological particles 216 may be sourced from a suspension of biological particles.
  • the channel segment 202 may be connected to a reservoir comprising an aqueous suspension of biological particles 216.
  • the aqueous fluid 212 in either the first channel segment 201 or the second channel segment 202, or in both segments can include one or more reagents, as further described below.
  • a second fluid 218 that is immiscible with the aqueous fluid 212 e.g., oil
  • the aqueous fluid 212 can be partitioned as discrete droplets 220 in the second fluid 218 and flow away from the junction 210 along channel segment 208.
  • the channel segment 208 may deliver the discrete droplets to an outlet reservoir fluidly coupled to the channel segment 208, where they may be harvested.
  • the channel segments 201 and 202 may meet at another junction upstream of the junction 210.
  • beads and biological particles may form a mixture that is directed along another channel to the junction 210 to yield droplets 220.
  • the mixture may provide the beads and biological particles in an alternating fashion, such that, for example, a droplet comprises a single bead and a single biological particle.
  • Beads, biological particles, and droplets may flow along channels at substantially regular flow profiles (e.g., at regular flow rates). Such regular flow profiles may permit a droplet to be formed such that it includes a single bead and a single biological particle. Such regular flow profiles may permit the droplets to have an occupancy (e.g., droplets having beads and biological particles) greater than 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95%.
  • occupancy e.g., droplets having beads and biological particles
  • the second fluid 218 can comprise an oil, such as a fluorinated oil, that includes a fluorosurfactant for stabilizing the resulting droplets, for example, inhibiting subsequent coalescence of the resulting droplets 220.
  • an oil such as a fluorinated oil, that includes a fluorosurfactant for stabilizing the resulting droplets, for example, inhibiting subsequent coalescence of the resulting droplets 220.
  • a discrete droplet that is generated may include an individual biological particle 216.
  • a discrete droplet that is generated may include a bead 214 comprising a barcode or other reagent.
  • bead 214 may comprise a plurality of nucleic acid barcode molecules each comprising a common barcode sequence.
  • a discrete droplet generated may include both an individual biological particle and a barcode-carrying bead, such as droplets 220.
  • a discrete droplet may include more than one individual biological particle or no biological particle.
  • a discrete droplet may include more than one bead or no bead.
  • a discrete droplet may be unoccupied (e.g., no beads, no biological particles).
  • a discrete droplet partitioning a biological particle and a barcode carrying bead may effectively allow the attribution of the barcode to macromolecular
  • the contents of a partition may remain discrete from the contents of other partitions.
  • the channel segments described herein may be coupled to any of a variety of different fluid sources or receiving components, including reservoirs, tubing, manifolds, or fluidic components of other systems.
  • the microfiuidic channel structure 200 may have other geometries.
  • a microfiuidic channel structure can have more than one channel junctions.
  • a microfiuidic channel structure can have 2, 3, 4, or 5 channel segments each carrying beads that meet at a channel junction.
  • Fluid may be directed flow along one or more channels or reservoirs via one or more fluid flow units.
  • a fluid flow unit can comprise compressors (e.g., providing positive pressure), pumps (e.g., providing negative pressure), actuators, and the like to control flow of the fluid. Fluid may also or otherwise be controlled via applied pressure differentials, centrifugal force, electrokinetic pumping, vacuum, capillary or gravity flow, or the like.
  • a bead may be porous, non-porous, solid, semi-solid, semi-fluidic, fluidic, and/or a combination thereof.
  • a bead may be dissolvable, disruptable, and/or degradable.
  • a bead may not be degradable.
  • the bead may be a gel bead.
  • a gel bead may be a hydrogel bead.
  • a gel bead may be formed from molecular precursors, such as a polymeric or monomelic species.
  • a semi-solid bead may be a liposomal bead.
  • Solid beads may comprise metals including iron oxide, gold, and silver.
  • the bead may be a silica bead.
  • the bead can be rigid. In other cases, the bead may be flexible and/or compressible.
  • a bead may be of any suitable shape.
  • bead shapes include, but are not limited to, spherical, non- spherical, oval, oblong, amorphous, circular, cylindrical, and variations thereof.
  • Beads may be of uniform size or heterogeneous size.
  • the diameter of a bead may be at least about 10 nanometers (nm), 100 nm, 500 nm, 1 micrometer ( ⁇ ), 5 ⁇ , 10 ⁇ , 20 ⁇ , 30 ⁇ , 40 ⁇ , 50 ⁇ , 60 ⁇ , 70 ⁇ , 80 ⁇ , 90 ⁇ , 100 ⁇ , 250 ⁇ , 500 ⁇ , 1 mm, or greater.
  • a bead may have a diameter of less than about 10 nm, 100 nm, 500 nm, ⁇ ⁇ , 5 ⁇ , 10 ⁇ , 20 ⁇ , 30 ⁇ , 40 ⁇ , 50 ⁇ , 60 ⁇ , 70 ⁇ , 80 ⁇ , 90 ⁇ , 100 ⁇ , 250 ⁇ , 500 ⁇ , 1 mm, or less.
  • a bead may have a diameter in the range of about 40-75 ⁇ , 30-75 ⁇ , 20-75 ⁇ , 40-85 ⁇ , 40-95 ⁇ , 20-100 ⁇ , 10-100 ⁇ , 1-100 ⁇ , 20-250 ⁇ , or 20-500 ⁇ .
  • beads can be provided as a population or plurality of beads having a relatively monodisperse size distribution. Where it may be desirable to provide relatively consistent amounts of reagents within partitions, maintaining relatively consistent bead characteristics, such as size, can contribute to the overall consistency.
  • the beads described herein may have size distributions that have a coefficient of variation in their cross- sectional dimensions of less than 50%, less than 40%, less than 30%, less than 20%, and in some cases less than 15%, less than 10%, less than 5%, or less.
  • a bead may comprise natural and/or synthetic materials.
  • a bead can comprise a natural polymer, a synthetic polymer or both natural and synthetic polymers.
  • natural polymers include proteins and sugars such as deoxyribonucleic acid, rubber, cellulose, starch (e.g., amylose, amylopectin), proteins, enzymes, polysaccharides, silks, polyhydroxyalkanoates, chitosan, dextran, collagen, carrageenan, ispaghula, acacia, agar, gelatin, shellac, sterculia gum, xanthan gum, Corn sugar gum, guar gum, gum karaya, agarose, alginic acid, alginate, or natural polymers thereof.
  • proteins and sugars such as deoxyribonucleic acid, rubber, cellulose, starch (e.g., amylose, amylopectin), proteins, enzymes, polysaccharides, silks, polyhydroxyalkanoates, chitosan, dextran, collagen, carrageenan, ispaghula, acacia, agar, gelatin, shellac, ster
  • Examples of synthetic polymers include acrylics, nylons, silicones, spandex, viscose rayon, polycarboxylic acids, polyvinyl acetate, polyacrylamide, polyacrylate, polyethylene glycol, polyurethanes, polylactic acid, silica, polystyrene, polyacrylonitrile, polybutadiene, polycarbonate, polyethylene, polyethylene terephthalate, poly(chlorotrifluoroethylene), poly(ethylene oxide), poly(ethylene terephthalate), polyethylene, polyisobutylene, poly(methyl methacrylate), poly(oxymethylene),
  • Beads may also be formed from materials other than polymers, including lipids, micelles, ceramics, glass- ceramics, material composites, metals, other inorganic materials, and others.
  • the bead may contain molecular precursors (e.g., monomers or polymers), which may form a polymer network via polymerization of the molecular precursors.
  • a precursor may be an already polymerized species capable of undergoing further polymerization via, for example, a chemical cross-linkage.
  • a precursor can comprise one or more of an acrylamide or a methacrylamide monomer, oligomer, or polymer.
  • the bead may comprise prepolymers, which are oligomers capable of further polymerization.
  • polyurethane beads may be prepared using prepolymers.
  • the bead may contain individual polymers that may be further polymerized together.
  • beads may be generated via polymerization of different precursors, such that they comprise mixed polymers, co-polymers, and/or block co-polymers.
  • the bead may comprise covalent or ionic bonds between polymeric precursors (e.g., monomers, oligomers, linear polymers), nucleic acid molecules (e.g., oligonucleotides), primers, and other entities.
  • the covalent bonds can be carbon-carbon bonds, thioether bonds, or carbon- heteroatom bonds.
  • Cross-linking may be permanent or reversible, depending upon the particular cross- linker used. Reversible cross-linking may allow for the polymer to linearize or dissociate under appropriate conditions. In some cases, reversible cross-linking may also allow for reversible attachment of a material bound to the surface of a bead. In some cases, a cross-linker may form disulfide linkages. In some cases, the chemical cross-linker forming disulfide linkages may be cystamine or a modified cystamine.
  • disulfide linkages can be formed between molecular precursor units (e.g., monomers, oligomers, or linear polymers) or precursors incorporated into a bead and nucleic acid molecules (e.g., oligonucleotides).
  • Cystamine is an organic agent comprising a disulfide bond that may be used as a crosslinker agent between individual monomelic or polymeric precursors of a bead.
  • Polyacrylamide may be polymerized in the presence of cystamine or a species comprising cystamine (e.g., a modified cystamine) to generate polyacryl amide gel beads comprising disulfide linkages (e.g., chemically degradable beads comprising chemically-reducible cross-linkers).
  • the disulfide linkages may permit the bead to be degraded (or dissolved) upon exposure of the bead to a reducing agent.
  • chitosan a linear polysaccharide polymer
  • glutaraldehyde via hydrophilic chains to form a bead.
  • Crosslinking of chitosan polymers may be achieved by chemical reactions that are initiated by heat, pressure, change in pH, and/or radiation.
  • a bead may comprise an acrydite moiety, which in certain aspects may be used to attach one or more nucleic acid molecules (e.g., barcode sequence, barcoded nucleic acid molecule, barcoded oligonucleotide, primer, or other oligonucleotide) to the bead.
  • an acrydite moiety can refer to an acrydite analogue generated from the reaction of acrydite with one or more species, such as, the reaction of acrydite with other monomers and cross-linkers during a polymerization reaction.
  • Acrydite moieties may be modified to form chemical bonds with a species to be attached, such as a nucleic acid molecule (e.g., barcode sequence, barcoded nucleic acid molecule, barcoded oligonucleotide, primer, or other oligonucleotide).
  • Acrydite moieties may be modified with thiol groups capable of forming a disulfide bond or may be modified with groups already comprising a disulfide bond. The thiol or disulfide (via disulfide exchange) may be used as an anchor point for a species to be attached or another part of the acrydite moiety may be used for attachment.
  • attachment can be reversible, such that when the disulfide bond is broken (e.g., in the presence of a reducing agent), the attached species is released from the bead.
  • an acrydite moiety can comprise a reactive hydroxyl group that may be used for attachment.
  • nucleic acid molecules e.g., oligonucleotides
  • Functionalization of beads for attachment of nucleic acid molecules may be achieved through a wide range of different approaches, including activation of chemical groups within a polymer, incorporation of active or activatable functional groups in the polymer structure, or attachment at the pre-polymer or monomer stage in bead production.
  • precursors e.g., monomers, cross-linkers
  • precursors that are polymerized to form a bead may comprise acrydite moieties, such that when a bead is generated, the bead also comprises acrydite moieties.
  • the acrydite moieties can be attached to a nucleic acid molecule (e.g., oligonucleotide), which may include a priming sequence (e.g., a primer for amplifying target nucleic acids, random primer, primer sequence for messenger RNA) and/or one or more barcode sequences.
  • the one more barcode sequences may include sequences that are the same for all nucleic acid molecules (e.g., nucleic acid barcode molecules) coupled to a given bead and/or sequences that are different across all nucleic acid molecules coupled to the given bead.
  • the nucleic acid molecule may be incorporated into the bead and/or may be attached to a surface of the bead.
  • the nucleic acid molecule (e.g., nucleic acid barcode molecule) can comprise a functional sequence, for example, for attachment to a sequencing flow cell, such as, for example, a P5 sequence for Illumina® sequencing.
  • a sequencing flow cell such as, for example, a P5 sequence for Illumina® sequencing.
  • the nucleic acid molecule e.g., nucleic acid barcode molecule
  • derivative thereof e.g., oligonucleotide or
  • polynucleotide generated from the nucleic acid molecule can comprise another functional sequence, such as, for example, a P7 sequence for attachment to a sequencing flow cell for Illumina sequencing.
  • the nucleic acid molecule can comprise a barcode sequence.
  • the primer can further comprise a unique molecular identifier (UMI).
  • UMI unique molecular identifier
  • the primer can comprise an Rl primer sequence for Illumina sequencing.
  • the primer can comprise an R2 primer sequence for Illumina sequencing. Examples of such nucleic acid molecules (e.g., oligonucleotides, polynucleotides, etc.) and uses thereof, as may be used with compositions, devices, methods and systems of the present disclosure, are provided in U.S. Patent Pub. Nos. 2014/0378345 and 2015/0376609, each of which is entirely incorporated herein by reference.
  • FIG. 8 illustrates an example of a barcode carrying bead.
  • a nucleic acid molecule 802 such as an oligonucleotide, can be coupled to a bead 804 by a releasable linkage 806, such as, for example, a disulfide linker.
  • the same bead 804 may be coupled (e.g., via releasable linkage) to one or more other nucleic acid molecules 818, 820.
  • the nucleic acid molecule 802 may be or comprise a barcode.
  • the structure of the barcode may comprise a number of sequence elements.
  • the nucleic acid molecule 802 may comprise a functional sequence 808 that may be used in subsequent processing.
  • the functional sequence 808 may include one or more of a sequencer specific flow cell attachment sequence (e.g., a P5 sequence for Illumina® sequencing systems) and a sequencing primer sequence (e.g., a Rl primer for Illumina® sequencing systems).
  • the nucleic acid molecule 802 may comprise a barcode sequence 810 for use in barcoding the sample (e.g., DNA, RNA, protein, etc.).
  • the barcode sequence 810 can be bead-specific such that the barcode sequence 810 is common to all nucleic acid molecules (e.g., including nucleic acid molecule 802) coupled to the same bead 804.
  • the barcode sequence 810 can be partition-specific such that the barcode sequence 810 is common to all nucleic acid molecules coupled to one or more beads that are partitioned into the same partition.
  • the nucleic acid molecule 802 may comprise a specific priming sequence 812, such as an mRNA specific priming sequence (e.g., poly-T sequence), a targeted priming sequence, and/or a random priming sequence.
  • the nucleic acid molecule 802 may comprise an anchoring sequence 814 to ensure that the specific priming sequence 812 hybridizes at the sequence end (e.g., of the mRNA).
  • the anchoring sequence 814 can include a random short sequence of nucleotides, such as a 1-mer, 2-mer, 3-mer or longer sequence, which can ensure that a poly-T segment is more likely to hybridize at the sequence end of the poly-A tail of the mRNA.
  • the nucleic acid molecule 802 may comprise a unique molecular identifying sequence 816 (e.g., unique molecular identifier (UMI)).
  • the unique molecular identifying sequence 816 may comprise from about 5 to about 8 nucleotides.
  • the unique molecular identifying sequence 816 may compress less than about 5 or more than about 8 nucleotides.
  • the unique molecular identifying sequence 816 may be a unique sequence that varies across individual nucleic acid molecules (e.g., 802, 818, 820, etc.) coupled to a single bead (e.g., bead 804).
  • the unique molecular identifying sequence 816 may be a random sequence (e.g., such as a random N-mer sequence).
  • the UMI may provide a unique identifier of the starting mRNA molecule that was captured, in order to allow
  • FIG. 8 shows three nucleic acid molecules 802, 818, 820 coupled to the surface of the bead 804, an individual bead may be coupled to any number of individual nucleic acid molecules, for example, from one to tens to hundreds of thousands or even millions of individual nucleic acid molecules.
  • the respective barcodes for the individual nucleic acid molecules can comprise both common sequence segments or relatively common sequence segments (e.g., 808, 810, 812, etc.) and variable or unique sequence segments (e.g., 816) between different individual nucleic acid molecules coupled to the same bead.
  • a biological particle e.g., cell, DNA, RNA, etc.
  • the barcoded nucleic acid molecules 802, 818, 820 can be released from the bead 804 in the partition.
  • the poly-T segment e.g., 812
  • one of the released nucleic acid molecules e.g., 802
  • Reverse transcription may result in a cDNA transcript of the mRNA, but which transcript includes each of the sequence segments 808, 810, 816 of the nucleic acid molecule 802.
  • the nucleic acid molecule 802 comprises an anchoring sequence 814, it will more likely hybridize to and prime reverse transcription at the sequence end of the poly-A tail of the mRNA.
  • all of the cDNA transcripts of the individual mRNA molecules may include a common barcode sequence segment 810.
  • the transcripts made from the different mRNA molecules within a given partition may vary at the unique molecular identifying sequence 812 segment (e.g., UMI segment).
  • UMI segment unique molecular identifying sequence
  • the number of different UMIs can be indicative of the quantity of mRNA originating from a given partition, and thus from the biological particle (e.g., cell).
  • the transcripts can be amplified, cleaned up and sequenced to identify the sequence of the cDNA transcript of the mRNA, as well as to sequence the barcode segment and the UMI segment.
  • nucleic acid molecules bound to the bead may be used to hybridize and capture the mRNA on the solid phase of the bead, for example, in order to facilitate the separation of the RNA from other cell contents.
  • precursors comprising a functional group that is reactive or capable of being activated such that it becomes reactive can be polymerized with other precursors to generate gel beads comprising the activated or activatable functional group.
  • the functional group may then be used to attach additional species (e.g., disulfide linkers, primers, other oligonucleotides, etc.) to the gel beads.
  • additional species e.g., disulfide linkers, primers, other oligonucleotides, etc.
  • some precursors comprising a carboxylic acid (COOH) group can co-polymerize with other precursors to form a gel bead that also comprises a COOH functional group.
  • acrylic acid a species comprising free COOH groups
  • acrylamide acrylamide
  • bis(acryloyl)cystamine can be co-polymerized together to generate a gel bead comprising free COOH groups.
  • the COOH groups of the gel bead can be activated (e.g., via l-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and N- Hydroxysuccinimide (NHS) or 4-(4,6-Dimethoxy-l,3,5-triazin-2-yl)-4-methylmo holinium chloride (DMTMM)) such that they are reactive (e.g., reactive to amine functional groups where EDC/NHS or DMTMM are used for activation).
  • EDC l-Ethyl-3-(3-dimethylaminopropyl)carbodiimide
  • NHS N- Hydroxysuccinimide
  • DTMM 4-(4,6-Dime
  • the activated COOH groups can then react with an appropriate species (e.g., a species comprising an amine functional group where the carboxylic acid groups are activated to be reactive with an amine functional group) comprising a moiety to be linked to the bead.
  • an appropriate species e.g., a species comprising an amine functional group where the carboxylic acid groups are activated to be reactive with an amine functional group
  • Beads comprising disulfide linkages in their polymeric network may be
  • the disulfide linkages may be reduced via, for example, the action of a reducing agent (e.g., DTT, TCEP, etc.) to generate free thiol groups, without dissolution of the bead.
  • a reducing agent e.g., DTT, TCEP, etc.
  • Free thiols of the beads can then react with free thiols of a species or a species comprising another disulfide bond (e.g., via thiol-disulfide exchange) such that the species can be linked to the beads (e.g., via a generated disulfide bond).
  • free thiols of the beads may react with any other suitable group.
  • free thiols of the beads may react with species comprising an acrydite moiety.
  • the free thiol groups of the beads can react with the acrydite via Michael addition chemistry, such that the species comprising the acrydite is linked to the bead.
  • uncontrolled reactions can be prevented by inclusion of a thiol capping agent such as N- ethylmalieamide or iodoacetate.
  • Activation of disulfide linkages within a bead can be controlled such that only a small number of disulfide linkages are activated. Control may be exerted, for example, by controlling the concentration of a reducing agent used to generate free thiol groups and/or concentration of reagents used to form disulfide bonds in bead polymerization. In some cases, a low concentration (e.g., molecules of reducing agen gel bead ratios of less than or equal to about 1 : 100,000,000,000, less than or equal to about 1 : 10,000,000,000, less than or equal to about 1 : 1,000,000,000, less than or equal to about 1 : 100,000,000, less than or equal to about
  • reducing agent may be used for reduction. Controlling the number of disulfide linkages that are reduced to free thiols may be useful in ensuring bead structural integrity during functionalization.
  • optically-active agents such as fluorescent dyes may be coupled to beads via free thiol groups of the beads and used to quantify the number of free thiols present in a bead and/or track a bead.
  • addition of moieties to a gel bead after gel bead formation may be advantageous.
  • addition of an oligonucleotide (e.g., barcoded oligonucleotide) after gel bead formation may avoid loss of the species during chain transfer termination that can occur during polymerization.
  • smaller precursors e.g., monomers or cross linkers that do not comprise side chain groups and linked moieties
  • oligonucleotides to be loaded with potentially damaging agents (e.g., free radicals) and/or chemical environments.
  • the generated gel may possess an upper critical solution temperature (UCST) that can permit temperature driven swelling and collapse of a bead.
  • UST upper critical solution temperature
  • Such functionality may aid in oligonucleotide (e.g., a primer) infiltration into the bead during subsequent functionalization of the bead with the oligonucleotide.
  • Species loading may also be performed in a batch process such that a plurality of beads can be functionalized with the species in a single batch.
  • a bead injected or otherwise introduced into a partition may comprise releasably, cleavably, or reversibly attached barcodes.
  • a bead injected or otherwise introduced into a partition may comprise activatable barcodes.
  • a bead injected or otherwise introduced into a partition may be degradable, disruptable, or dissolvable beads.
  • Barcodes can be releasably, cleavably or reversibly attached to the beads such that barcodes can be released or be releasable through cleavage of a linkage between the barcode molecule and the bead, or released through degradation of the underlying bead itself, allowing the barcodes to be accessed or be accessible by other reagents, or both.
  • cleavage may be achieved through reduction of di-sulfide bonds, use of restriction enzymes, photo-activated cleavage, or cleavage via other types of stimuli (e.g., chemical, thermal, pH, enzymatic, etc.) and/or reactions, such as described elsewhere herein.
  • Releasable barcodes may sometimes be referred to as being activatable, in that they are available for reaction once released.
  • an activatable barcode may be activated by releasing the barcode from a bead (or other suitable type of partition described herein).
  • Other activatable configurations are also envisioned in the context of the described methods and systems.
  • the beads may be degradable, disruptable, or dissolvable spontaneously or upon exposure to one or more stimuli (e.g., temperature changes, pH changes, exposure to particular chemical species or phase, exposure to light, reducing agent, etc.).
  • a bead may be dissolvable, such that material components of the beads are solubilized when exposed to a particular chemical species or an environmental change, such as a change temperature or a change in pH.
  • a gel bead can be degraded or dissolved at elevated temperature and/or in basic conditions.
  • a bead may be thermally degradable such that when the bead is exposed to an appropriate change in temperature (e.g., heat), the bead degrades.
  • Degradation or dissolution of a bead bound to a species e.g., a nucleic acid molecule, e.g., barcoded oligonucleotide
  • a species e.g., a nucleic acid molecule, e.g., barcoded oligonucleotide
  • the degradation of a bead may refer to the disassociation of a bound or entrained species from a bead, both with and without structurally degrading the physical bead itself.
  • the degradation of the bead may involve cleavage of a cleavable linkage via one or more species and/or methods described elsewhere herein.
  • entrained species may be released from beads through osmotic pressure differences due to, for example, changing chemical environments.
  • alteration of bead pore sizes due to osmotic pressure differences can generally occur without structural degradation of the bead itself.
  • an increase in pore size due to osmotic swelling of a bead can permit the release of entrained species within the bead.
  • osmotic shrinking of a bead may cause a bead to better retain an entrained species due to pore size contraction.
  • a degradable bead may be introduced into a partition, such as a droplet of an emulsion or a well, such that the bead degrades within the partition and any associated species (e.g., oligonucleotides) are released within the droplet when the appropriate stimulus is applied.
  • the free species e.g., oligonucleotides, nucleic acid molecules
  • a polyacrylamide bead comprising cystamine and linked, via a disulfide bond, to a barcode sequence, may be combined with a reducing agent within a droplet of a water-in-oil emulsion.
  • the reducing agent can break the various disulfide bonds, resulting in bead degradation and release of the barcode sequence into the aqueous, inner environment of the droplet.
  • heating of a droplet comprising a bead-bound barcode sequence in basic solution may also result in bead degradation and release of the attached barcode sequence into the aqueous, inner environment of the droplet.
  • oligonucleotide can be associated with a bead such that, upon release from the bead, the molecular tag molecules (e.g., primer, e.g., barcoded oligonucleotide) are present in the partition at a pre-defined concentration.
  • the pre-defined concentration may be selected to facilitate certain reactions for generating a sequencing library, e.g., amplification, within the partition.
  • the pre-defined concentration of the primer can be limited by the process of producing nucleic acid molecule (e.g., oligonucleotide) bearing beads.
  • beads can be non-covalently loaded with one or more reagents.
  • the beads can be non-covalently loaded by, for instance, subjecting the beads to conditions sufficient to swell the beads, allowing sufficient time for the reagents to diffuse into the interiors of the beads, and subjecting the beads to conditions sufficient to de-swell the beads.
  • the swelling of the beads may be accomplished, for instance, by placing the beads in a thermodynamically favorable solvent, subjecting the beads to a higher or lower temperature, subjecting the beads to a higher or lower ion concentration, and/or subjecting the beads to an electric field.
  • the swelling of the beads may be accomplished by various swelling methods.
  • the de-swelling of the beads may be accomplished, for instance, by transferring the beads in a thermodynamically
  • the de-swelling of the beads may be accomplished by various de-swelling methods. Transferring the beads may cause pores in the bead to shrink. The shrinking may then hinder reagents within the beads from diffusing out of the interiors of the beads. The hindrance may be due to steric interactions between the reagents and the interiors of the beads.
  • the transfer may be accomplished microfluidically. For instance, the transfer may be achieved by moving the beads from one co- flowing solvent stream to a different co-flowing solvent stream.
  • the swellability and/or pore size of the beads may be adjusted by changing the polymer composition of the bead.
  • an acrydite moiety linked to a precursor, another species linked to a precursor, or a precursor itself can comprise a labile bond, such as chemically, thermally, or photo-sensitive bond e.g., disulfide bond, UV sensitive bond, or the like.
  • a labile bond such as chemically, thermally, or photo-sensitive bond e.g., disulfide bond, UV sensitive bond, or the like.
  • the bead may also comprise the labile bond.
  • the labile bond may be, for example, useful in reversibly linking (e.g., covalently linking) species (e.g., barcodes, primers, etc.) to a bead.
  • a thermally labile bond may include a nucleic acid hybridization based attachment, e.g., where an
  • oligonucleotide is hybridized to a complementary sequence that is attached to the bead, such that thermal melting of the hybrid releases the oligonucleotide, e.g., a barcode containing sequence, from the bead or microcapsule.
  • each type of labile bond may be sensitive to an associated stimulus (e.g., chemical stimulus, light, temperature, enzymatic, etc.) such that release of species attached to a bead via each labile bond may be controlled by the application of the appropriate stimulus.
  • an associated stimulus e.g., chemical stimulus, light, temperature, enzymatic, etc.
  • Such functionality may be useful in controlled release of species from a gel bead.
  • another species comprising a labile bond may be linked to a gel bead after gel bead formation via, for example, an activated functional group of the gel bead as described above.
  • barcodes that are releasably, cleavably or reversibly attached to the beads described herein include barcodes that are released or releasable through cleavage of a linkage between the barcode molecule and the bead, or that are released through degradation of the underlying bead itself, allowing the barcodes to be accessed or accessible by other reagents, or both.
  • the barcodes that are releasable as described herein may sometimes be referred to as being activatable, in that they are available for reaction once released.
  • an activatable barcode may be activated by releasing the barcode from a bead (or other suitable type of partition described herein).
  • Other activatable configurations are also envisioned in the context of the described methods and systems.
  • labile bonds that may be coupled to a precursor or bead include an ester linkage (e.g., cleavable with an acid, a base, or hydroxylamine), a vicinal diol linkage (e.g., cleavable via sodium periodate), a Diels-Alder linkage (e.g., cleavable via heat), a sulfone linkage (e.g., cleavable via a base), a silyl ether linkage (e.g., cleavable via an acid), a glycosidic linkage (e.g., cleavable via an amylase), a peptide linkage (e.g., cleavable via a protease), or a phosphodiester linkage (e.g., cleavable via a nucle
  • ester linkage e.g., cleavable with an acid, a base, or hydroxylamine
  • Species may be encapsulated in beads during bead generation (e.g., during polymerization of precursors). Such species may or may not participate in polymerization. Such species may be entered into polymerization reaction mixtures such that generated beads comprise the species upon bead formation. In some cases, such species may be added to the gel beads after formation.
  • Such species may include, for example, nucleic acid molecules (e.g., oligonucleotides), reagents for a nucleic acid amplification reaction (e.g., primers, polymerases, dNTPs, co-factors (e.g., ionic co-factors), buffers) including those described herein, reagents for enzymatic reactions (e.g., enzymes, co-factors, substrates, buffers), reagents for nucleic acid modification reactions such as polymerization, ligation, or digestion, and/or reagents for template preparation (e.g., tagmentation) for one or more sequencing platforms (e.g., Nextera® for Illumina®).
  • nucleic acid molecules e.g., oligonucleotides
  • reagents for a nucleic acid amplification reaction e.g., primers, polymerases, dNTPs, co-factors (e.g., i
  • Such species may include one or more enzymes described herein, including without limitation, polymerase, reverse transcriptase, restriction enzymes (e.g., endonuclease), transposase, ligase, proteinase K, DNAse, etc.
  • Such species may include one or more reagents described elsewhere herein (e.g., lysis agents, inhibitors, inactivating agents, chelating agents, stimulus). Trapping of such species may be controlled by the polymer network density generated during polymerization of precursors, control of ionic charge within the gel bead (e.g., via ionic species linked to polymerized species), or by the release of other species.
  • Encapsulated species may be released from a bead upon bead degradation and/or by application of a stimulus capable of releasing the species from the bead.
  • species may be partitioned in a partition (e.g., droplet) during or subsequent to partition formation.
  • a partition e.g., droplet
  • Such species may include, without limitation, the abovementioned species that may also be encapsulated in a bead.
  • a degradable bead may comprise one or more species with a labile bond such that, when the bead/species is exposed to the appropriate stimuli, the bond is broken and the bead degrades.
  • the labile bond may be a chemical bond (e.g., covalent bond, ionic bond) or may be another type of physical interaction (e.g., van der Waals interactions, dipole-dipole interactions, etc.).
  • a crosslinker used to generate a bead may comprise a labile bond. Upon exposure to the appropriate conditions, the labile bond can be broken and the bead degraded.
  • a degradable bead may be useful in more quickly releasing an attached species (e.g., a nucleic acid molecule, a barcode sequence, a primer, etc) from the bead when the appropriate stimulus is applied to the bead as compared to a bead that does not degrade.
  • an attached species e.g., a nucleic acid molecule, a barcode sequence, a primer, etc
  • the species may have greater mobility and accessibility to other species in solution upon degradation of the bead.
  • a species may also be attached to a degradable bead via a degradable linker (e.g., disulfide linker).
  • the degradable linker may respond to the same stimuli as the degradable bead or the two degradable species may respond to different stimuli.
  • a barcode sequence may be attached, via a disulfide bond, to a polyacrylamide bead comprising cystamine. Upon exposure of the barcoded-bead to a reducing agent, the bead degrades and the barcode sequence is released upon breakage of both the disulfide linkage between the barcode sequence and the bead and the disulfide linkages of the cystamine in the bead.
  • degradation may refer to the disassociation of a bound or entrained species from a bead, both with and without structurally degrading the physical bead itself.
  • entrained species may be released from beads through osmotic pressure differences due to, for example, changing chemical environments.
  • alteration of bead pore sizes due to osmotic pressure differences can generally occur without structural degradation of the bead itself.
  • an increase in pore size due to osmotic swelling of a bead can permit the release of entrained species within the bead.
  • osmotic shrinking of a bead may cause a bead to better retain an entrained species due to pore size contraction.
  • degradable beads it may be beneficial to avoid exposing such beads to the stimulus or stimuli that cause such degradation prior to a given time, in order to, for example, avoid premature bead degradation and issues that arise from such degradation, including for example poor flow characteristics and aggregation.
  • beads comprise reducible cross-linking groups, such as disulfide groups
  • reducing agents e.g., DTT or other disulfide cleaving reagents.
  • treatment to the beads described herein will, in some cases be provided free of reducing agents, such as DTT.
  • reducing agent free (or DTT free) enzyme preparations in treating the beads described herein.
  • enzymes include, e.g., polymerase enzyme preparations, reverse transcriptase enzyme preparations, ligase enzyme preparations, as well as many other enzyme preparations that may be used to treat the beads described herein.
  • the terms "reducing agent free” or "DTT free” preparations can refer to a preparation having less than about 1/lOth, less than about l/50th, or even less than about 1/lOOth of the lower ranges for such materials used in degrading the beads.
  • the reducing agent free preparation can have less than about 0.01 millimolar (mM), 0.005 mM, 0.001 mM DTT, 0.0005 mM DTT, or even less than about 0.0001 mM DTT. In many cases, the amount of DTT can be undetectable.
  • Examples of these chemical changes may include, but are not limited to pH-mediated changes to the integrity of a component within the bead, degradation of a component of a bead via cleavage of cross-linked bonds, and depolymerization of a component of a bead.
  • a bead may be formed from materials that comprise degradable chemical crosslinkers, such as BAC or cystamine. Degradation of such degradable crosslinkers may be accomplished through a number of mechanisms.
  • a bead may be contacted with a chemical degrading agent that may induce oxidation, reduction or other chemical changes.
  • a chemical degrading agent may be a reducing agent, such as dithiothreitol (DTT).
  • reducing agents may include ⁇ -mercaptoethanol, (2S)-2-amino-l,4-dimercaptobutane (dithiobutylamine or DTBA), tris(2-carboxyethyl) phosphine (TCEP), or combinations thereof.
  • a reducing agent may degrade the disulfide bonds formed between gel precursors forming the bead, and thus, degrade the bead.
  • a change in pH of a solution such as an increase in pH, may trigger degradation of a bead.
  • exposure to an aqueous solution, such as water may trigger hydrolytic degradation, and thus degradation of the bead.
  • any combination of stimuli may trigger degradation of a bead.
  • a change in pH may enable a chemical agent (e.g., DTT) to become an effective reducing agent.
  • Beads may also be induced to release their contents upon the application of a thermal stimulus.
  • a change in temperature can cause a variety of changes to a bead. For example, heat can cause a solid bead to liquefy. A change in heat may cause melting of a bead such that a portion of the bead degrades. In other cases, heat may increase the internal pressure of the bead components such that the bead ruptures or explodes. Heat may also act upon heat-sensitive polymers used as materials to construct beads.
  • any suitable agent may degrade beads.
  • changes in temperature or pH may be used to degrade thermo-sensitive or pH-sensitive bonds within beads.
  • chemical degrading agents may be used to degrade chemical bonds within beads by oxidation, reduction or other chemical changes.
  • a chemical degrading agent may be a reducing agent, such as DTT, wherein DTT may degrade the disulfide bonds formed between a crosslinker and gel precursors, thus degrading the bead.
  • a reducing agent may be added to degrade the bead, which may or may not cause the bead to release its contents.
  • reducing agents may include dithiothreitol (DTT), ⁇ -mercaptoethanol, (2S)-2-amino-l,4-dimercaptobutane (dithiobutylamine or DTBA), tris(2- carboxyethyl) phosphine (TCEP), or combinations thereof.
  • the reducing agent may be present at a concentration of about 0. ImM, 0.5mM, ImM, 5mM, lOmM.
  • the reducing agent may be present at a concentration of at least about O. lmM, 0.5mM, ImM, 5mM, lOmM, or greater than 10 mM.
  • the reducing agent may be present at concentration of at most about lOmM, 5mM, ImM, 0.5mM, O. lmM, or less.
  • oligonucleotide can be associated with a bead such that, upon release from the bead, the molecular tag molecules (e.g., primer, e.g., barcoded oligonucleotide) are present in the partition at a pre-defined concentration.
  • the molecular tag molecules e.g., primer, e.g., barcoded oligonucleotide
  • pre-defined concentration may be selected to facilitate certain reactions for generating a sequencing library, e.g., amplification, within the partition.
  • the pre-defined concentration of the primer can be limited by the process of producing oligonucleotide bearing beads.
  • FIG. 1 and FIG. 2 have been described in terms of providing substantially singly occupied partitions, above, in certain cases, it may be desirable to provide multiply occupied partitions, e.g., containing two, three, four or more cells and/or microcapsules (e.g., beads) comprising barcoded nucleic acid molecules (e.g., oligonucleotides) within a single partition.
  • multiply occupied partitions e.g., containing two, three, four or more cells and/or microcapsules (e.g., beads) comprising barcoded nucleic acid molecules (e.g., oligonucleotides) within a single partition.
  • the flow characteristics of the biological particle and/or bead containing fluids and partitioning fluids may be controlled to provide for such multiply occupied partitions.
  • the flow parameters may be controlled to provide a given occupancy rate at greater than about 50% of the partitions, greater than about 75%, and in some cases greater than about 80%, 90%, 95%,
  • additional microcapsules can be used to deliver additional reagents to a partition.
  • the flow and frequency of the different beads into the channel or junction may be controlled to provide for a certain ratio of
  • microcapsules from each source while ensuring a given pairing or combination of such beads into a partition with a given number of biological particles (e.g., one biological particle and one bead per partition).
  • the partitions described herein may comprise small volumes, for example, less than about 10 microliters ( J ), 5 ⁇ , ⁇ ⁇ , 900 picoliters (pL), 800 pL, 700 pL, 600 pL, 500 pL, 400pL, 300 pL, 200 pL, lOOpL, 50 pL, 20 pL, 10 pL, 1 pL, 500 nanoliters (nL), 100 nL, 50 nL, or less.
  • small volumes for example, less than about 10 microliters ( J ), 5 ⁇ , ⁇ ⁇ , 900 picoliters (pL), 800 pL, 700 pL, 600 pL, 500 pL, 400pL, 300 pL, 200 pL, lOOpL, 50 pL, 20 pL, 10 pL, 1 pL, 500 nanoliters (nL), 100 nL, 50 nL, or less.
  • the droplets may have overall volumes that are less than about 1000 pL, 900 pL, 800 pL, 700 pL, 600 pL, 500 pL, 400pL, 300 pL, 200 pL, lOOpL, 50 pL, 20 pL, 10 pL, 1 pL, or less.
  • overall volumes that are less than about 1000 pL, 900 pL, 800 pL, 700 pL, 600 pL, 500 pL, 400pL, 300 pL, 200 pL, lOOpL, 50 pL, 20 pL, 10 pL, 1 pL, or less.
  • the sample fluid volume, e.g., including co-partitioned biological particles and/or beads, within the partitions may be less than about 90% of the above described volumes, less than about 80%, less than about 70%, less than about 60%, less than about 50%), less than about 40%>, less than about 30%>, less than about 20%>, or less than about 10%) of the above described volumes.
  • FIG. 49 shows exemplary parameters of - 1,000 pL droplets vs. smaller ⁇ 400 pL droplets. In some cases, the use of a smaller droplet size may result in a decrease in Poisson derived cell doublet rate. The use of a smaller droplet size may also result in an ⁇ 2-fold increase in cell throughput.
  • partitioning species may generate a population or plurality of partitions.
  • any suitable number of partitions can be generated or otherwise provided. For example, at least about 1,000 partitions, at least about 5,000 partitions, at least about 10,000 partitions, at least about 50,000 partitions, at least about 100,000 partitions, at least about 500,000 partitions, at least about 1,000,000 partitions, at least about 5,000,000 partitions at least about 10,000,000 partitions, at least about 50,000,000 partitions, at least about 100,000,000 partitions, at least about 500,000,000 partitions, at least about 1,000,000,000 partitions, or more partitions can be generated or otherwise provided.
  • the plurality of partitions may comprise both unoccupied partitions (e.g., empty partitions) and occupied partitions.
  • biological particles may be partitioned along with lysis reagents in order to release the contents of the biological particles within the partition.
  • the lysis agents can be contacted with the biological particle suspension concurrently with, or immediately prior to, the introduction of the biological particles into the partitioning junction/droplet generation zone (e.g., junction 210), such as through an additional channel or channels upstream of the channel junction.
  • biological particles may be partitioned along with other reagents, as will be described further below.
  • FIG. 3 shows an example of a microfluidic channel structure 300 for co-partitioning biological particles and reagents.
  • the channel structure 300 can include channel segments 301, 302, 304, 306 and 308. Channel segments 301 and 302 communicate at a first channel junction
  • Channel segments 302, 304, 306, and 308 communicate at a second channel junction 310.
  • the channel segment 301 may transport an aqueous fluid 312 that includes a plurality of biological particles 314 along the channel segment 301 into the second junction 310.
  • channel segment 301 may transport beads (e.g., gel beads).
  • the beads may comprise barcode molecules.
  • the channel segment 301 may be connected to a reservoir comprising an aqueous suspension of biological particles 314. Upstream of, and immediately prior to reaching, the second junction 310, the channel segment 301 may meet the channel segment 302 at the first junction 309.
  • the channel segment 302 may transport a plurality of reagents 315 (e.g., lysis agents) suspended in the aqueous fluid 312 along the channel segment 302 into the first junction 309.
  • the channel segment 302 may be connected to a reservoir comprising the reagents 315.
  • the aqueous fluid 312 in the channel segment 301 can carry both the biological particles 314 and the reagents 315 towards the second junction 310.
  • the aqueous fluid 312 in the channel segment 301 can include one or more reagents, which can be the same or different reagents as the reagents 315.
  • a second fluid 316 that is immiscible with the aqueous fluid 312 e.g., oil
  • the aqueous fluid 312 can be partitioned as discrete droplets 318 in the second fluid 316 and flow away from the second junction 310 along channel segment 308.
  • the channel segment 308 may deliver the discrete droplets 318 to an outlet reservoir fluidly coupled to the channel segment 308, where they may be harvested.
  • the second fluid 316 can comprise an oil, such as a fluorinated oil, that includes a fluorosurfactant for stabilizing the resulting droplets, for example, inhibiting subsequent coalescence of the resulting droplets 318.
  • an oil such as a fluorinated oil, that includes a fluorosurfactant for stabilizing the resulting droplets, for example, inhibiting subsequent coalescence of the resulting droplets 318.
  • a discrete droplet generated may include an individual biological particle 314 and/or one or more reagents 315.
  • a discrete droplet generated may include a barcode carrying bead (not shown), such as via other microfluidics structures described elsewhere herein.
  • a discrete droplet may be unoccupied (e.g., no reagents, no biological particles).
  • the lysis reagents can facilitate the release of the contents of the biological particles within the partition.
  • the contents released in a partition may remain discrete from the contents of other partitions.
  • the channel segments described herein may be coupled to any of a variety of different fluid sources or receiving components, including reservoirs, tubing, manifolds, or fluidic components of other systems.
  • the microfluidic channel structure 300 may have other geometries. For example, a microfluidic channel structure can have more than two channel junctions.
  • a microfluidic channel structure can have 2, 3, 4, 5 channel segments or more each carrying the same or different types of beads, reagents, and/or biological particles that meet at a channel junction. Fluid flow in each channel segment may be controlled to control the partitioning of the different elements into droplets. Fluid may be directed flow along one or more channels or reservoirs via one or more fluid flow units.
  • a fluid flow unit can comprise compressors (e.g., providing positive pressure), pumps (e.g., providing negative pressure), actuators, and the like to control flow of the fluid. Fluid may also or otherwise be controlled via applied pressure differentials, centrifugal force, electrokinetic pumping, vacuum, capillary or gravity flow, or the like.
  • lysis agents include bioactive reagents, such as lysis enzymes that are used for lysis of different cell types, e.g., gram positive or negative bacteria, plants, yeast, mammalian, etc., such as lysozymes, achromopeptidase, lysostaphin, labiase, kitalase, lyticase, and a variety of other lysis enzymes available from, e.g., Sigma-Aldrich, Inc. (St Louis, MO), as well as other commercially available lysis enzymes.
  • Other lysis agents may additionally or alternatively be co-partitioned with the biological particles to cause the release of the biological particles' s contents into the partitions.
  • surfactant-based lysis solutions may be used to lyse cells, although these may be less desirable for emulsion based systems where the surfactants can interfere with stable emulsions.
  • lysis solutions may include non-ionic surfactants such as, for example, TritonX-100 and Tween 20.
  • lysis solutions may include ionic surfactants such as, for example, sarcosyl and sodium dodecyl sulfate (SDS).
  • Electroporation, thermal, acoustic or mechanical cellular disruption may also be used in certain cases, e.g., non-emulsion based partitioning such as encapsulation of biological particles that may be in addition to or in place of droplet partitioning, where any pore size of the encapsulate is sufficiently small to retain nucleic acid fragments of a given size, following cellular disruption.
  • non-emulsion based partitioning such as encapsulation of biological particles that may be in addition to or in place of droplet partitioning, where any pore size of the encapsulate is sufficiently small to retain nucleic acid fragments of a given size, following cellular disruption.
  • reagents can also be co-partitioned with the biological particles, including, for example, DNase and RNase inactivating agents or inhibitors, such as proteinase K, chelating agents, such as EDTA, and other reagents employed in removing or otherwise reducing negative activity or impact of different cell lysate components on subsequent processing of nucleic acids.
  • DNase and RNase inactivating agents or inhibitors such as proteinase K
  • chelating agents such as EDTA
  • the biological particles may be exposed to an appropriate stimulus to release the biological particles or their contents from a co-partitioned microcapsule.
  • a chemical stimulus may be co-partitioned along with an encapsulated biological particle to allow for the degradation of the microcapsule and release of the cell or its contents into the larger partition.
  • this stimulus may be the same as the stimulus described elsewhere herein for release of nucleic acid molecules (e.g., oligonucleotides) from their respective microcapsule (e.g., bead).
  • this may be a different and non-overlapping stimulus, in order to allow an encapsulated biological particle to be released into a partition at a different time from the release of nucleic acid molecules into the same partition.
  • Additional reagents may also be co-partitioned with the biological particles, such as endonucleases to fragment a biological particle's DNA, DNA polymerase enzymes and dNTPs used to amplify the biological particle's nucleic acid fragments and to attach the barcode molecular tags to the amplified fragments.
  • Other enzymes may be co-partitioned, including without limitation, polymerase, transposase, ligase, proteinase K, DNAse, etc.
  • Additional reagents may also include reverse transcriptase enzymes, including enzymes with terminal transferase activity, primers and oligonucleotides, and switch oligonucleotides (also referred to herein as "switch oligos" or "template switching oligonucleotides”) which can be used for template switching.
  • reverse transcriptase enzymes including enzymes with terminal transferase activity
  • primers and oligonucleotides include primers and oligonucleotides, and switch oligonucleotides (also referred to herein as "switch oligos" or "template switching oligonucleotides”) which can be used for template switching.
  • switch oligonucleotides also referred to herein as "switch oligos” or "template switching oligonucleotides” which can be used for template switching.
  • template switching can be used to increase the length of a cDNA.
  • template switching can
  • cDNA can be generated from reverse transcription of a template, e.g., cellular mRNA, where a reverse transcriptase with terminal transferase activity can add additional nucleotides, e.g., polyC, to the cDNA in a template independent manner.
  • Switch oligos can include sequences complementary to the additional nucleotides, e.g., polyG.
  • the additional nucleotides (e.g., polyC) on the cDNA can hybridize to the additional nucleotides (e.g., polyG) on the switch oligo, whereby the switch oligo can be used by the reverse transcriptase as template to further extend the cDNA.
  • Template switching oligonucleotides may comprise a hybridization region and a template region.
  • the hybridization region can comprise any sequence capable of hybridizing to the target.
  • the hybridization region comprises a series of G bases to complement the overhanging C bases at the 3' end of a cDNA molecule.
  • the series of G bases may comprise 1 G base, 2 G bases, 3 G bases, 4 G bases, 5 G bases or more than 5 G bases.
  • the template sequence can comprise any sequence to be incorporated into the cDNA.
  • the template region comprises at least 1 (e.g., at least 2, 3, 4, 5 or more) tag sequences and/or functional sequences.
  • Switch oligos may comprise deoxyribonucleic acids; ribonucleic acids; modified nucleic acids including 2-Aminopurine, 2,6-Diaminopurine (2-Amino-dA), inverted dT, 5-Methyl dC, 2'-deoxyInosine, Super T (5-hydroxybutynl-2'-deoxyuridine), Super G (8-aza-
  • LNAs locked nucleic acids
  • UNAs unlocked nucleic acids
  • Iso-dG Iso-dC
  • 2' Fluoro bases e.g., Fluoro C, Fluoro U, Fluoro A, and Fluoro G
  • the length of a switch oligo may be at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112,
  • the length of a switch oligo may be at most about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112,
  • the macromolecular components e.g., macromolecular constituents of biological particles, such as RNA, DNA, or proteins
  • the macromolecular component contents of individual biological particles can be provided with unique identifiers such that, upon characterization of those macromolecular components they may be attributed as having been derived from the same biological particle or particles.
  • unique identifiers e.g., in the form of nucleic acid barcodes can be assigned or associated with individual biological particles or populations of biological particles, in order to tag or label the biological particle's macromolecular components (and as a result, its
  • unique identifiers can then be used to attribute the biological particle's components and characteristics to an individual biological particle or group of biological particles.
  • this is performed by co-partitioning the individual biological particle or groups of biological particles with the unique identifiers, such as described above (with reference to FIG. 2).
  • the unique identifiers are provided in the form of nucleic acid molecules (e.g., oligonucleotides) that comprise nucleic acid barcode sequences that may be attached to or otherwise associated with the nucleic acid contents of individual biological particle, or to other components of the biological particle, and particularly to fragments of those nucleic acids.
  • the nucleic acid molecules are partitioned such that as between nucleic acid molecules in a given partition, the nucleic acid barcode sequences contained therein are the same, but as between different partitions, the nucleic acid molecule can, and do have differing barcode sequences, or at least represent a large number of different barcode sequences across all of the partitions in a given analysis. In some aspects, only one nucleic acid barcode sequence can be associated with a given partition, although in some cases, two or more different barcode sequences may be present.
  • the nucleic acid barcode sequences can include from about 6 to about 20 or more nucleotides within the sequence of the nucleic acid molecules (e.g., oligonucleotides).
  • the nucleic acid barcode sequences can include from about 6 to about 20, 30, 40, 50, 60, 70, 80, 90, 100 or more nucleotides.
  • the length of a barcode sequence may be about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 nucleotides or longer.
  • the length of a barcode sequence may be at least about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 nucleotides or longer.
  • the length of a barcode sequence may be at most about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 nucleotides or shorter. These nucleotides may be completely contiguous, i.e., in a single stretch of adjacent nucleotides, or they may be separated into two or more separate subsequences that are separated by 1 or more nucleotides. In some cases, separated barcode subsequences can be from about 4 to about 16 nucleotides in length. In some cases, the barcode subsequence may be about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 nucleotides or longer.
  • the barcode subsequence may be at least about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 nucleotides or longer. In some cases, the barcode subsequence may be at most about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 nucleotides or shorter.
  • the co-partitioned nucleic acid molecules can also comprise other functional sequences useful in the processing of the nucleic acids from the co-partitioned biological particles.
  • These sequences include, e.g., targeted or random/universal amplification primer sequences for amplifying the genomic DNA from the individual biological particles within the partitions while attaching the associated barcode sequences, sequencing primers or primer recognition sites, hybridization or probing sequences, e.g., for identification of presence of the sequences or for pulling down barcoded nucleic acids, or any of a number of other potential functional sequences.
  • oligonucleotides may also be employed, including, e.g., coalescence of two or more droplets, where one droplet contains oligonucleotides, or microdispensing of oligonucleotides into partitions, e.g., droplets within microfluidic systems.
  • microcapsules such as beads, are provided that each include large numbers of the above described barcoded nucleic acid molecules (e.g., barcoded
  • hydrogel beads e.g., comprising polyacrylamide polymer matrices, are used as a solid support and delivery vehicle for the nucleic acid molecules into the partitions, as they are capable of carrying large numbers of nucleic acid molecules, and may be configured to release those nucleic acid molecules upon exposure to a particular stimulus, as described elsewhere herein.
  • the population of beads provides a diverse barcode sequence library that includes at least about 1,000 different barcode sequences, at least about 5,000 different barcode sequences, at least about 10,000 different barcode sequences, at least about 50,000 different barcode sequences, at least about 100,000 different barcode sequences, at least about 1,000,000 different barcode sequences, at least about 5,000,000 different barcode sequences, or at least about 10,000,000 different barcode sequences, or more.
  • each bead can be provided with large numbers of nucleic acid (e.g., oligonucleotide) molecules attached.
  • the number of molecules of nucleic acid molecules including the barcode sequence on an individual bead can be at least about 1,000 nucleic acid molecules, at least about 5,000 nucleic acid molecules, at least about 10,000 nucleic acid molecules, at least about 50,000 nucleic acid molecules, at least about 100,000 nucleic acid molecules, at least about 500,000 nucleic acids, at least about 1,000,000 nucleic acid molecules, at least about 5,000,000 nucleic acid molecules, at least about 10,000,000 nucleic acid molecules, at least about 50,000,000 nucleic acid molecules, at least about 100,000,000 nucleic acid molecules, at least about
  • Nucleic acid molecules of a given bead can include identical (or common) barcode sequences, different barcode sequences, or a combination of both. Nucleic acid molecules of a given bead can include multiple sets of nucleic acid molecules. Nucleic acid molecules of a given set can include identical barcode sequences. The identical barcode sequences can be different from barcode sequences of nucleic acid molecules of another set.
  • the resulting population of partitions can also include a diverse barcode library that includes at least about 1,000 different barcode sequences, at least about 5,000 different barcode sequences, at least about 10,000 different barcode sequences, at least at least about 50,000 different barcode sequences, at least about 100,000 different barcode sequences, at least about 1,000,000 different barcode sequences, at least about 5,000,000 different barcode sequences, or at least about 10,000,000 different barcode sequences.
  • each partition of the population can include at least about 1,000 nucleic acid molecules, at least about 5,000 nucleic acid molecules, at least about 10,000 nucleic acid molecules, at least about 50,000 nucleic acid molecules, at least about 100,000 nucleic acid molecules, at least about 500,000 nucleic acids, at least about 1,000,000 nucleic acid molecules, at least about 5,000,000 nucleic acid molecules, at least about 10,000,000 nucleic acid molecules, at least about 50,000,000 nucleic acid molecules, at least about 100,000,000 nucleic acid molecules, at least about 250,000,000 nucleic acid molecules and in some cases at least about 1 billion nucleic acid molecules.
  • a mixed, but known set of barcode sequences may provide greater assurance of identification in the subsequent processing, e.g., by providing a stronger address or attribution of the barcodes to a given partition, as a duplicate or independent confirmation of the output from a given partition.
  • the nucleic acid molecules are releasable from the beads upon the application of a particular stimulus to the beads.
  • the stimulus may be a photo-stimulus, e.g., through cleavage of a photo-labile linkage that releases the nucleic acid molecules.
  • a thermal stimulus may be used, where elevation of the temperature of the beads environment will result in cleavage of a linkage or other release of the nucleic acid molecules form the beads.
  • a chemical stimulus can be used that cleaves a linkage of the nucleic acid molecules to the beads, or otherwise results in release of the nucleic acid molecules from the beads.
  • such compositions include the polyacrylamide matrices described above for encapsulation of biological particles, and may be degraded for release of the attached nucleic acid molecules through exposure to a reducing agent, such as DTT.
  • Droplet size may be controlled by adjusting certain geometric features in channel architecture (e.g., microfluidics channel architecture). For example, an expansion angle, width, and/or length of a channel may be adjusted to control droplet size.
  • channel architecture e.g., microfluidics channel architecture
  • FIG. 4 shows an example of a microfluidic channel structure for the controlled partitioning of beads into discrete droplets.
  • a channel structure 400 can include a channel segment 402 communicating at a channel junction 406 (or intersection) with a reservoir 404.
  • the reservoir 404 can be a chamber. Any reference to "reservoir,” as used herein, can also refer to a "chamber.”
  • an aqueous fluid 408 that includes suspended beads 412 may be transported along the channel segment 402 into the junction 406 to meet a second fluid 410 that is immiscible with the aqueous fluid 408 in the reservoir 404 to create droplets 416, 418 of the aqueous fluid 408 flowing into the reservoir 404.
  • droplets can form based on factors such as the hydrodynamic forces at the junction 406, flow rates of the two fluids 408, 410, fluid properties, and certain geometric parameters (e.g., w, h 0 , a, etc.) of the channel structure 400.
  • a plurality of droplets can be collected in the reservoir 404 by continuously injecting the aqueous fluid 408 from the channel segment 402 through the junction 406.
  • a discrete droplet generated may include a bead (e.g., as in occupied droplets 416). Alternatively, a discrete droplet generated may include more than one bead. Alternatively, a discrete droplet generated may not include any beads (e.g., as in unoccupied droplet 418). In some instances, a discrete droplet generated may contain one or more biological particles, as described elsewhere herein. In some instances, a discrete droplet generated may comprise one or more reagents, as described elsewhere herein.
  • the aqueous fluid 408 can have a substantially uniform
  • the beads 412 can be introduced into the channel segment 402 from a separate channel (not shown in FIG. 4).
  • the frequency of beads 412 in the channel segment 402 may be controlled by controlling the frequency in which the beads 412 are introduced into the channel segment 402 and/or the relative flow rates of the fluids in the channel segment 402 and the separate channel.
  • the beads can be introduced into the channel segment 402 from a plurality of different channels, and the frequency controlled accordingly.
  • the aqueous fluid 408 in the channel segment 402 can comprise biological particles (e.g., described with reference to FIGS. 1 and 2).
  • the aqueous fluid 408 can have a substantially uniform concentration or frequency of biological particles.
  • the biological particles can be introduced into the channel segment 402 from a separate channel.
  • the frequency or concentration of the biological particles in the aqueous fluid 408 in the channel segment 402 may be controlled by controlling the frequency in which the biological particles are introduced into the channel segment 402 and/or the relative flow rates of the fluids in the channel segment 402 and the separate channel.
  • the biological particles can be introduced into the channel segment 402 from a plurality of different channels, and the frequency controlled accordingly.
  • a first separate channel can introduce beads and a second separate channel can introduce biological particles into the channel segment 402. The first separate channel introducing the beads may be upstream or downstream of the second separate channel introducing the biological particles.
  • the second fluid 410 can comprise an oil, such as a fluorinated oil, that includes a fluorosurfactant for stabilizing the resulting droplets, for example, inhibiting subsequent coalescence of the resulting droplets.
  • an oil such as a fluorinated oil, that includes a fluorosurfactant for stabilizing the resulting droplets, for example, inhibiting subsequent coalescence of the resulting droplets.
  • the second fluid 410 may not be subjected to and/or directed to any flow in or out of the reservoir 404.
  • the second fluid 410 may be substantially stationary in the reservoir 404.
  • the second fluid 410 may be subjected to flow within the reservoir 404, but not in or out of the reservoir 404, such as via application of pressure to the reservoir 404 and/or as affected by the incoming flow of the aqueous fluid 408 at the junction 406.
  • the second fluid 410 may be subjected and/or directed to flow in or out of the reservoir 404.
  • the reservoir 404 can be a channel directing the second fluid 410 from upstream to downstream, transporting the generated droplets.
  • the channel structure 400 at or near the junction 406 may have certain geometric features that at least partly determine the sizes of the droplets formed by the channel structure 400.
  • the channel segment 402 can have a height, h 0 and width, w, at or near the junction 406.
  • the channel segment 402 can comprise a rectangular cross-section that leads to a reservoir 404 having a wider cross-section (such as in width or diameter).
  • the cross-section of the channel segment 402 can be other shapes, such as a circular shape, trapezoidal shape, polygonal shape, or any other shapes.
  • the top and bottom walls of the reservoir 404 at or near the junction 406 can be inclined at an expansion angle, a.
  • the expansion angle, a allows the tongue (portion of the aqueous fluid 408 leaving channel segment 402 at junction 406 and entering the reservoir 404 before droplet formation) to increase in depth and facilitate decrease in curvature of the intermediately formed droplet.
  • Droplet size may decrease with increasing expansion angle.
  • the resulting droplet radius, 3 ⁇ 4 may be predicted by the following equation for the aforementioned geometric parameters of ho, w, and a:
  • the predicted droplet size is 121 ⁇ .
  • the predicted droplet size is 123 ⁇ .
  • the predicted droplet size is 124 ⁇ .
  • the expansion angle, a may be between a range of from about
  • the expansion angle can be at least about 0.0F, 0. ⁇ , 0.2°, 0.3°, 0.4°, 0.5°, 0.6°, 0.7°, 0.8°, 0.9°, 1°,
  • the expansion angle can be at most about 89°, 88°, 87°,
  • the width, w can be between a range of from about 100 micrometers ( ⁇ ) to about 500 ⁇ . In some instances, the width, w, can be between a range of from about 10 ⁇ to about 200 ⁇ . Alternatively, the width can be less than about 10 ⁇ . Alternatively, the width can be greater than about 500 ⁇ .
  • the flow rate of the aqueous fluid 408 entering the junction 406 can be between about 0.04 microliters ⁇ L)/minute (min) and about 40 ⁇ 7 ⁇ . In some instances, the flow rate of the aqueous fluid 408 entering the junction 406 can be between about 0.01 microliters ⁇ L)/minute (min) and about 100 ⁇ 7 ⁇ . Alternatively, the flow rate of the aqueous fluid 408 entering the junction 406 can be less than about 0.01 ⁇ 7 ⁇ .
  • the flow rate of the aqueous fluid 408 entering the junction 406 can be greater than about 40 ⁇ 7 ⁇ , such as 45 ⁇ 7 ⁇ , 50 ⁇ 7 ⁇ , 55 ⁇ 7 ⁇ , 60 ⁇ 7 ⁇ , 65 ⁇ 7 ⁇ , 70 ⁇ 7 ⁇ , 75 ⁇ 7 ⁇ , 80 ⁇ 7 ⁇ , 85 ⁇ 7 ⁇ , 90 ⁇ 7 ⁇ , 95 ⁇ 7 ⁇ , 100 ⁇ 7 ⁇ , 110 ⁇ 7 ⁇ , 120 ⁇ 7 ⁇ , 130 ⁇ 7 ⁇
  • the droplet radius may not be dependent on the flow rate of the aqueous fluid 408 entering the junction 406.
  • At least about 50% of the droplets generated can have uniform size. In some instances, at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%), 98%), 99%), or greater of the droplets generated can have uniform size. Alternatively, less than about 50% of the droplets generated can have uniform size.
  • the throughput of droplet generation can be increased by increasing the points of generation, such as increasing the number of junctions (e.g., junction 406) between aqueous fluid 408 channel segments (e.g., channel segment 402) and the reservoir 404.
  • the throughput of droplet generation can be increased by increasing the flow rate of the aqueous fluid 408 in the channel segment 402.
  • FIG. 5 shows an example of a microfluidic channel structure for increased droplet generation throughput.
  • a microfluidic channel structure 500 can comprise a plurality of channel segments 502 and a reservoir 504. Each of the plurality of channel segments 502 may be in fluid communication with the reservoir 504.
  • the channel structure 500 can comprise a plurality of channel junctions 506 between the plurality of channel segments 502 and the reservoir 504. Each channel junction can be a point of droplet generation.
  • the channel segment 402 from the channel structure 400 in FIG. 4 and any description to the components thereof may correspond to a given channel segment of the plurality of channel segments 502 in channel structure 500 and any description to the corresponding components thereof.
  • the reservoir 404 from the channel structure 400 and any description to the components thereof may correspond to the reservoir 504 from the channel structure 500 and any description to the corresponding components thereof.
  • Each channel segment of the plurality of channel segments 502 may comprise an aqueous fluid 508 that includes suspended beads 512.
  • the reservoir 504 may comprise a second fluid 510 that is immiscible with the aqueous fluid 508.
  • the second fluid 510 may not be subjected to and/or directed to any flow in or out of the reservoir 504.
  • the second fluid 510 may be substantially stationary in the reservoir 504.
  • the second fluid 510 may be subjected to flow within the reservoir 504, but not in or out of the reservoir 504, such as via application of pressure to the reservoir 504 and/or as affected by the incoming flow of the aqueous fluid 508 at the junctions.
  • the second fluid 510 may be subjected and/or directed to flow in or out of the reservoir 504.
  • the reservoir 504 can be a channel directing the second fluid 510 from upstream to downstream, transporting the generated droplets.
  • the aqueous fluid 508 that includes suspended beads 512 may be transported along the plurality of channel segments 502 into the plurality of junctions 506 to meet the second fluid 510 in the reservoir 504 to create droplets 516, 518.
  • a droplet may form from each channel segment at each corresponding junction with the reservoir 504.
  • droplets can form based on factors such as the hydrodynamic forces at the junction, flow rates of the two fluids 508, 510, fluid properties, and certain geometric parameters (e.g., w, h 0 , a, etc.) of the channel structure 500, as described elsewhere herein.
  • a plurality of droplets can be collected in the reservoir 504 by continuously injecting the aqueous fluid 508 from the plurality of channel segments 502 through the plurality of junctions 506.
  • Throughput may significantly increase with the parallel channel configuration of channel structure 500.
  • a channel structure having five inlet channel segments comprising the aqueous fluid 508 may generate droplets five times as frequently than a channel structure having one inlet channel segment, provided that the fluid flow rate in the channel segments are substantially the same.
  • the fluid flow rate in the different inlet channel segments may or may not be substantially the same.
  • a channel structure may have as many parallel channel segments as is practical and allowed for the size of the reservoir.
  • the channel structure may have at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 500, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 1500, 5000 or more parallel or substantially parallel channel segments.
  • the geometric parameters, w, h 0 , and a may or may not be uniform for each of the channel segments in the plurality of channel segments 502.
  • each channel segment may have the same or different widths at or near its respective channel junction with the reservoir 504.
  • each channel segment may have the same or different height at or near its respective channel junction with the reservoir 504.
  • the reservoir 504 may have the same or different expansion angle at the different channel junctions with the plurality of channel segments 502.
  • droplet size may also be controlled to be uniform even with the increased throughput.
  • the geometric parameters for the plurality of channel segments 502 may be varied accordingly.
  • At least about 50% of the droplets generated can have uniform size. In some instances, at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%), 98%), 99%), or greater of the droplets generated can have uniform size. Alternatively, less than about 50% of the droplets generated can have uniform size.
  • FIG. 6 shows another example of a microfluidic channel structure for increased droplet generation throughput.
  • a microfluidic channel structure 600 can comprise a plurality of channel segments 602 arranged generally circularly around the perimeter of a reservoir 604. Each of the plurality of channel segments 602 may be in fluid communication with the reservoir 604.
  • the channel structure 600 can comprise a plurality of channel junctions 606 between the plurality of channel segments 602 and the reservoir 604. Each channel junction can be a point of droplet generation.
  • the channel segment 402 from the channel structure 400 in FIG. 2 and any description to the components thereof may correspond to a given channel segment of the plurality of channel segments 602 in channel structure 600 and any description to the
  • Each channel segment of the plurality of channel segments 602 may comprise an aqueous fluid 608 that includes suspended beads 612.
  • the reservoir 604 may comprise a second fluid 610 that is immiscible with the aqueous fluid 608.
  • the second fluid 610 may not be subjected to and/or directed to any flow in or out of the reservoir 604.
  • the second fluid 610 may be substantially stationary in the reservoir 604.
  • the second fluid 610 may be subjected to flow within the reservoir 604, but not in or out of the reservoir 604, such as via application of pressure to the reservoir 604 and/or as affected by the incoming flow of the aqueous fluid 608 at the junctions.
  • the second fluid 610 may be subjected and/or directed to flow in or out of the reservoir 604.
  • the reservoir 604 can be a channel directing the second fluid 610 from upstream to downstream, transporting the generated droplets.
  • the aqueous fluid 608 that includes suspended beads 612 may be transported along the plurality of channel segments 602 into the plurality of junctions 606 to meet the second fluid 610 in the reservoir 604 to create a plurality of droplets 616.
  • a droplet may form from each channel segment at each corresponding junction with the reservoir 604.
  • droplets can form based on factors such as the hydrodynamic forces at the junction, flow rates of the two fluids 608, 610, fluid properties, and certain geometric parameters (e.g., widths and heights of the channel segments 602, expansion angle of the reservoir 604, etc.) of the channel structure 600, as described elsewhere herein.
  • a plurality of droplets can be collected in the reservoir 604 by continuously injecting the aqueous fluid 608 from the plurality of channel segments 602 through the plurality of junctions 606. Throughput may significantly increase with the substantially parallel channel configuration of the channel structure 600.
  • a channel structure may have as many substantially parallel channel segments as is practical and allowed for by the size of the reservoir.
  • the channel structure may have at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, 1000, 1500, 5000 or more parallel or substantially parallel channel segments.
  • the plurality of channel segments may be substantially evenly spaced apart, for example, around an edge or perimeter of the reservoir. Alternatively, the spacing of the plurality of channel segments may be uneven.
  • the reservoir 604 may have an expansion angle, a (not shown in FIG. 6) at or near each channel junction.
  • Each channel segment of the plurality of channel segments 602 may have a width, w, and a height, h 0 , at or near the channel junction.
  • the geometric parameters, w, h 0 , and a may or may not be uniform for each of the channel segments in the plurality of channel segments 602.
  • each channel segment may have the same or different widths at or near its respective channel junction with the reservoir 604.
  • each channel segment may have the same or different height at or near its respective channel junction with the reservoir
  • the reservoir 604 may have the same or different expansion angle at the different channel junctions with the plurality of channel segments 602.
  • a circular reservoir (as shown in FIG. 6) may have a conical, dome-like, or hemispherical ceiling (e.g., top wall) to provide the same or substantially same expansion angle for each channel segments 602 at or near the plurality of channel junctions 606.
  • the geometric parameters are uniform, beneficially, resulting droplet size may be controlled to be uniform even with the increased throughput.
  • the geometric parameters for the plurality of channel segments 602 may be varied accordingly.
  • At least about 50% of the droplets generated can have uniform size. In some instances, at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%), 98%), 99%), or greater of the droplets generated can have uniform size. Alternatively, less than about 50% of the droplets generated can have uniform size.
  • the beads and/or biological particle injected into the droplets may or may not have uniform size.
  • FIG. 7A shows a cross-section view of another example of a microfluidic channel structure with a geometric feature for controlled partitioning.
  • a channel structure 700 can include a channel segment 702 communicating at a channel junction 706 (or intersection) with a reservoir 704.
  • the channel structure 700 and one or more of its components can correspond to the channel structure 100 and one or more of its components.
  • FIG. 7B shows a perspective view of the channel structure 700 of FIG. 7A.
  • An aqueous fluid 712 comprising a plurality of particles 716 may be transported along the channel segment 702 into the junction 706 to meet a second fluid 714 (e.g., oil, etc.) that is immiscible with the aqueous fluid 712 in the reservoir 704 to create droplets 720 of the aqueous fluid 712 flowing into the reservoir 704.
  • a second fluid 714 e.g., oil, etc.
  • droplets can form based on factors such as the hydrodynamic forces at the junction 706, relative flow rates of the two fluids 712, 714, fluid properties, and certain geometric parameters (e.g., Ah, etc.) of the channel structure 700.
  • a plurality of droplets can be collected in the reservoir 704 by continuously injecting the aqueous fluid 712 from the channel segment 702 at the junction 706.
  • a discrete droplet generated may comprise one or more particles of the plurality of particles 716.
  • a particle may be any particle, such as a bead, cell bead, gel bead, biological particle, macromolecular constituents of biological particle, or other particles.
  • a discrete droplet generated may not include any particles.
  • the aqueous fluid 712 can have a substantially uniform concentration or frequency of particles 716.
  • the particles 716 e.g., beads
  • the 702 may be controlled by controlling the frequency in which the particles 716 are introduced into the channel segment 702 and/or the relative flow rates of the fluids in the channel segment 702 and the separate channel.
  • the particles 716 can be introduced into the channel segment 702 from a plurality of different channels, and the frequency controlled accordingly.
  • different particles may be introduced via separate channels.
  • a first separate channel can introduce beads and a second separate channel can introduce biological particles into the channel segment 702.
  • the first separate channel introducing the beads may be upstream or downstream of the second separate channel introducing the biological particles.
  • the second fluid 714 may not be subjected to and/or directed to any flow in or out of the reservoir 704.
  • the second fluid 714 may be substantially stationary in the reservoir 704.
  • the second fluid 714 may be subjected to flow within the reservoir 704, but not in or out of the reservoir 704, such as via application of pressure to the reservoir 704 and/or as affected by the incoming flow of the aqueous fluid 712 at the junction 706.
  • the second fluid 714 may be subjected and/or directed to flow in or out of the reservoir 704.
  • the reservoir 704 can be a channel directing the second fluid 714 from upstream to downstream, transporting the generated droplets.
  • the channel structure 700 at or near the junction 706 may have certain geometric features that at least partly determine the sizes and/or shapes of the droplets formed by the channel structure 700.
  • the channel segment 702 can have a first cross-section height, h and the reservoir 704 can have a second cross-section height, h 2 .
  • the first cross-section height, h and the second cross-section height, h 2 may be different, such that at the junction 706, there is a height difference of Ah.
  • the second cross-section height, h 2 may be greater than the first cross- section height, i. In some instances, the reservoir may thereafter gradually increase in cross- section height, for example, the more distant it is from the junction 706.
  • the cross-section height of the reservoir may increase in accordance with expansion angle, ⁇ , at or near the junction 706.
  • the height difference, Ah, and/or expansion angle, ⁇ can allow the tongue (portion of the aqueous fluid 712 leaving channel segment 702 at junction 706 and entering the reservoir 704 before droplet formation) to increase in depth and facilitate decrease in curvature of the intermediately formed droplet.
  • droplet size may decrease with increasing height difference and/or increasing expansion angle.
  • the height difference, Ah can be at least about 1 ⁇ .
  • the height difference can be at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500 ⁇ or more.
  • the height difference can be at most about 500, 400, 300, 200, 100, 90, 80, 70, 60, 50, 45, 40, 35, 30, 25, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1 ⁇ or less.
  • the expansion angle, ⁇ may be between a range of from about 0.5° to about 4°, from about 0.1° to about 10°, or from about 0° to about 90°.
  • the expansion angle can be at least about 0.0F, 0.
  • the expansion angle can be at most about 89°, 88°, 87°, 86°, 85°, 84°, 83°, 82°, 81°, 80°, 75°, 70°, 65°, 60°, 55°, 50°, 45°, 40°, 35°, 30°, 25°, 20°, 15°, 10°, 9°, 8°, 7°, 6°, 5°, 4°, 3°, 2°, 1°, 0. ⁇ , 0.0F, or less.
  • the flow rate of the aqueous fluid 712 entering the junction 706 can be between about 0.04 microliters ⁇ L)/minute (min) and about 40 ⁇ 7 ⁇ . In some instances, the flow rate of the aqueous fluid 712 entering the junction 706 can be between about 0.01 microliters ⁇ L)/minute (min) and about 100 ⁇ 7 ⁇ . Alternatively, the flow rate of the aqueous fluid 712 entering the junction 706 can be less than about 0.01 ⁇ 7 ⁇ .
  • the flow rate of the aqueous fluid 712 entering the junction 706 can be greater than about 40 ⁇ 7 ⁇ , such as 45 ⁇ 7 ⁇ , 50 ⁇ 7 ⁇ , 55 ⁇ 7 ⁇ , 60 ⁇ 7 ⁇ , 65 ⁇ 7 ⁇ , 70 ⁇ 7 ⁇ , 75 ⁇ 7 ⁇ , 80 ⁇ 7 ⁇ , 85 ⁇ 7 ⁇ , 90 ⁇ 7 ⁇ , 95 ⁇ 7 ⁇ , 100 ⁇ 7 ⁇ , 110 ⁇ 7 ⁇ , 120 ⁇ 7 ⁇ , 130 ⁇ 7 ⁇ , 140 ⁇ 7 ⁇ , 150 ⁇ 7 ⁇ , or greater.
  • the droplet radius may not be dependent on the flow rate of the aqueous fluid 712 entering the junction 706.
  • the second fluid 714 may be stationary, or substantially stationary, in the reservoir 704. Alternatively, the second fluid 714 may be flowing, such as at the above flow rates described for the aqueous fluid 712.
  • At least about 50% of the droplets generated can have uniform size. In some instances, at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%), 98%), 99%), or greater of the droplets generated can have uniform size. Alternatively, less than about 50%> of the droplets generated can have uniform size.
  • FIGs. 7A and 7B illustrate the height difference, Ah, being abrupt at the junction 706 (e.g., a step increase)
  • the height difference may increase gradually (e.g., from about 0 ⁇ to a maximum height difference).
  • the height difference may decrease gradually (e.g., taper) from a maximum height difference.
  • a gradual increase or decrease in height difference may refer to a continuous incremental increase or decrease in height difference, wherein an angle between any one differential segment of a height profile and an immediately adjacent differential segment of the height profile is greater than 90°.
  • a bottom wall of the channel and a bottom wall of the reservoir can meet at an angle greater than 90°.
  • a top wall (e.g., ceiling) of the channel and a top wall (e.g., ceiling) of the reservoir can meet an angle greater than 90°.
  • a gradual increase or decrease may be linear or non-linear (e.g., exponential, sinusoidal, etc.).
  • the height difference may variably increase and/or decrease linearly or non-linearly. While FIGs. 7A and 7B illustrate the expanding reservoir cross-section height as linear (e.g., constant expansion angle, ⁇ ), the cross-section height may expand non-linearly.
  • the reservoir may be defined at least partially by a dome-like (e.g., hemispherical) shape having variable expansion angles.
  • the cross-section height may expand in any shape.
  • the channel networks can be fluidly coupled to appropriate fluidic components.
  • the inlet channel segments are fluidly coupled to appropriate sources of the materials they are to deliver to a channel junction.
  • These sources may include any of a variety of different fluidic components, from simple reservoirs defined in or connected to a body structure of a microfluidic device, to fluid conduits that deliver fluids from off-device sources, manifolds, fluid flow units (e.g., actuators, pumps, compressors) or the like.
  • the outlet channel segment e.g., channel segment 208, reservoir 604, etc.
  • this may be a reservoir defined in the body of a microfluidic device, or it may be a fluidic conduit for delivering the partitioned cells to a subsequent process operation, instrument or component.
  • the methods and systems described herein may be used to greatly increase the efficiency of single cell applications and/or other applications receiving droplet-based input.
  • subsequent operations that can be performed can include generation of amplification products, purification (e.g., via solid phase reversible immobilization (SPRI)), further processing (e.g., shearing, ligation of functional sequences, and subsequent amplification (e.g., via PCR)).
  • SPRI solid phase reversible immobilization
  • further processing e.g., shearing, ligation of functional sequences
  • subsequent amplification e.g., via PCR
  • Additional reagents that may be co-partitioned along with the barcode bearing bead may include oligonucleotides to block ribosomal RNA (rRNA) and nucleases to digest genomic DNA from cells. Alternatively, rRNA removal agents may be applied during additional processing operations.
  • the configuration of the constructs generated by such a method can help minimize (or avoid) sequencing of the poly-T sequence during sequencing and/or sequence the 5' end of a polynucleotide sequence.
  • the amplification products for example, first amplification products and/or second amplification products, may be subject to sequencing for sequence analysis. In some cases, amplification may be performed using the Partial Hairpin Amplification for Sequencing (PHASE) method.
  • a variety of applications require the evaluation of the presence and quantification of different biological particle or organism types within a population of biological particles, including, for example, microbiome analysis and characterization, environmental testing, food safety testing, epidemiological analysis, e.g., in tracing contamination or the like.
  • Cells comprise both nuclear DNA (e.g., DNA comprising chromatin) and
  • both nuclear DNA and mitochondrial DNA may be susceptible to tagmentation.
  • a method for measuring accessible chromatin may yield a plurality of sequencing reads, where between about 20 and 80% of the sequencing reads may be attributable to mitochondrial DNA. Such reads may be discarded if nuclear DNA (e.g., accessible chromatin) is of interest.
  • Techniques to either eliminate or reduce mitochondrial DNA prior to tagmentation or to remove or reduce tagmented mitochondrial DNA fragments prior to sequencing may result in enhancement in chromatin-attributable data.
  • the present disclosure further provides a method of enhancing nuclear DNA within a sample.
  • the method may comprise reducing or removing mitochondrial DNA.
  • the method may comprise providing a sample comprising both mitochondrial DNA and nuclear DNA, and removing mitochondrial DNA from or reducing the relative amount of mitochondrial DNA in the sample prior to analyzing cells or nuclei within the sample for accessible chromatin (e.g., tagmentation).
  • the method may comprise providing a sample comprising both mitochondrial DNA and nuclear DNA; subjecting the sample to analysis for accessible chromatin (e.g., as described herein), thereby generating a processed sample comprising both tagmented mitochondrial DNA fragments and tagmented nuclear DNA fragments; and removing tagmented mitochondrial DNA fragments from the processed sample or reducing the relative amount of tagmented mitochondrial DNA fragments within the processed sample.
  • whole cells may be used as the input material for an ATAC-seq analysis (e.g., as described herein).
  • nuclei may be used as the input material for an ATAC-seq analysis.
  • nuclei may be used as the input material where mitochondrial DNA is removed prior to tagmentation of genomic DNA.
  • whole cells may be gently lysed to remove their cytoplasmic membrane whilst leaving the nuclear membrane and nucleoprotein packaging of the genome intact.
  • a lysis buffer used to lyse whole cells may comprise one or more of Tris-HCl, NaCl, magnesium ions (e.g., MgCl 2 ), and a lysis agent.
  • a lysis agent may be, for example, P40, Tween-20, Digitonin, Nonident P40, or DBDM. Mitochondria may be washed away along with other cellular debris during subsequent centrifugation steps to yield a suspension of nuclei.
  • mitochondrial membranes may be lysed along with their cytoplasmic counterparts. This may result in mitochondrial DNA non-specifically binding to nuclear membranes during this step and thus being carried into a subsequent tagmentation reaction.
  • a blocking agent e.g., a blocking protein
  • a blocking agent may be used to prevent nonspecific binding of mitochondrial DNA to nuclei membranes during cell lysis.
  • a blocking agent may not inhibit downstream biochemistry.
  • a blocking agent may be selected from the group consisting of, for example, a single purified protein (e.g., bovine serum albumin or casein), a single purified glycoprotein, a milk protein, fish gelatin, a normal serum (e.g., fetal calf serum, rabbit serum, goat serum, or the like), a buffer such as ThermoFisher Scientific' s SuperBlock, and polyvinylpyrrolidone (PVP).
  • the blocking agent e.g., blocking protein
  • BSA bovine serum albumin
  • the blocking protein e.g., BSA
  • the blocking protein may be added to a detergent formulation used during cell lysis.
  • the blocking protein may block available binding sites on nuclei membrane, thereby preventing nonspecific binding of mitochondrial DNA.
  • the blocking agent e.g., blocking protein
  • the blocking agent may be provided in any useful concentration.
  • the blocking agent may be provided in a solution comprising a buffer. After providing a blocking agent to a sample (e.g., a solution, partition, or plurality of partitions, such as a plurality of aqueous droplets) comprising one or more cells and/or nuclei, the sample may be agitated and/or centrifuged one or more times, and/or undergo one or more washing steps.
  • cell debris and mitochondrial DNA may be washed away (e.g., in a supernatant).
  • This approach may reduce the amount of sequencing reads associated with mitochondrial DNA in an ATAC- seq library by at least about 5%.
  • the amount of sequencing reads associated with mitochondrial DNA may be reduced by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or by 100%.
  • the amount of sequencing reads associated with mitochondrial DNA may be reduced by at least about 50%, such as from about 30% to about 60%.
  • the fraction of sequencing reads associated with mitochondrial DNA of a plurality of sequencing reads derived from a sample may be reduced to be less than about 60%.
  • the fraction of sequencing reads associated with mitochondrial DNA may be reduced to less than about 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, 1%, or less of the total sequencing reads derived from a sample.
  • the fraction of sequencing reads associated with mitochondrial DNA may be reduced to between about 1-5% of the total sequencing reads derived from a sample.
  • a method of generating barcoded nucleic acid fragments comprises: (a) lysing a plurality of cells in the presence of a cell lysis agent and a blocking agent to generate a plurality of lysed cells; (b) separating a plurality of nuclei from the plurality of lysed cells to generate a plurality of biological particles, where an individual biological particle (e.g., cell) comprises a non-template nucleic acid and chromatin comprising a template nucleic acid; (c) providing (i) a plurality of transposon end nucleic acid molecules comprising a transposon end sequence and (ii) a plurality of transposase nucleic acid molecules; (d) generating a plurality of template nucleic acid fragments in a biological particle of the plurality of biological particles with the aid of a transposase-nucleic acid complex comprising a transposase nucleic acid molecule of the plurality of trans
  • the blocking agent may comprise bovine serum albumin (BSA).
  • BSA bovine serum albumin
  • Lysing the plurality of cells may comprise providing a lysis buffer comprising the cell lysis agent to the plurality of cells.
  • the biological particles may be nuclei, which may be isolated from lysed cells by, e.g., washing the lysed cells.
  • the method further comprises generating sequencing reads.
  • Application of the method may reduce the fraction of sequencing reads deriving from
  • the template nucleic acid may comprise chromatin.
  • a method of generating barcoded nucleic acid fragments comprises: (a) lysing a plurality of cells in the presence of a cell lysis agent and a blocking agent to generate a plurality of lysed cells; (b) separating a plurality of nuclei from the plurality of lysed cells to generate a plurality of biological particles, where an individual biological particle comprises non-template DNA molecules (e.g., mitochondrial DNA molecules), template DNA molecules, and template RNA molecules; (c) providing (i) a plurality of transposon end nucleic acid molecules comprising a transposon end sequence and (ii) a plurality of transposase nucleic acid molecules; (d) generating a plurality of template DNA fragments in biological particles of the plurality of biological particles with the aid of a transposase-nucleic acid complex comprising a transposase nucleic acid molecule of the plurality of transposase nucleic acid molecules and
  • the blocking agent may comprise bovine serum albumin (BSA).
  • BSA bovine serum albumin
  • Lysing the plurality of cells may comprise providing a lysis buffer comprising the cell lysis agent to the plurality of cells.
  • the biological particles may be nuclei, which may be isolated from lysed cells by, e.g., washing the lysed cells.
  • the method further comprises generating sequencing reads. Application of the method may reduce the fraction of sequencing reads deriving from mitochondrial DNA relative to the total number of sequencing reads generated.
  • the template DNA molecules may comprise chromatin.
  • a method of reducing or removing mitochondrial DNA from a sample may comprise providing a sample comprising a plurality of cells comprising nuclear DNA and mitochondrial DNA; subjecting the plurality of cells to analysis for accessible chromatin (e.g., tagmentation, as described herein), thereby generating tagmented mitochondrial DNA fragments and tagmented nuclear DNA fragments; and using an enzyme to deplete tagmented
  • the enzyme may be an endonuclease enzyme.
  • the enzyme may be an RNA-guided DNA endonuclease enzyme.
  • the enzyme may be a clustered regularly interspaced short palindromic (CRISPR) associated protein (e.g., nuclease) such as Cas9.
  • CRISPR regularly interspaced short palindromic
  • the enzyme e.g., Cas9, such as recombinant Cas9
  • gRNAs guide RNAs
  • the Cas9-gRNA scheme may be used to target species for cleavage.
  • tagmented mitochondrial DNA fragments may be cleaved so that mitochondrial -derived DNA fragments will not be processed in subsequent sequencing.
  • a gRNA may be specifically designed to target a species of interest (e.g., a tagmented mitochondrial DNA fragment).
  • An enzyme e.g., Cas9, such as recombinant Cas9
  • Cas9 such as recombinant Cas9
  • Application of the enzyme-gRNA system may result in a reduction in the fraction of mitochondrial DNA fragments relative to a total number of fragments.
  • a plurality of gRNAs may be provided to a mixture comprising mitochondrial DNA fragments, where the plurality of gRNAs target different regions of mitochondrial DNA.
  • the plurality of gRNAs may target mitochondrial DNA (e.g., human mitochondrial chromosome) about every 250 base pairs.
  • the amount of sequencing reads associated with mitochondrial DNA in an ATAC-seq library may be reduced by at least about 5%.
  • the amount of sequencing reads associated with mitochondrial DNA may be reduced by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%), or more.
  • the amount of sequencing reads associated with mitochondrial DNA may be reduced by at least about 50%, such as from about 30% to about 60%.
  • the fraction of sequencing reads associated with mitochondrial DNA of a plurality of sequencing reads derived from a sample may be reduced to be less than about 60%.
  • the fraction of sequencing reads associated with mitochondrial DNA may be reduced to less than about 60%, 55%, 50%, 45%, 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, 1%, or less of the total sequencing reads derived from a sample.
  • the fraction of sequencing reads associated with mitochondrial DNA may be reduced to between about 1-5% of the total sequencing reads derived from a sample.
  • ATAC-seq and RNA-seq methods may be combined with a method of reducing non-template (e.g., mitochondrial) fragments.
  • a method may comprise generating both barcoded template nucleic acid fragments and barcoded cDNA fragments (e.g., generated via reverse transcription of template RNA molecules) as well as using a blocking agent to reduce non-template fragments (e.g., as described herein).
  • a method may comprise generating both barcoded template nucleic acid fragments and barcoded cDNA fragments (e.g., generated via reverse transcription of template RNA molecules) as well as using a CRISPR-associated protein to reduce non-template fragments (e.g., as described herein).
  • non-template fragments may comprise mitochondrial DNA.
  • non-template fragments may comprise mitochondrial RNA.
  • a biological particle comprising a template DNA molecule, a non-template nucleic acid molecule comprising ribosomal RNA (rRNA, e.g., mitochondrial rRNA), and a template RNA molecule is provided, and a barcoded cDNA is generated from the template RNA molecule by reverse transcription using a barcode oligonucleotide (e.g., nucleic acid barcode molecule) (e.g., as described herein).
  • rRNA ribosomal RNA
  • a template RNA molecule e.g., as described herein.
  • RNA molecules targeted to specific non-template rRNA (e.g., specific regions of mitochondrial rRNA) or cDNA molecule generated from rRNA molecules may be used in combination with a CRISPR associated protein such as Cas9 to selectively deplete sequences associated with rRNA, e.g., upon sequencing a plurality of sequences derived from the biological particle. Therefore, the methods described herein may allow for selective depletion of fragments and/or sequences (e.g., sequence reads) associated with a non-template species such as a non-template rRNA and corresponding enhancement of fragments and/or sequences (e.g., sequence reads) associated with template DNA and RNA species.
  • a non-template species such as a non-template rRNA
  • sequence reads e.g., sequence reads
  • a method for nucleic acid processing comprises: (a) generating a partition (e.g., a droplet or well), wherein the partition comprises: (i) a biological particle (e.g., cell); (ii) a plurality of barcode oligonucleotide molecules (e.g., nucleic acid barcode molecules) comprising a common barcode sequence; (iii) a plurality of transposon end oligonucleotide molecules (e.g., transposon end nucleic acid molecules) comprising a transposon end sequence; and (iv) a plurality of transposase molecules, wherein the biological particle (e.g., cell) comprises a template nucleic acid and a non-template nucleic acid; (b) generating a plurality of template nucleic acid fragments and a plurality of non-template nucleic acid fragments (e.g., mitochondrial nucleic acid fragments) with the aid of
  • one or more barcoded non- template nucleic acid fragments are generated using barcode oligonucleotide molecules of the plurality of barcode oligonucleotide molecules and one or more non -template nucleic acid fragments (e.g., mitochondrial nucleic acid fragments) of the plurality of non-template nucleic acid fragments.
  • the method may reduce the amount of fragments and/or barcoded fragments comprising and/or deriving from non-template nucleic acids.
  • the method may reduce the total number of non-template nucleic acid fragments and barcoded non- template nucleic acid fragments, e.g., in a mixture comprising one or more of template nucleic acid fragments, barcoded template nucleic acid fragments, non-template nucleic acid fragments, and barcoded non-template nucleic acid fragments.
  • the endonuclease may be
  • the non-template nucleic acid fragment may comprise a mitochondrial DNA fragment.
  • the template nucleic acid fragment may comprise a nuclear DNA fragment.
  • a method of generating barcoded nucleic acid fragments comprises: (a) providing a plurality of biological particles (e.g., cells or nuclei), an individual biological particle (e.g., cell or nucleus) comprising a template nucleic acid (e.g., chromatin) and a non- template nucleic acid (e.g., mitochondrial nucleic acid); (b) generating a plurality of template nucleic acid fragments and a plurality of non-template nucleic acid fragments (e.g.,
  • mitochondrial nucleic acid fragments in a biological particle of the plurality of biological particles with the aid of a transposase-nucleic acid complex comprising a transposase nucleic acid molecule and a transposon end nucleic acid molecule; (c) generating a partition (e.g., a droplet or well) comprising the biological particle comprising the plurality of template nucleic acid fragments and the plurality of non-template nucleic acid fragments, and a plurality of barcode oligonucleotide molecules (e.g., nucleic acid barcode molecules) comprising a barcode sequence; (d) generating a barcoded template nucleic acid fragment using a barcode
  • a partition e.g., a droplet or well
  • barcode oligonucleotide molecules e.g., nucleic acid barcode molecules
  • gRNAs guide ribonucleic acid molecules
  • CaRISPR clustered regularly interspaced short palindromic
  • one or more barcoded non- template nucleic acid fragments are generated using barcode oligonucleotide molecules of the plurality of barcode oligonucleotide molecules and one or more non -template nucleic acid fragments (e.g., mitochondrial nucleic acid fragments) of the plurality of non-template nucleic acid fragments.
  • the method may reduce the amount of fragments and/or barcoded fragments comprising and/or deriving from non-template nucleic acids.
  • the method may reduce the total number of non-template nucleic acid fragments and barcoded non- template nucleic acid fragments, e.g., in a mixture comprising one or more of template nucleic acid fragments, barcoded template nucleic acid fragments, non-template nucleic acid fragments, and barcoded non-template nucleic acid fragments.
  • the endonuclease may be Cas9, such as recombinant Cas9.
  • the non-template nucleic acid fragment may comprise a mitochondrial DNA fragment.
  • the template nucleic acid fragment may comprise chromatin.
  • a method of generating barcoded nucleic acid fragments comprises: (a) generating a partition (e.g., a droplet or well), wherein the partition comprises: (i) a biological particle (e.g., cell or nucleus), wherein the biological particle comprises template DNA molecules (e.g., chromatin), non-template DNA molecules (e.g., mitochondrial DNA molecules), and template RNA molecules; (ii) a plurality of first barcode oligonucleotide molecules (e.g., first nucleic acid barcode molecules) comprising a barcode sequence; (iii) a plurality of transposon end nucleic acid molecules comprising a transposon end sequence; (iv) a plurality of transposase nucleic acid molecules; (v) a plurality of second barcode oligonucleotide molecules (e.g., second nucleic acid barcode molecules) comprising a barcode sequence and a capture sequence; and (vi)
  • one or more barcoded non-template DNA fragments are generated using barcode oligonucleotide molecules of the plurality of barcode oligonucleotide molecules and one or more non-template DNA fragments (e.g., mitochondrial DNA fragments) of the plurality of non-template DNA fragments.
  • the method may reduce the amount of fragments and/or barcoded fragments comprising and/or deriving from non-template DNA.
  • the method may reduce the total number of non-template DNA fragments and barcoded non-template DNA fragments, e.g., in a mixture comprising one or more of template DNA fragments, barcoded template DNA fragments, non-template DNA fragments, and barcoded non-template DNA fragments.
  • the endonuclease may be Cas9, such as recombinant Cas9.
  • the non- template DNA fragment may comprise a mitochondrial DNA fragment.
  • the template DNA fragment may comprise chromatin.
  • a method of generating barcoded nucleic acid fragments comprises: (a) providing a biological particle (e.g., cell) comprising template DNA molecules, non-template DNA molecules, and template RNA molecules; (b) generating a plurality of template DNA fragments and non-template DNA fragments in the biological particle with the aid of a transposase-nucleic acid complex comprising a transposase nucleic acid molecule and a transposon end nucleic acid molecule; (c) generating a partition (e.g., a droplet or
  • the biological particle comprising template DNA fragments, non-template DNA fragments, and template RNA molecules; (ii) a plurality of first barcode oligonucleotide molecules (e.g., first nucleic acid barcode molecules) comprising a common barcode sequence; (iii) a plurality of second barcode oligonucleotide molecules (e.g., second nucleic acid molecules) comprising a barcode sequence and a capture sequence; and (iv) a plurality of reverse transcriptase molecules; (d) generating a barcoded template DNA fragment using a barcode oligonucleotide molecule of the plurality of first barcode oligonucleotide molecules and a template DNA fragment of the plurality of template DNA fragments; (e) generating a barcoded cDNA molecule from the template RNA molecules by reverse transcription using a barcode oligonucleotide molecule of the plurality of second barcode oligonu
  • one or more barcoded non-template DNA fragments are generated using barcode oligonucleotide molecules of the plurality of barcode oligonucleotide molecules and one or more non-template DNA fragments (e.g., mitochondrial DNA fragments) of the plurality of non-template DNA fragments.
  • the method may reduce the amount of fragments and/or barcoded fragments comprising and/or deriving from non-template DNA.
  • the method may reduce the total number of non-template DNA fragments and barcoded non-template DNA fragments, e.g., in a mixture comprising one or more of template DNA fragments, barcoded template DNA fragments, non-template DNA fragments, and barcoded non-template DNA fragments.
  • the endonuclease may be Cas9, such as recombinant Cas9.
  • the non-template DNA fragment may comprise a mitochondrial DNA fragment.
  • the template DNA fragment may comprise a nuclear DNA fragment.
  • a method of generating barcoded nucleic acid fragments comprises: (a) providing a partition (e.g., a droplet or well), wherein the partition comprises (i) a biological particle (e.g., cell or nucleus), (ii) a single solid or semi-solid particle (e.g., bead, such as a gel bead) , and (iii) a plurality of transposase nucleic acid molecules, wherein the single biological particle comprises a template nucleic acid molecule and a non-template nucleic acid molecule and wherein the single solid or semi-solid particle (e.g., bead) comprises a barcoded
  • oligonucleotide e.g., nucleic acid barcode molecule
  • partition subjecting the partition to conditions sufficient to release the template nucleic acid molecule and the non- template nucleic acid molecule from the single biological particle;
  • partition subjecting the partition to conditions sufficient to release the barcoded oligonucleotide from the solid or semi-solid particle;
  • subjecting the partition to conditions sufficient to cause transposition of the barcoded oligonucleotides into the template nucleic acid molecule and the non-template nucleic acid molecule with the aid of a transposome complex generated from at least a subset of the plurality of transposase nucleic acid molecules;
  • fragmenting (i) the template nucleic acid molecule into a plurality of double-stranded template nucleic acid fragments comprising the barcoded oligonucleotides and (ii) the non-template nucleic acid molecule into a plurality of
  • the method may reduce the amount of fragments comprising and/or deriving from non-template nucleic acids. For example, the method may reduce the total number of non- template nucleic acid fragments, e.g., in a mixture comprising one or more of template nucleic acid fragments, barcoded template nucleic acid fragments, non-template nucleic acid fragments, and barcoded non-template nucleic acid fragments.
  • the endonuclease may be Cas9, such as recombinant Cas9.
  • the non-template nucleic acid fragment may comprise a mitochondrial DNA fragment.
  • the template nucleic acid fragment may comprise chromatin.
  • the present methods may have the effect of reducing or removing non-template nucleic acids (e.g., mitochondrial DNA) and/or enhancing accessible chromatin.
  • the methods may be used with any cell type (e.g., as described herein).
  • the methods may be used with a human or a mammalian cell.
  • the methods may also be used with any concentration of cells.
  • the methods of reducing or removing non-template nucleic acids (e.g., mitochondrial DNA) and/or enhancing accessible chromatin may be used with an isolated cell.
  • the method of reducing or removing non-template nucleic acids (e.g., mitochondrial DNA) and/or enhancing accessible chromatin may be used with a plurality of cells, such as a plurality of cells within a plurality of droplets or a plurality of cells in a bulk solution.
  • the method of reducing or removing non-template nucleic acids (e.g., mitochondrial DNA) and/or enhancing accessible chromatin may be applied to any library type that requires a reducing in sequencing reads associated with non-template nucleic acids (e.g., mitochondrial DNA) or RNA, including RNA-seq.
  • a method of reducing non-template (e.g., mitochondrial) reads and/or enhancing reads associated with accessible chromatin relative to a total number of reads associated with a sample may be applied to any of the methods described herein.
  • a blocking agent e.g., BSA
  • use of a blocking agent may reduce or prevent non-specific adsorption of mitochondrial DNA to nuclei such that mitochondrial DNA can be washed away during nuclei isolation.
  • an endonuclease may be provided after any tagmentation process described herein to reduce the relative fraction of tagmented mitochondrial DNA in a sample comprising tagmented DNA.
  • nucleic acid samples and reducing non-template (e.g., mitochondrial) reads can be found in, for example: Gu et al. (Gu, W.; Crawford, E.D.; O'Donovan, B.D., Wilson, M.R., Chow, E.D., Retallack, H., and DeRisi, J.L. "Depletion of Abundant Sequences by Hybridization (DASH): using Cas9 to remove unwanted high- abundance species in sequencing libraries and molecular counting applications," Genome Biology (2016) 17:41), Montefiori et al.
  • kits for analyzing the accessible chromatin (e.g., for ATAC- seq) and/or RNA transcripts of individual cells or small populations of cells may include one or more of the following: one, two, three, four, five or more, up to all of partitioning fluids, including both aqueous buffers and non-aqueous partitioning fluids or oils, nucleic acid barcode libraries that are releasably associated with beads, as described herein, microfluidic devices, reagents for disrupting cells amplifying nucleic acids, and providing additional functional sequences on fragments of cellular nucleic acids or replicates thereof, as well as instructions for using any of the foregoing in the methods described herein.
  • FIG. 9 shows a computer system 901 that is programmed or otherwise configured to, e.g., (i) control a microfluidics system (e.g., fluid flow), (ii) sort occupied droplets from unoccupied droplets, (iii) polymerize droplets, (iv) perform sequencing applications, (v) generate and maintain a library of DNA or cDNA fragments, and/or (vi) analyze areas of accessible chromatin.
  • a microfluidics system e.g., fluid flow
  • the computer system 901 can regulate various aspects of the present disclosure, such as, for example, e.g., regulating fluid flow rate in one or more channels in a microfluidic structure, regulating polymerization application units, regulating conditions for certain reactions described herein.
  • the computer system 901 can be an electronic device of a user or a computer system that is remotely located with respect to the electronic device.
  • the electronic device can be a mobile electronic device.
  • the computer system 901 includes a central processing unit (CPU, also "processor” and “computer processor” herein) 905, which can be a single core or multi core processor, or a plurality of processors for parallel processing.
  • the computer system 901 also includes memory or memory location 910 (e.g., random-access memory, read-only memory, flash memory), electronic storage unit 915 (e.g., hard disk), communication interface 920 (e.g., network adapter) for communicating with one or more other systems, and peripheral devices 925, such as cache, other memory, data storage and/or electronic display adapters.
  • the memory 910, storage unit 915, interface 920 and peripheral devices 925 are in communication with the CPU 905 through a communication bus (solid lines), such as a motherboard.
  • the storage unit 915 can be a data storage unit (or data repository) for storing data.
  • the computer system 901 can be operatively coupled to a computer network ("network") 930 with the aid of the communication interface 920.
  • the network 930 can be the Internet, an internet and/or extranet, or an intranet and/or extranet that is in communication with the Internet.
  • the network 930 in some cases is a telecommunication and/or data network.
  • the network 930 can include one or more computer servers, which can enable distributed computing, such as cloud computing.
  • the network 930, in some cases with the aid of the computer system 901, can implement a peer-to-peer network, which may enable devices coupled to the computer system 901 to behave as a client or a server.
  • the CPU 905 can execute a sequence of machine-readable instructions, which can be embodied in a program or software.
  • the instructions may be stored in a memory location, such as the memory 910.
  • the instructions can be directed to the CPU 905, which can subsequently program or otherwise configure the CPU 905 to implement methods of the present disclosure.
  • Examples of operations performed by the CPU 905 can include fetch, decode, execute, and writeback.
  • the CPU 905 can be part of a circuit, such as an integrated circuit.
  • a circuit such as an integrated circuit.
  • One or more other components of the system 901 can be included in the circuit.
  • the circuit is an application specific integrated circuit (ASIC).
  • ASIC application specific integrated circuit
  • the storage unit 915 can store files, such as drivers, libraries and saved programs.
  • the storage unit 915 can store user data, e.g., user preferences and user programs.
  • the computer system 901 in some cases can include one or more additional data storage units that are external to the computer system 901, such as located on a remote server that is in communication with the computer system 901 through an intranet or the Internet.
  • the computer system 901 can communicate with one or more remote computer systems through the network 930.
  • the computer system 901 can communicate with a remote computer system of a user (e.g., operator).
  • remote computer systems include personal computers (e.g., portable PC), slate or tablet PC's (e.g., Apple® iPad,
  • the user can access the computer system 901 via the network 930.
  • Methods as described herein can be implemented by way of machine (e.g., computer processor) executable code stored on an electronic storage location of the computer system 901, such as, for example, on the memory 910 or electronic storage unit 915.
  • the machine executable or machine readable code can be provided in the form of software.
  • the code can be executed by the processor 905.
  • the code can be retrieved from the storage unit 915 and stored on the memory 910 for ready access by the processor 905.
  • the electronic storage unit 915 can be precluded, and machine-executable instructions are stored on memory 910.
  • the code can be pre-compiled and configured for use with a machine having a processor adapted to execute the code, or can be compiled during runtime.
  • the code can be supplied in a programming language that can be selected to enable the code to execute in a precompiled or as-compiled fashion.
  • aspects of the systems and methods provided herein can be embodied in programming.
  • Various aspects of the technology may be thought of as “products” or “articles of manufacture” typically in the form of machine (or processor) executable code and/or associated data that is carried on or embodied in a type of machine readable medium.
  • Machine-executable code can be stored on an electronic storage unit, such as memory (e.g., read-only memory, random-access memory, flash memory) or a hard disk.
  • Storage type media can include any or all of the tangible memory of the computers, processors or the like, or associated modules thereof, such as various semiconductor memories, tape drives, disk drives and the like, which may provide non-transitory storage at any time for the software programming. All or portions of the software may at times be communicated through the Internet or various other telecommunication networks. Such communications, for example, may enable loading of the software from one computer or processor into another, for example, from a management server or host computer into the computer platform of an application server.
  • another type of media that may bear the software elements includes optical, electrical and electromagnetic waves, such as used across physical interfaces between local devices, through wired and optical landline networks and over various air-links. The physical elements that carry such waves, such as wired or wireless links, optical links or the like, also may be considered as media bearing the software. As used herein, unless restricted to non-transitory, tangible
  • storage media terms such as computer or machine “readable medium” refer to any medium that participates in providing instructions to a processor for execution.
  • a machine readable medium such as computer-executable code
  • a tangible storage medium such as computer-executable code
  • Non-volatile storage media include, for example, optical or magnetic disks, such as any of the storage devices in any computer(s) or the like, such as may be used to implement the databases, etc. shown in the drawings.
  • Volatile storage media include dynamic memory, such as main memory of such a computer platform.
  • Tangible transmission media include coaxial cables; copper wire and fiber optics, including the wires that comprise a bus within a computer system.
  • Carrier-wave transmission media may take the form of electric or electromagnetic signals, or acoustic or light waves such as those generated during radio frequency (RF) and infrared (IR) data communications.
  • RF radio frequency
  • IR infrared
  • Common forms of computer-readable media therefore include for example: a floppy disk, a flexible disk, hard disk, magnetic tape, any other magnetic medium, a CD-ROM, DVD or DVD-ROM, any other optical medium, punch cards paper tape, any other physical storage medium with patterns of holes, a RAM, a ROM, a PROM and EPROM, a FLASH-EPROM, any other memory chip or cartridge, a carrier wave transporting data or instructions, cables or links transporting such a carrier wave, or any other medium from which a computer may read programming code and/or data.
  • Many of these forms of computer readable media may be involved in carrying one or more sequences of one or more instructions to a processor for execution.
  • the computer system 901 can include or be in communication with an electronic display 935 that comprises a user interface (UI) 940 for providing, for example, results of sequencing analysis, correlating sequencing reads to areas of accessible chromatin, etc.
  • UI user interface
  • UIs include, without limitation, a graphical user interface (GUI) and web-based user interface.
  • GUI graphical user interface
  • Methods and systems of the present disclosure can be implemented by way of one or more algorithms.
  • An algorithm can be implemented by way of software upon execution by the central processing unit 905.
  • the algorithm can, for example, perform sequencing reactions, correlating sequencing reads to areas of accessible chromatin, etc.
  • Devices, systems, compositions and methods of the present disclosure may be used for various applications, such as, for example, processing a single analyte (e.g., RNA, DNA, or protein) or multiple analytes (e.g., DNA and RNA, DNA and protein, RNA and protein, or RNA, DNA and protein) form a single cell.
  • a biological particle e.g., a cell or cell bead
  • a partition e.g., droplet
  • multiple analytes from the biological particle are processed for subsequent processing.
  • the multiple analytes may be from the single cell. This may enable, for example, simultaneous proteomic, transcriptomic and genomic analysis of the cell.
  • partitions that comprise droplets in an emulsion (e.g., droplet emulsion partitions)
  • any of the above-described partitions can be utilized in the methods, systems, and compositions described below.
  • a plurality of transposase molecules, a plurality of cells of interest (or a plurality of nuclei harvested from cells of interest, e.g., by nonionic detergents such as NP-40 (IGEPAL CA- 630) or Triton X-100), and a plurality of barcode oligonucleotides (e.g., nucleic acid barcode molecules) are partitioned such that at least some partitions (e.g., droplets or wells) comprise a plurality of transposase molecules, a single cell (or nucleus), and a plurality of barcode oligonucleotides comprising a sequencing primer sequence, a barcode sequence, and a transposon end sequence.
  • the plurality of barcode oligonucleotides are attached to a solid or semi-solid particle such as a gel bead and partitioned such that at least some partitions (e.g., droplets or wells) comprise transposase molecules, a single cell (or nucleus), and support (e.g., a single gel bead).
  • a solid or semi-solid particle such as a gel bead and partitioned such that at least some partitions (e.g., droplets or wells) comprise transposase molecules, a single cell (or nucleus), and support (e.g., a single gel bead).
  • aqueous droplet emulsion partitions are generated as described herein such that at least some of the droplets formed will comprise transposase molecules, cell lysis reagents, a single cell, and a single bead (e.g., gel bead) comprising a plurality of barcoded forked adapter oligonucleotides. See, e.g., FIG. 10.
  • the cells are then lysed within the droplets in a manner that releases template nucleic acid molecules from cell nuclei into their respective droplets, but that substantially maintains native chromatin organization. Droplets are then generally processed as outlined in FIG. 11 A.
  • a droplet is subjected to conditions such that the barcoded forked adaptor oligonucleotides are released from the bead (e.g., gel bead) into the aqueous droplet (e.g., by depolymerization or degradation of the bead using a reducing agent, such as DTT).
  • the forked adaptors can be prepared in a variety of different configurations, an exemplary forked adaptor is illustrated in FIG.
  • the first strand comprises a transposon end sequence ("mosaic end” or "ME"), a barcode sequence ("BC”), and a sequencing primer sequence ("Rl").
  • ME transposon end sequence
  • BC barcode sequence
  • Rl sequencing primer sequence
  • the partially complementary second strand comprises: (i) a region fully complementary to the transposon end sequence ("ME rc "); (ii) a region fully complementary to the barcode sequence ("BC rc "); and (iii) a primer sequence ("R2") partially complementary to the first strand primer sequence.
  • the double-stranded forked adaptor of FIG. 12A further comprises: (a) a first oligonucleotide strand further comprising a P5 sequence releasably attached to the gel bead; and (b) a second partially complementary oligonucleotide strand further comprising an index sequence ("i7") and a P7 sequence.
  • a transposase-nucleic acid complex is formed comprising a transposase molecule and two forked adaptors. See FIG. 11 A, step 2.
  • the droplets are then subj ected to conditions such that the transposase-nucleic acid complexes integrate the transposon end sequences into the template nucleic acid and fragment the template nucleic acid into double-stranded template nucleic acid fragments flanked by the forked adaptors. See FIG. 11 A, step 3.
  • cells (or nuclei) are
  • transposase-nucleic acid complexes enter the nucleus to fragment the template nucleic acid.
  • Cells are then lysed to release double-stranded template nucleic acid fragments. Because the transposase-nucleic acid complex can only act on a nucleosome-free template, the double-stranded template nucleic acid fragments are
  • the double-stranded template nucleic acid fragments are then collected from the droplets and processed in bulk to fill any gaps created from the transposition reaction and to generate a library suitable for next generation high throughput sequencing (e.g., subjecting the fragments, or derivatives thereof, to one or more reactions (e.g., nucleic acid amplification) to add functional sequences to facilitate Illumina sequencing; see FIG. 11B).
  • the fully constructed library is then sequenced according to any suitable sequencing protocol.
  • a plurality of transposase-nucleic acid complexes, a plurality of cells of interest (or a plurality of nuclei harvested from cells of interest), and a plurality of barcode oligonucleotides are partitioned such that at least some partitions (e.g., droplets or wells) comprise a plurality of transposase-nucleic acid complexes, a single cell (or nucleus), and a plurality of barcode oligonucleotides (e.g., nucleic acid barcode molecules) comprising a sequencing primer sequence and a barcode sequence.
  • the plurality of barcode e.g., nucleic acid barcode molecules
  • oligonucleotides are attached to a solid or semi-solid particle (e.g., a bead, such as a gel bead) and partitioned such that at least some partitions (e.g., droplets or wells) comprise transposase- nucleic acid complexes, a single cell (or nucleus), and a single solid or semi-solid particle (e.g., gel bead).
  • a solid or semi-solid particle e.g., a bead, such as a gel bead
  • partitions e.g., droplets or wells
  • a plurality of transposase molecules and a plurality of transposon end sequence oligonucleotides are partitioned along with a single cell (or nucleus) and the barcode oligonucleotides and transposase-nucleic acid complexes are generated in the partition (e.g., droplet or well).
  • droplet emulsion partitions are generated as described herein such that at least some of the droplets comprise transposase-nucleic acid complexes, cell lysis reagents, T4 DNA ligase, a single cell or cell nucleus, and a single bead (e.g., gel bead) comprising a plurality of barcoded forked adapter oligonucleotides. See, e.g., FIG. 13
  • An individual transposase-nucleic acid complex comprises a transposase and a pair of double-stranded oligonucleotides each comprising a transposon end sequence (e.g., an ME sequence). See FIGs. 13-15.
  • the double-stranded transposon-end sequence containing oligonucleotides further comprise a spacer sequence.
  • a droplet is subjected to conditions such that the forked adaptors are released from the bead (e.g., gel bead) into the aqueous droplet (e.g., by depolymerization or degradation of the bead using a reducing agent, such as DTT).
  • a reducing agent such as DTT
  • the forked adaptors can be prepared in a variety of different configurations, an exemplary forked adaptor is illustrated in FIG.
  • the first strand comprises a barcode sequence ("BC"), a primer sequence ("Rl”), and a transposon end sequence ("mosaic end” or "ME”).
  • the partially complementary second strand comprises a region fully complementary to the barcode sequence ("BC rc "), a primer sequence ("R2”) partially
  • the first strand further comprises a phosphorothioate linkage in the terminal nucleotide at the 3' end. In other embodiments, the first strand comprises phosphorothioate linkages in the last 3-5 nucleotides at the 3' end. In still other embodiments, the first strand comprises phosphorothioate linkages throughout the first strand.
  • the first oligonucleotide strand may further comprise a P5 adapter sequence releasably attached to the bead (e.g., gel bead).
  • the second partially complementary oligonucleotide strand may further comprise an index primer ("i7") and an adaptor sequence different than the first strand ("P7").
  • FIG. 15B shows a double-stranded oligonucleotide comprising a first oligonucleotide strand releasably attached to a bead (e.g., gel bead) and a second partially complementary oligonucleotide strand.
  • the first strand comprises a barcode sequence ("BC") and a primer sequence ("Rl").
  • complementary second strand comprises a region fully complementary to the barcode sequence ("BC rc ”) and a primer sequence ("R2") partially complementary to the first strand primer sequence.
  • the first strand further comprises a phosphorothioate linkage in the terminal nucleotide at the 3' end.
  • the first strand comprises phosphorothioate linkages in the last 3-5 nucleotides at the 3' end.
  • the first strand comprises phosphorothioate linkages throughout the first strand.
  • the first oligonucleotide strand may further comprise a P5 adapter sequence releasably attached to the bead (e.g., gel bead).
  • the second partially complementary oligonucleotide strand may further comprise an index primer ("i7") and an adaptor sequence different than the first strand (“P7").
  • a bead e.g., gel bead
  • the droplet is subjected to conditions such that the transposase-nucleic acid complexes integrate the transposon end sequences into the template nucleic acid and fragment the template nucleic acid into double-stranded template nucleic acid fragments flanked by transposon end sequences. See FIG. 14A, step lb.
  • cells (or nuclei) are permeabilized/permeable and the transposase-nucleic acid complexes enter the nuclei to fragment the template nucleic acids therein.
  • the double-stranded template nucleic acid fragments are representative of genome- wide areas of accessible chromatin in a single cell or nucleus.
  • the forked adaptors are then ligated onto the ends of the double-stranded stranded template nucleic acid fragments. See FIG. 14 A, step 2.
  • the double-stranded template nucleic acid fragments are then collected from the droplets and processed in bulk to fill any gaps created from the transposition reaction and to generate a library suitable for next generation high throughput sequencing (e.g., subjecting the fragments, or derivatives thereof, to one or more reactions (e.g., nucleic acid amplification) to add functional sequences to facilitate Illumina sequencing; see FIG. 14B).
  • the fully constructed library is then sequenced according to any suitable sequencing protocol.
  • custom sequencing primers directed against the spacer-ME sequence are utilized to avoid sequencing the barcode-spacer-ME region of the library.
  • a plurality of transposase molecules, a plurality of cells of interest (or a plurality of nuclei harvested from cells of interest), and a plurality of barcode oligonucleotides are partitioned such that at least some partitions (e.g., droplets or wells) comprise a plurality of transposase molecules, a single cell (or nucleus), and a plurality of barcode oligonucleotides (e.g., nucleic acid barcode molecules) comprising a T7 promoter sequence, a sequencing primer sequence, a barcode sequence, and a transposon end sequence.
  • the plurality of barcode oligonucleotides are attached to a solid or semi-solid particle (e.g., a bead, such as a gel bead) and partitioned such that at least some partitions (e.g., droplets or wells) comprise transposase molecules, a single cell (or nucleus), and a single solid or semi-solid particle (e.g., gel bead).
  • a solid or semi-solid particle e.g., a bead, such as a gel bead
  • partitions e.g., droplets or wells
  • droplet emulsion partitions are generated as previously described such that at least some droplets (e.g., aqueous droplets) that comprise transposase molecules, cell lysis reagents, a single cell (or nucleus), and a single bead (e.g., gel bead) comprising partially double-stranded T7 promoter oligonucleotide adaptors. See, e.g., FIG. 16.
  • the cells if present, are then lysed in a manner that releases template nucleic acid molecules from the nucleus into the droplet, but that substantially maintains native chromatin organization. Droplets are then generally processed as outlined in FIG. 17.
  • a droplet e.g., an aqueous droplet
  • the partially double-stranded adaptors are released from the bead (e.g., gel bead) into the droplet (e.g., by depolymerization or degradation of the bead using a reducing agent, such as DTT).
  • a reducing agent such as DTT
  • oligonucleotide 18 shows a partially double-stranded oligonucleotide comprising a first oligonucleotide strand releasably attached to a bead (e.g., a gel bead) and a second, shorter complementary
  • a bead e.g., a gel bead
  • the first strand comprises a transposon end ("mosaic end” or “ME”) sequence, a barcode sequence ("BC”), a partial sequencing primer sequence ("pRl” or “Partial Rl”), and a T7 promoter sequence while the second oligonucleotide strand comprises a sequence fully complementary to the transposon end sequence ("ME rc ").
  • a transposase-nucleic acid complex is formed comprising a transposase molecule and two partially double-stranded oligonucleotides adaptors. See FIG. 17, step 2.
  • the droplet or plurality of droplets is then subjected to conditions such that the transposase-nucleic acid complexes integrate the adaptors into the template nucleic acid and produce double-stranded template nucleic acid fragments flanked by the partially double-stranded adaptors. See FIG. 17, step 3.
  • cells are permeabilized/permeable and the transposase-nucleic acid complexes enter the nuclei to fragment the template nucleic acids therein. Cells, if present, are then lysed to release the double-stranded template nucleic acid fragments. Because the transposase-nucleic acid complex can only act on a nucleosome-free template, the double-stranded template nucleic acid fragments are representative of genome-wide areas of accessible chromatin in a single cell or nucleus.
  • RNA is generated from the double-stranded template nucleic acid fragments using an in vitro
  • RNA is collected and purified, followed by first and second strand cDNA synthesis. Double-stranded cDNA molecules are then further processed (including fragmentation and adaptor insertion by, e.g., a second transposase-mediated fragmentation) to generate a library suitable for next generation high throughput sequencing ⁇ e.g., subjecting the fragments, or derivatives thereof, to one or more reactions ⁇ e.g., nucleic acid amplification) to add functional sequences to facilitate Illumina sequencing). The fully constructed library is then sequenced according to any suitable sequencing protocol.
  • Example 4 Generation of Barcoded Nucleic Acid Fragments from Single Cells using Transposition of Sequencing Adaptors followed by Random Priming and Extension
  • a plurality of transposase molecules, a plurality of cells of interest (or a plurality of nuclei harvested from cells of interest), and a plurality of barcode oligonucleotides are partitioned such that at least some partitions (e.g., droplets or wells) comprise a plurality of transposase molecules, a single cell (or nucleus), and a plurality of barcode oligonucleotides (e.g., nucleic acid barcode molecules) comprising a sequencing primer sequence, a barcode sequence, and a transposon end sequence.
  • the plurality of barcode oligonucleotides are attached to a solid or semi-solid particle (e.g., a bead, such as a gel bead) and partitioned such that at least some partitions (e.g., droplets or wells) comprise transposase molecules, a single cell (or nucleus), and a single solid or semi-solid particle (e.g., gel bead).
  • a solid or semi-solid particle e.g., a bead, such as a gel bead
  • partitions e.g., droplets or wells
  • droplet emulsion partitions are generated as previously described such that at least some droplets that comprise transposase molecules, cell lysis reagents, a single cell (or nucleus), and a single bead (e.g., gel bead) comprising partially double-stranded barcoded oligonucleotide adaptors. See, e.g., FIG. 19.
  • the cells if present, are then lysed in a manner that releases template nucleic acid molecules from the nucleus into the aqueous droplet, but that substantially maintains native chromatin organization. Droplets are then generally processed as outlined in FIG. 20.
  • a droplet e.g., an aqueous droplet
  • a bead e.g., gel bead
  • DTT reducing agent
  • oligonucleotide 21 shows a partially double-stranded oligonucleotide comprising a first oligonucleotide strand releasably attached to a bead (e.g., gel bead) and a second, shorter complementary
  • a bead e.g., gel bead
  • the first strand comprises a transposon end ("mosaic end” or “ME”) sequence, a barcode sequence ("BC”), and a partial sequencing primer sequence ("pRl” or “Partial Rl”) while the second oligonucleotide strand comprises a sequence fully complementary to the transposon end sequence ("ME rc ").
  • a transposase- nucleic acid complex is formed comprising a transposase molecule and two partially double- stranded oligonucleotides. See FIG. 20, step 2.
  • the droplets are then subjected to conditions such that the transposase-nucleic acid complexes integrate the adaptors into the template nucleic acid and produce double-stranded template nucleic acid fragments flanked by the partially double-stranded adaptors. See FIG. 20, step 3.
  • cells are permeabilized/permeable and the transposase-nucleic acid complexes enter the nucleus to fragment the template nucleic acid.
  • Cells, if present, are then lysed to release the double- stranded template nucleic acid fragments. Because the transposase-nucleic acid complex can only act on a nucleosome-free template, the double-stranded template nucleic acid fragments are representative of genome-wide areas of accessible chromatin in a single cell or nucleus.
  • double-stranded template nucleic acid fragments are then collected from the droplets and processed in bulk to generate a library suitable for next generation high throughput sequencing.
  • double-stranded template nucleic acid fragments are processed in bulk in a random priming extension reaction. See, e,g, FIG. 22.
  • the random extension primer has a sequence of random nucleotides (N-mer) and, for example, can be attached to second PCR handle (e.g., partial R2 sequence, see FIG. 22).
  • the random extension primers are annealed to the double-stranded template nucleic acid fragments, or derivatives thereof, and extended (e.g., FIG. 22).
  • Reactions can then be cleaned-up and extension products subjected to one or more reactions (e.g., nucleic acid amplification) to add functional sequences to facilitate Illumina sequencing (e.g., FIG. 22).
  • the fully constructed library is then sequenced according to any suitable sequencing protocol.
  • artificial transposons are designed to insert sequences of interest into a target DNA molecule (e.g., open chromatin).
  • a target DNA molecule e.g., open chromatin
  • an artificial transposon oligonucleotide comprising a barcode sequence and an adapter sequence is flanked by a transposon end sequence on each end of the oligonucleotide (see, e.g., FIG. 23).
  • a plurality of transposase molecules, a plurality of cells of interest (or a plurality of nuclei harvested from cells of interest), and a plurality of artificial transposon oligonucleotides are partitioned such that at least some partitions (e.g., droplets or wells) comprise a plurality of artificial transposon oligonucleotides, a plurality of transposase molecules, and a single cell (or nucleus).
  • the plurality of artificial transposon oligonucleotides are attached to a solid or semi-solid particle (e.g., bead, such as a gel bead) and partitioned such that at least some partitions (e.g., droplets or wells) comprise a plurality of transposase molecules, a single cell (or nucleus), and a single solid or semi-solid particle (e.g., gel bead).
  • a plurality of transposon nucleic acid complexes comprising an artificial transposon
  • oligonucleotide comprising a barcode sequence and an adapter sequence flanked by transposon end sequenced are partitioned such that at least some partitions comprise a plurality of transposon nucleic acid complexes and a single cell (or nucleus).
  • the plurality of artificial transposon oligonucleotides are attached to a solid or semi-solid particle (e.g., bead, such as a gel bead) and partitioned such that at least some partitions (e.g., droplets or wells) comprise a single cell (or nucleus) and a single solid or semi-solid particle (e.g., gel bead).
  • droplet emulsion partitions are generated as previously described such that at least some droplets that comprise transposase molecules, cell lysis reagents, a single cell (or nucleus), and a single bead (e.g., gel bead). The cells are then lysed to release template nucleic acid molecules from the nucleus into the aqueous droplet.
  • Droplets are then generally processed as outlined in FIG. 23.
  • a droplet e.g., aqueous droplet
  • a bead e.g., gel bead
  • the barcoded adaptors can be prepared in a variety of different configurations, an exemplary barcoded adaptor is illustrated in FIG. 23 and is a double-stranded oligonucleotide releasably attached to a bead (e.g., gel bead), wherein the barcoded adaptor comprises a pair of transposon end ("mosaic end” or "ME") sequences flanking a barcode sequence ("BC”) and an adaptor sequence ("P5").
  • a bead e.g., gel bead
  • a transposase-nucleic acid complex is formed comprising a transposase molecule and a barcoded adaptor comprising a pair of transposon end sequences. See FIG. 23.
  • the droplet or plurality of droplets is then subjected to conditions such that the transposase-nucleic acid complexes integrate the barcoded adaptors into the template nucleic acid. See FIG. 23.
  • cells (or nuclei) are
  • transposase-nucleic acid complexes enter the nuclei to perform the transposition reaction.
  • Cells, if present, are then lysed to release the transposon-containing template nucleic acid fragments.
  • the barcode-transposed template nucleic acids are then collected from the droplets and processed in bulk to fragment the barcode-transposed template nucleic acids and to generate a library suitable for next generation high throughput sequencing (e.g., subj ecting the fragments, or derivatives thereof, to one or more reactions (e.g., nucleic acid amplification) to add functional sequences to facilitate Illumina sequencing).
  • the fully constructed library is then sequenced according to any suitable sequencing protocol.
  • a plurality of transposase nucleic acid complexes and a plurality of cells of interest are partitioned such that at least some partitions (e.g., droplets or wells) comprise a single cell (or nucleus) and a plurality of transposase nucleic acid complexes comprising a transposase molecule and a barcode
  • oligonucleotide e.g., nucleic acid barcode molecule
  • a sequencing primer sequence e.g., a barcode sequence
  • a transposon end sequence e.g., FIGs. 24A-24B and 25A-25B
  • the plurality of transposase nucleic acid complexes are attached to a solid or semi-solid particle (e.g., bead, such as a gel bead) (see, e.g., FIGs. 24A-24B and 26) and partitioned such that at least some partitions (e.g., droplets or wells) comprise a single cell (or nucleus) and a single solid or semi-solid particle (e.g., gel bead).
  • a solid or semi-solid particle e.g., bead, such as a gel bead
  • partitioned e.g., droplets or wells
  • droplet emulsion partitions are generated as previously described such that at least some droplets (e.g., aqueous droplets) comprise cell lysis reagents, a single cell (or nucleus), and a single bead (e.g., gel bead) functionalized with a transposase-nucleic acid complex.
  • the cells are then lysed in a manner that releases template nucleic acid molecules from the nuclei into the respective droplets, but that substantially maintains native chromatin organization.
  • Droplets e.g., aqueous droplets
  • the transposase-nucleic acid complexes are released from beads (e.g., gel beads) into the respective droplets (e.g., by depolymerization or degradation of beads using a reducing agent, such as DTT).
  • beads e.g., gel beads
  • DTT a reducing agent
  • the transposase-nucleic acid complexes can be prepared in a variety of different configurations
  • a transposase-nucleic acid complex is illustrated in FIG. 24A and shows a complex comprising a transposase, a first partially double-stranded oligonucleotide, and a second partially double-stranded oligonucleotide.
  • the first partially double-stranded oligonucleotide comprises: (a) a first strand releasably attached to a bead (e.g., gel bead), wherein the first strand comprises a transposon end sequence ("ME"), a barcode sequence ("BC”), and a first sequencing primer sequence ("Rl”); and (b) a second strand complementary to the transposon end sequence of the first oligonucleotide strand
  • a bead e.g., gel bead
  • ME transposon end sequence
  • BC barcode sequence
  • Rl first sequencing primer sequence
  • the second partially double-stranded oligonucleotide comprises: (a) a first oligonucleotide strand comprising a transposon end sequence ("ME") and a second primer sequence ("R2"); and (b) a second strand complementary to the transposon end sequence ("ME rc "). See also FIG.
  • bead- (e.g., gel bead) functionalized transposase-nucleic acid complexes are prepared as illustrated in FIG. 26, which shows a complex comprising a transposase, a first partially double-stranded oligonucleotide and a second double-stranded oligonucleotide.
  • the first partially double-stranded oligonucleotide comprises: (a) a first strand releasably attached to a bead (e.g., gel bead), wherein the first strand comprises a transposon end sequence ("ME”) and a barcode sequence ("BC”) and (b) a second strand complementary to the transposon end sequence of the first oligonucleotide strand
  • the second double-stranded oligonucleotide comprises: (a) a first strand releasably attached to a bead (e.g., gel bead), wherein the first strand comprises a transposon end sequence ("ME) and (b) a second strand complementary to the first oligonucleotide strand ("ME rc ").
  • Alternative embodiments of FIG. 26 comprise additional functional sequences, such as a sequencing primer sequence (e.g., Rl and/or R2) or an adapter sequence (e.g., P5 and/or P7).
  • droplets are partitioned such that at least some droplets comprise cell lysis reagents, a plurality of transpose molecules, a single cell (or nucleus), and a single bead (e.g., gel bead) comprising a barcode oligonucleotide (e.g., nucleic acid barcode molecule) comprising a barcode sequence ("BC") and a transposon end sequence ("ME").
  • barcode oligonucleotide e.g., nucleic acid barcode molecule
  • BC barcode sequence
  • ME transposon end sequence
  • a transposase-nucleic acid complex is released from a bead (e.g., gel bead) into a droplet (or is formed in the partition in embodiments such as FIGs. 25A-25B)
  • the droplet is subjected to conditions such that the transposase-nucleic acid complexes integrate the transposon end sequences into the template nucleic acid and fragments the template nucleic acid into double-stranded template nucleic acid fragments flanked by first and second partially double- stranded oligonucleotides.
  • cells are not limited to the cells.
  • transposase-nucleic acid complexes enter the nuclei to fragment the template nucleic acids therein.
  • Cells, if present, are then lysed to release the double-stranded template nucleic acid fragments. Because the transposase-nucleic acid complex can only act on a nucleosome-free template, the double-stranded template nucleic acid fragments are representative of genome-wide areas of accessible chromatin in a single cell or nucleus.
  • the double-stranded template nucleic acid fragments are then collected from the droplets and processed in bulk to fill any gaps created from the transposition reaction and to generate a library suitable for next generation high throughput sequencing (e.g., subjecting the fragments, or derivatives thereof, to one or more reactions (e.g., nucleic acid amplification) to add functional sequences to facilitate Illumina sequencing; see, e.g., FIG. 27).
  • the fully constructed library is then sequenced according to any suitable sequencing protocol.
  • a plurality of transposase nucleic acid complexes and a plurality of cells of interest are partitioned such that at least some partitions (e.g., droplets or wells) comprise a single cell (or nucleus), a plurality of transposase nucleic acid complexes comprising a transposon end sequence, and a plurality of barcoded oligonucleotides (e.g., nucleic acid barcode molecules) comprising a barcode sequence and a sequencing primer sequence (see, e.g., FIGs. 28A-28B).
  • partitions e.g., droplets or wells
  • a plurality of transposase nucleic acid complexes comprising a transposon end sequence
  • barcoded oligonucleotides e.g., nucleic acid barcode molecules
  • the plurality of barcode oligonucleotides further comprise a transposon end sequence.
  • the plurality of barcode oligonucleotides are attached to a solid or semi-solid particle (e.g., gel bead) (see, e.g., FIG. 28B) and partitioned such that at least some partitions (e.g., droplets or wells) comprise a plurality of transposase nucleic acid complexes, a single cell (or nucleus), and a single solid or semi-solid particle (e.g., gel bead).
  • a solid or semi-solid particle e.g., gel bead
  • partitions e.g., droplets or wells
  • droplet emulsion partitions are generated as previously described such that at least some droplets (e.g., aqueous droplets) comprise a transposase-nucleic acid complex comprising a transposase and a pair of double-stranded oligonucleotides, cell lysis reagents, a single cell (or nucleus), and a single bead (e.g., gel bead) comprising a barcoded adaptor.
  • the transposase-nucleic acid complexes can be prepared in a variety of different configurations, a transposase-nucleic acid complex is illustrated in FIG. 28A and shows a complex comprising a transposase, a first double-stranded
  • oligonucleotide comprising a transposon end ("mosaic end” or “ME”) sequence
  • a second double-stranded oligonucleotide comprising a transposon end (“mosaic end” or “ME”) sequence.
  • Cells if present, are lysed in a manner that releases template nucleic acid molecules from nuclei into droplets (e.g., aqueous droplets), but that substantially maintains native chromatin organization. Droplets are then subjected to conditions such that barcoded adaptors are released from beads (e.g., gel beads) into the respective droplets.
  • beads e.g., gel beads
  • oligonucleotide 28B shows a single-stranded oligonucleotide comprising a transposon end ("mosaic end” or “ME”) sequence, a barcode sequence ("BC”), and a primer sequence ("Rl”) releasably attached to a bead (e.g., gel bead).
  • ME transposon end
  • BC barcode sequence
  • Rl primer sequence
  • a bead e.g., gel bead
  • the droplet is subjected to conditions such that the transposase-nucleic acid complexes integrate the transposon end sequences into the template nucleic acid and fragment the template nucleic acid into double-stranded template nucleic acid fragments.
  • cells or nuclei
  • the transposase-nucleic acid complexes enter the nuclei to fragment the template nucleic acids therein. Cells, if present, are then lysed to release the double-stranded template nucleic acid fragments.
  • the double-stranded template nucleic acid fragments are representative of genome-wide areas of accessible chromatin in a single cell or nucleus.
  • a PCR reaction is performed to fill any gaps created from the transposition reaction and to add the barcoded adaptors to the ends of the double-stranded template nucleic acid fragments.
  • the double-stranded template nucleic acid fragments are then collected from the droplets and processed in bulk to generate a library suitable for next generation high throughput sequencing (e.g., subjecting the fragments, or derivatives thereof, to one or more reactions (e.g., nucleic acid amplification) to add functional sequences to facilitate Illumina sequencing).
  • the fully constructed library is then sequenced according to any suitable sequencing protocol.
  • Tn5-based tagmentation systems typically rely upon sample processing steps that take place in two independent reactions to generate the final transposase-fragmented nucleic acid sample.
  • Reaction #1 oligonucleotide adaptors containing the Tn5 transposon end sequences and the Tn5 transposase enzyme are incubated to form a transposase-nucleic acid complex.
  • magnesium or other divalent cations
  • Reaction #2 the transposase-nucleic acid complex from Reaction #1 is combined with a target double-stranded DNA and an appropriate reaction buffer containing magnesium (or other divalent cations) to activate the transposase-nucleic acid complex and cause fragmentation of the target DNA and ligation of the adapter oligonucleotide sequences.
  • an appropriate reaction buffer containing magnesium (or other divalent cations) to activate the transposase-nucleic acid complex and cause fragmentation of the target DNA and ligation of the adapter oligonucleotide sequences.
  • one-pot reaction implementing a tagmentation reaction within a single reaction or reaction vessel
  • a one-pot transposition reaction was performed on 50,000 HEK293T cells and compared to a traditional two-step tagmentation reaction. Sequencing libraries were prepared from each reaction type and sequenced on an Illumina sequencer. Sequencing data is presented in Table 1 below and demonstrates comparable sequencing metrics between the traditional and one-pot tagment
  • transposition methods described herein can be utilized in a one-pot reaction as described above. These one-pot reactions can be done either in bulk or in discrete partitions, such as a well or droplet.
  • Intact nuclei are harvested in bulk from cells in a cell population of interest in a manner that substantially maintains native chromatin organization (e.g., using IGEPAL CA-630 mediated cell lysis). Nuclei are then incubated in the presence of a transposase-nucleic acid complex comprising a transposase molecule and two partially double-stranded adaptor oligonucleotides. See, e.g., FIG. 29A. Alternatively, cells are permeable/permeabilized, allowing the transposase-nucleic acid complex to gain access to the nucleus.
  • the first adapter oligonucleotide comprises a double stranded transposon end sequence ("ME") and a single stranded Readl sequencing primer sequence ("Rl”) while the second adapter oligonucleotide comprises a double stranded transposon end sequence ("ME") and a single stranded Read2 sequencing primer sequence ("R2"). See FIG. 29A.
  • the Rl and/or R2 sequencing primer in the first and/or second adapter oligonucleotide comprises a TruSeq Rl and/or R2 sequence, or a portion thereof.
  • the transposase-nucleic acid complexes integrate the adaptors into the template nucleic acid and produce template nucleic acid fragments flanked by the partially double-stranded adaptors. See FIG. 29C. Because the transposase-nucleic acid complex can only act on a nucleosome-free template, the fragmented template nucleic acid fragments are representative of genome-wide areas of accessible chromatin. In some
  • the transposase molecules are inactivated prior to further processing steps.
  • Nuclei (or cells) comprising the adapter-flanked template nucleic acid fragments are then partitioned into a plurality of partitions (e.g., droplets or wells) such that at least some partitions comprise (1) a single nucleus (or cell) comprising the adapter-flanked template nucleic acid fragments; and (2) a plurality of partially double-stranded barcode oligonucleotide molecules comprising a doubled stranded barcode sequence ("BC"), a double-stranded P5 adapter sequence ("P5"), and a single stranded sequence complementary to the Read 1 sequence ("Rl rc "). See FIG. 29B.
  • partitions e.g., droplets or wells
  • the partially double-stranded barcode oligonucleotide molecules are attached to a solid or semi-solid particle (e.g., a bead, such as a gel bead) and partitioned such that at least some partitions (e.g., droplets or wells) comprise (1) a single nucleus (or cell) and (2) a single solid or semi-solid particle (e.g., bead, such as a gel bead).
  • the plurality of partitions e.g., droplets or wells
  • further comprises reagents e.g., enzymes and buffers
  • barcode oligonucleotides e.g., nucleic acid barcode molecules
  • partitions e.g., droplets or wells
  • conditions to cause release of the barcode oligonucleotide molecules from the bead e.g., gel bead
  • a reducing agent such as DTT
  • the adapter-flanked template nucleic acid fragments are subjected to conditions to phosphorylate the 5' end of the Readl sequence (e.g., using T4 polynucleotide kinase) for subsequent ligation steps.
  • the barcode oligonucleotide molecules are ligated onto the adapter-flanked template nucleic acid fragments using a suitable DNA ligase enzyme (e.g., T4 or s, coli DNA ligase) and the complementary Readl sequences in the barcode oligonucleotides and the adapter- flanked template nucleic acid fragments. See FIG. 29C.
  • a suitable DNA ligase enzyme e.g., T4 or s, coli DNA ligase
  • the gap filling reaction is completed in bulk after barcoded, adapter-flanked template nucleic acid fragments have been released from the partitions (e.g., droplets or wells).
  • the fully constructed library is then sequenced according to a suitable next-generation sequencing protocol (e.g., Ulumina sequencing).
  • Cells from a cell population of interest are partitioned into a plurality of partitions (e.g., droplets or wells) such that at least some partitions comprise (1) a single cell (or a single nucleus) comprising a template nucleic acid; and (2) a plurality of partially double-stranded barcode oligonucleotide molecules (e.g., nucleic acid barcode molecules) comprising a doubled stranded barcode sequence ("BC"), a doubled stranded P5 adapter sequence ("P5"), and a single stranded sequence complementary to a Read 1 sequence ("Rl rc ”) (e.g., FIG. 29B).
  • partitions e.g., droplets or wells
  • a plurality of partially double-stranded barcode oligonucleotide molecules comprising a doubled stranded barcode sequence ("BC"), a doubled stranded P5 adapter sequence ("P5"), and a single stranded sequence
  • the partially double- stranded barcode oligonucleotide molecules are attached to a solid or semi-solid particle (e.g., bead, such as a gel bead) and partitioned such that at least some partitions (e.g., droplets or wells) comprise (1) a single cell (or a single nucleus) and (2) a single solid or semi-solid particle (e.g., gel bead).
  • a solid or semi-solid particle e.g., bead, such as a gel bead
  • partitions e.g., droplets or wells
  • the plurality of partitions e.g., droplets or wells
  • further comprises reagents e.g., enzymes and buffers
  • partitions e.g., droplets or wells
  • the single cells (or nuclei) are lysed to release the template genomic DNA in a manner that substantially maintains native chromatin organization.
  • Partitions e.g., droplets or wells
  • Partitions are then subjected to conditions to generate a transposase-nucleic acid complex as described in Example 9 and shown in FIG. 29A.
  • a plurality of pre-formed transposase-nucleic acid complexes as shown in FIG. 29A are partitioned into the plurality of partitions (e.g., droplets or wells).
  • Partitions e.g., droplets or wells
  • the transposase-nucleic acid complexes integrate the first and second adapter sequences into the template nucleic acid to generate double-stranded adapter-flanked template nucleic acid fragments.
  • the transposase-nucleic acid complex can only act on nucleosome-free DNA
  • the adapter-flanked template nucleic acid fragments are representative of genome-wide areas of accessible chromatin in a single cell or nucleus.
  • the tagmentation reaction is performed in intact nuclei, and the nuclei are lysed after transposition to release the double-stranded adapter-flanked template nucleic acid fragments.
  • Samples are then processed generally as described in Example 9.
  • barcode oligonucleotides e.g., nucleic acid barcode molecules
  • a solid or semi-solid particle e.g., bead, such as a gel bead
  • droplets are subjected to conditions to cause release of the barcode oligonucleotide molecules from the solid or semi-solid particle (e.g., gel bead) (e.g., depolymerization or degradation of beads, for example, using a reducing agent such as DTT).
  • the transposase molecules are inactivated (e.g., by heat inactivation) prior to further processing steps.
  • the adapter-flanked template nucleic acid fragments are subjected to conditions to phosphorylate the 5' end of the Readl sequence (e.g., using T4 polynucleotide kinase) of the adapter-flanked template nucleic acid fragments.
  • the barcode oligonucleotide molecules are ligated onto the adapter-flanked template nucleic acid fragments using a suitable DNA ligase enzyme (e.g., T4, 9°N, or E. coli DNA ligase) and the complementary Readl sequences in the barcode
  • gaps remaining from the transposition reaction are filled to produce barcoded, adapter-flanked template nucleic acid fragments. See FIG. 29C.
  • the barcoded, adapter-flanked template nucleic acid fragments are then released from the partitions (e.g., droplets or wells) and processed in bulk to complete library preparation for next generation high throughput sequencing (e.g., to add sample index (SI) sequences (e.g., "i7") and/or further adapter sequences (e.g., "P7”)).
  • SI sample index
  • i7 sample index sequences
  • P7 further adapter sequences
  • the gap filling reaction is completed in bulk after barcoded, adapter-flanked template nucleic acid fragments have been released from the droplets.
  • the fully constructed library is then sequenced according to a suitable next- generation sequencing protocol (e.g., Illumina sequencing).
  • Nuclei are harvested in bulk from cells in a cell population of interest in a manner that substantially maintains native chromatin organization. Alternatively, cells are
  • transposase-nucleic acid complex permeabilized/permeable, allowing the transposase-nucleic acid complex to gain access to the nucleus. Nuclei (or permeabilized cells) are then incubated in the presence of a transposase- nucleic acid complex as described in Example 9. See FIG. 29A.
  • Nuclei (or cells) comprising the adapter-flanked template nucleic acid fragments are then partitioned into a plurality of partitions (e.g., droplets or wells) such that at least some partitions comprise (1) a single nucleus (or cell) comprising the adapter-flanked template nucleic acid fragments; and (2) a plurality of single-stranded barcode oligonucleotide molecules (e.g., nucleic acid barcode molecules) comprising a transposon end sequence ("ME"), a Readl sequence ("Rl”), or a portion thereof, a barcode sequence ("BC”), and a P5 adapter sequence ("P5"). See FIG. 30A.
  • partitions e.g., droplets or wells
  • the single-stranded barcode oligonucleotide molecules are attached to a solid or semi-solid particle (e.g., a bead, such as a gel bead) and partitioned such that at least some partitions (e.g., droplets or wells) comprise (1) a single nucleus (or cell) comprising the adapter-flanked template nucleic acid fragments and (2) a single solid or semi-solid particle (e.g., gel bead).
  • the plurality of partitions e.g., droplets or wells
  • further comprises reagents e.g., enzymes and buffers
  • barcode oligonucleotides e.g., nucleic acid barcode molecules
  • a solid or semi-solid particle e.g., bead, such as a gel bead
  • partitions e.g., droplets or wells
  • conditions to cause release of the barcode oligonucleotide molecules from the solid or semi-solid particle e.g., bead, such as a gel bead
  • a reducing agent such as DTT
  • Gap-filled adapter-flanked template nucleic acid fragments are then subjected to a linear amplification reaction using the single- stranded barcode oligonucleotide molecules as primers to produce barcoded, adapter-flanked template nucleic acid fragments. See FIG. 30B.
  • the barcoded, adapter-flanked template nucleic acid fragments are then released from the partitions (e.g., droplets or wells) and processed in bulk to complete library preparation for next generation high throughput sequencing (e.g., to add sample index (SI) sequences (e.g., "i7") and/or further adapter sequences (e.g., "P7”)).
  • next generation sequencing e.g., to add sample index (SI) sequences (e.g., "i7") and/or further adapter sequences (e.g., "P7"
  • SI sample index
  • P7 further adapter sequences
  • Cells from a cell population of interest are partitioned into a plurality of partitions (e.g., droplets or wells) such that at least some partitions comprise (1) a single cell (or a single nucleus) comprising a template nucleic acid; and (2) a plurality of single-stranded barcode oligonucleotide molecules (e.g., nucleic acid barcode molecules) comprising a transposon end sequence ("ME"), a Readl sequence ("Rl”), a barcode sequence ("BC”), and a P5 adapter sequence ("P5"). See, e.g, FIG. 30A.
  • partitions e.g., droplets or wells
  • the single-stranded barcode oligonucleotide molecules are attached to a solid or semi-solid particle (e.g., bead, such as a gel bead) and partitioned such that at least some partitions (e.g., droplets or wells) comprise (1) a single cell (or a single nucleus) and (2) a single solid or semi-solid particle (e.g., bead, such as a gel bead).
  • the plurality of partitions e.g., droplets or wells
  • further comprises reagents e.g., enzymes and buffers
  • partitions e.g., droplets or wells
  • the single cells (or nuclei) are lysed to release the template genomic DNA in a manner that substantially maintains native chromatin organization.
  • barcode oligonucleotides e.g., nucleic acid barcode molecules
  • partitions e.g., droplets or wells
  • partitions are subjected to conditions to cause release of the barcode oligonucleotide molecules from the solid or semi-solid particle (e.g., bead, such as a gel bead) (e.g., depolymerization or degradation of beads, for example, using a reducing agent such as DTT).
  • Partitions e.g., droplets or wells
  • a plurality of pre-formed transposase-nucleic acid complexes as shown in FIG. 29A are partitioned into the plurality of partitions (e.g., droplets or wells). Partitions (e.g., droplets or wells) are then subjected to conditions such that the transposase-nucleic acid complexes integrate the first and second adapter sequences into the template nucleic acid to generate double-stranded adapter-flanked template nucleic acid fragments.
  • partitions e.g., droplets or wells
  • the adapter-flanked template nucleic acid fragments are representative of genome-wide areas of accessible chromatin in a single cell or nucleus.
  • the tagmentation reaction is performed in intact nuclei, and the nuclei are lysed to release the double-stranded adapter-flanked template nucleic acid fragments.
  • Samples are then processed generally as described in Example 11. After tagmentation, gaps from the transposition reaction are filled with a suitable gap-filling enzyme. See FIG. 31. Gap-filled adapter-flanked template nucleic acid fragments are then subjected to a linear amplification reaction using the single- stranded barcode oligonucleotide molecules as primers to produce barcoded, adapter-flanked template nucleic acid fragments. See FIG. 31.
  • the barcoded, adapter-flanked template nucleic acid fragments are then released from the partitions (e.g., droplets or wells) and processed in bulk to complete library preparation for next generation high throughput sequencing (e.g., to add sample index (SI) sequences (e.g., "i7") and/or further adapter sequences (e.g., "P7”)).
  • next generation sequencing e.g., to add sample index (SI) sequences (e.g., "i7") and/or further adapter sequences (e.g., "P7"
  • SI sample index
  • P7 further adapter sequences
  • Nuclei are harvested in bulk from cells in a cell population of interest in a manner that substantially maintains native chromatin organization. Alternatively, cells are
  • transposase-nucleic acid complex permeabilized/permeable, allowing the transposase-nucleic acid complex to gain access to the nucleus. Nuclei are then incubated in the presence of a transposase-nucleic acid complex as described in Example 9. See FIG. 29A.
  • the transposase is inactivated or dissociated from the adapter-flanked template nucleic acid fragments.
  • Nuclei (or cells) comprising the adapter-flanked template nucleic acid fragments are then partitioned into a plurality of partitions (e.g., droplets or wells) such that at least some partitions comprise (1) a single nucleus comprising the adapter-flanked template nucleic acid fragments; (2) a plurality of double-stranded barcode oligonucleotide molecules (e.g., nucleic acid barcode molecules) comprising a barcode sequence (BC) and a TruSeqRl sequencing primer sequence (e.g., FIG.
  • the double-stranded barcode oligonucleotide molecules are attached to a solid or semi-solid particle (e.g., bead, such as a gel bead) and partitioned such that at least some droplets comprise (1) a single nucleus; (2) a single solid or semi-solid particle (e.g., gel bead); and (3) a plurality of CRISPR/Cas9 complexes.
  • the plurality of partitions e.g., droplets or wells
  • further comprises reagents e.g., enzymes and buffers
  • Single nucleus-containing partitions e.g., droplets or wells
  • Single nucleus-containing partitions are then subjected to conditions to release the adapter-flanked template nucleic acid fragments from the nuclei.
  • the adapter-flanked template nucleic acid fragments are released, gaps from the transposition reaction are filled with a suitable gap-filling enzyme. Gap-filled adapter-flanked template nucleic acid fragments are then subjected to Cas9-mediated cleavage of the Rl/ME adaptor, or some portion thereof. See FIG. 32B.
  • barcode oligonucleotides e.g., nucleic acid barcode molecules
  • a solid or semi-solid particle e.g., a bead, such as a gel bead
  • partitions e.g., droplets or wells
  • the barcode oligonucleotide molecules are then ligated onto the Rl adapter-cleaved ends of the template nucleic acid fragments to produce barcoded, adapter-flanked template nucleic acid fragments. See FIG.32B.
  • the barcoded, adapter-flanked template nucleic acid fragments are then released from the partitions (e.g., droplets or wells) and processed in bulk to complete library preparation for next generation high throughput sequencing (e.g., subj ecting the fragments, or derivatives thereof, to one or more reactions (e.g., nucleic acid amplification) to add functional sequences to facilitate Illumina sequencing).
  • a second CRISPR/Cas9 mediated cleavage event using a synthetic guide RNA (gRNA) that targets the Read2/ME adapter sequence is performed either in the partitions or in bulk after release from the partitions.
  • the fully constructed library is then sequenced according to any suitable sequencing protocol.
  • Cells from a cell population of interest are partitioned into a plurality of partitions (e.g., droplets or wells) such that at least some partitions comprise (1) a single cell (or a single nucleus) comprising a template nucleic acid; (2) a plurality of double-stranded barcode oligonucleotide molecules (e.g., nucleic acid barcode molecules) comprising a barcode sequence ("BC") and a TruSeqRl sequencing primer sequence (e.g., FIG.
  • CRISPR/Cas9 complexes comprising a Cas9 nuclease and a synthetic guide RNA (gRNA) that targets the Readl/ME adapter sequence in the adapter-flanked template nucleic acid fragments. See, e.g., FIG. 32C.
  • gRNA synthetic guide RNA
  • the double-stranded barcode oligonucleotide molecules are attached to a solid or semi-solid particle (e.g., bead, such as a gel bead) and partitioned such that at least some partitions (e.g., droplets or wells) comprise (1) a single cell (or single nucleus); (2) a single solid or semi-solid particle (e.g., gel bead); and (3) a plurality of CRISPR/Cas9 complexes.
  • the plurality of partitions e.g., droplets or wells
  • further comprises reagents e.g., enzymes and buffers
  • partitions e.g., droplets or wells
  • the single cells (or nuclei) are lysed to release the template genomic DNA in a manner that substantially maintains native chromatin organization.
  • Partitions e.g., droplets or wells
  • Partitions are then subjected to conditions to generate a transposase-nucleic acid complex as described in Example 9 and shown in FIG. 29A.
  • a plurality of pre-formed transposase-nucleic acid complexes as shown in FIG. 29A are partitioned into the plurality of partitions (e.g., droplets or wells).
  • Partitions (E.g., droplets or wells) are then subjected to conditions such that the transposase-nucleic acid complexes integrate the first and second adapter sequences into the template nucleic acid to generate double-stranded adapter-flanked template nucleic acid fragments.
  • the transposase-nucleic acid complex can only act on nucleosome-free DNA, the adapter-flanked template nucleic acid fragments are representative of genome-wide areas of accessible chromatin in a single cell or nucleus.
  • the tagmentation reaction is performed in intact nuclei, and the nuclei are lysed to release the double-stranded adapter-flanked template nucleic acid fragments.
  • gaps from the transposition reaction are filled with a suitable gap-filling enzyme. See FIG. 32C.
  • Gap-filled adapter-flanked template nucleic acid fragments are then subjected to Cas9-mediated cleavage of the Rl adaptor. See FIG. 32C.
  • barcode oligonucleotides e.g., nucleic acid barcode molecules
  • a solid or semisolid particle e.g., bead, such as a gel bead
  • partitions e.g., droplets or wells
  • the barcode oligonucleotide molecules are then ligated onto the Rl adapter-cleaved ends of the template nucleic acid fragments to produce barcoded, adapter- flanked template nucleic acid fragments. See FIG. 32C.
  • the barcoded, adapter-flanked template nucleic acid fragments are then released from the partitions (e.g., droplets or wells) and processed in bulk to complete library preparation for next generation high throughput sequencing (e.g., subj ecting the fragments, or derivatives thereof, to one or more reactions (e.g., nucleic acid amplification) to add functional sequences to facilitate Illumina sequencing).
  • a second CRISPR/Cas9 mediated cleavage event using a synthetic guide RNA (gRNA) that targets the Read2/ME adapter sequence is performed either in the partitions or in bulk after release from the partitions.
  • the fully constructed library is then sequenced according to any suitable sequencing protocol.
  • Nuclei are harvested in bulk from cells in a cell population of interest in a manner that substantially maintains native chromatin organization. Alternatively, cells are
  • transposase-nucleic acid complex permeabilized/permable, allowing the transposase-nucleic acid complex to gain access to the nucleus. Nuclei are then incubated in the presence of a transposase-nucleic acid complex as described in Example 9. See FIG. 29A.
  • the transposase is inactivated or dissociated from the adapter-flanked template nucleic acid fragments.
  • Nuclei (or cell) comprising the adapter-flanked template nucleic acid fragments are then partitioned into a plurality of partitions (e.g., droplets or wells) such that at least some partitions comprise (1) a single nucleus comprising the adapter-flanked template nucleic acid fragments; (2) a plurality of Y-adaptor barcode oligonucleotide molecules (e.g., nucleic acid barcode molecules) comprising a barcode sequence ("BC"), a Readl sequencing primer sequence (“Rl”), and a Read2 sequencing primer sequence ("R2”), e,g, FIG.
  • partitions e.g., droplets or wells
  • the Y-adaptor barcode oligonucleotide molecules are attached to a solid or semi-solid particle (e.g., a bead, such as a gel bead) (e.g., FIG. 15A) and partitioned such that at least some partitions (e.g., droplets or wells) comprise (1) a single nucleus; (2) a single solid or semi-solid particle (e.g., bead, such as a gel bead); (3) the first plurality of CRISPR/Cas9 complexes; and (4) the second plurality of CRISPR/Cas9 complexes.
  • the plurality of partitions e.g., droplets or wells
  • further comprises reagents e.g., enzymes and buffers
  • barcode oligonucleotides e.g., nucleic acid barcode molecules
  • a solid or semi-solid particle e.g., a bead, such as a gel bead
  • partitions e.g., droplets or wells
  • conditions to cause release of the barcode oligonucleotide molecules from the solid or semi-solid particle e.g., gel bead
  • a reducing agent such as DTT
  • the Y-adaptor barcode oligonucleotides are then ligated onto the R1/R2 adapter-cleaved ends of the template nucleic acid fragments to produce barcoded, adapter-flanked template nucleic acid fragments. See FIG. 33B.
  • the barcoded, adapter-flanked template nucleic acid fragments are then released from the partitions (e.g., droplets or wells) and processed in bulk to complete library preparation for next generation high throughput sequencing (e.g., subj ecting the fragments, or derivatives thereof, to one or more reactions (e.g., nucleic acid amplification) to add functional sequences to facilitate Illumina sequencing).
  • the fully constructed library is then sequenced according to any suitable sequencing protocol.
  • Cells from a cell population of interest are partitioned into a plurality of partitions (e.g., droplets or wells) such that at least some partitions comprise (1) a single cell (or a single nucleus) comprising a template nucleic acid; (2) a plurality of Y-adaptor barcode oligonucleotide molecules (e.g., nucleic acid barcode molecules) comprising a barcode sequence ("BC"), a Readl sequencing primer sequence ("Rl”), and a Read2 sequencing primer sequence ("R2”) (e.g., FIG. 33 A); (3) a first plurality of partitions (e.g., droplets or wells) such that at least some partitions comprise (1) a single cell (or a single nucleus) comprising a template nucleic acid; (2) a plurality of Y-adaptor barcode oligonucleotide molecules (e.g., nucleic acid barcode molecules) comprising a barcode sequence ("BC"), a Readl sequencing primer sequence
  • CRISPR/Cas9 complexes comprising a Cas9 nuclease and a synthetic guide RNA (gRNA) that targets the Readl/ME adapter sequence in the adapter-flanked template nucleic acid fragments; and (4) a second plurality of CRISPR/Cas9 complexes comprising a Cas9 nuclease and a synthetic guide RNA (gRNA) that targets the Read2/ME adapter sequence in the adapter-flanked template nucleic acid fragments. See FIG. 33C.
  • the Y-adaptor barcode oligonucleotide molecules are attached to a solid or semi-solid particle (e.g., a bead, such as a gel bead) and partitioned such that at least some partitions (e.g., droplets or wells) comprise (1) a single cell (or single nucleus); (2) a single solid or semi-solid particle (e.g., gel bead); (3) the first plurality of CRISPR/Cas9 complexes; and (4) the second plurality of CRISPR/Cas9 complexes.
  • the plurality of partitions e.g., droplets or wells
  • further comprises reagents e.g., enzymes and buffers
  • partitions e.g., droplets or wells
  • the single cells (or nuclei) are lysed to release the template genomic DNA in a manner that substantially maintains native chromatin organization.
  • Partitions e.g., droplets or wells
  • Partitions are then subjected to conditions to generate a transposase-nucleic acid complex as described in Example 9 and shown in FIG. 29A.
  • a plurality of pre-formed transposase-nucleic acid complexes as shown in FIG. 29A are partitioned into the plurality of partitions (e.g., droplets or wells).
  • Partitions e.g., droplets or wells
  • the transposase-nucleic acid complexes integrate the first and second adapter sequences into the template nucleic acid to generate double-stranded adapter-flanked template nucleic acid fragments.
  • the transposase-nucleic acid complex can only act on nucleosome-free DNA
  • the adapter-flanked template nucleic acid fragments are representative of genome-wide areas of accessible chromatin in a single cell or nucleus.
  • the tagmentation reaction is performed in intact nuclei, and the nuclei are lysed to release the double-stranded adapter-flanked template nucleic acid fragments.
  • gaps from the transposition reaction are filled with a suitable gap-filling enzyme. See FIG. 33C.
  • Gap-filled adapter-flanked template nucleic acid fragments are then subjected to Cas9-mediated cleavage of the Rl and R2 adaptors, or a portion thereof. See FIG. 33C.
  • barcode oligonucleotides e.g., nucleic acid barcode molecules
  • a solid or semi-solid particle e.g., a bead, such as a gel bead
  • partitions e.g., droplets or wells
  • conditions to cause release of the barcode oligonucleotide molecules from the solid or semi-solid particle e.g., gel bead
  • a reducing agent such as DTT
  • the Y-adaptor barcode oligonucleotides are then ligated onto the R1/R2 adapter-cleaved ends of the template nucleic acid fragments to produce barcoded, adapter-flanked template nucleic acid fragments. See FIG. 33C
  • the barcoded, adapter-flanked template nucleic acid fragments are then released from the partitions (e.g., droplets or wells) and processed in bulk to complete library preparation for next generation high throughput sequencing (e.g., subj ecting the fragments, or derivatives thereof, to one or more reactions (e.g., nucleic acid amplification) to add functional sequences to facilitate Illumina sequencing).
  • the fully constructed library is then sequenced according to any suitable sequencing protocol.
  • Cells from a cell population of interest are partitioned into a plurality of partitions (e.g., droplets or wells) such that at least some partitions comprise (1) a single cell (or a single nucleus) comprising template genomic DNA molecules and template RNA molecules; (2) a plurality of first barcoded oligonucleotide molecules (e.g., first nucleic acid barcode molecules) comprising a barcode sequence; (3) a plurality of transposase molecules, (4) a plurality of second barcode oligonucleotide molecules (e.g., second nucleic acid barcode molecules) comprising a barcode sequence and a capture sequence; and (5) a plurality of reverse transcriptase molecules.
  • partitions e.g., droplets or wells
  • the barcode sequence from the first barcoded oligonucleotide and the barcode sequence from the second barcoded oligonucleotide is the same. In some embodiments, the barcode sequence from the first barcoded oligonucleotide and the barcode sequence from the second barcoded oligonucleotide are different.
  • the plurality of first barcoded oligonucleotides (e.g., first nucleic acid barcode molecules) and the plurality of second barcoded oligonucleotides (e.g., second nucleic acid barcode molecules) are attached to a solid or semi-solid particle (e.g., a bead, such as a gel bead) and partitioned such that at least some partitions (e.g., droplets or wells) comprise (1) a single cell (or single nucleus); (2) a single solid or semi-solid particle (e.g., gel bead) comprising the first and second plurality of barcoded oligonucleotides; (3) a plurality of transposase molecules; and (4) a plurality of reverse transcriptase molecules.
  • a solid or semi-solid particle e.g., a bead, such as a gel bead
  • partitioned such that at least some partitions (e.g., droplets or wells
  • the plurality of first barcoded oligonucleotides are attached to a first solid or semi-solid particle (e.g,. bead, such as a gel bead) while the plurality of second barcoded oligonucleotides (e.g., second nucleic acid barcode molecules) are attached to a second solid or semi-solid particle (e.g., bead, such as a gel bead) and partitioned such that at least some partitions (e.g., droplets or wells) comprise (1) a single cell (or single nucleus); (2) a single first solid or semi-solid particle (e.g., gel bead); (2) a single second solid or semi-solid particle (e.g., gel bead); (3) a plurality of transposase molecules; and (4) a plurality of reverse transcriptase molecules.
  • a first solid or semi-solid particle e.g. bead, such as a gel bead
  • the plurality of first barcoded oligonucleotides are attached to a plurality of solid or semi-solid particles (e.g., beads, such as gel beads) while the plurality of second barcoded oligonucleotides (e.g., second nucleic acid barcode molecules) are attached to a plurality of magnetic particles (e.g., beads), wherein the plurality of magnetic particles are embedded within the solid or semi-solid particles (e.g., gel beads).
  • the plurality of solid or semi-solid particles is partitioned such that at least some partitions (e.g., droplets or wells) comprise: (1) a single cell (or single nucleus); (2) a single solid or semi-solid particle (e.g., gel bead) comprising (i) a plurality of first barcoded oligonucleotides attached to the single solid or semisolid particle (e.g., gel bead); and (ii) a plurality of magnetic particles embedded within the single solid or semi-solid particle (e.g., gel bead), wherein the magnetic particles comprise the second barcode oligonucleotide attached thereto; (3) a plurality of transposase molecules; and (4) a plurality of reverse transcriptase molecules. See, e.g., FIG. 34. Similarly, in other partitions (e.g., droplets or wells) comprise: (1) a single cell (or single nucleus); (2) a single solid or semi-solid particle (e.g.,
  • the second barcode oligonucleotides are attached to the solid or semi-solid particle (e.g., gel bead) while the first oligonucleotides (e.g., first nucleic acid barcode molecules) are attached to a plurality of magnetic particles embedded within the solid or semi-solid particle (e.g., gel bead). See, e.g., FIG. 34.
  • the plurality of partitions e.g., droplets or wells
  • reagents e.g., enzymes and buffers
  • the first barcoded oligonucleotide and related nucleic acid processing steps can take on the structure of any of the aforementioned Examples and may include additional components as described therein.
  • the first barcoded oligonucleotide comprises a barcode sequence and a transposon end sequence (e.g., a ME sequence) and is, for example, (1) a forked adapter such as those described in Example 1, FIGs. 12A-12B; (2) a T7- containing oligonucleotide such as those described in Example 3, FIG. 18; or (3) a barcoded oligonucleotide such as those described in (i) Example 7, FIG. 28B; (ii) Example 1 1, FIGs. 30A-30B; and (iii) Example 12, FIG. 31.
  • the first barcoded a barcode sequence and a transposon end sequence
  • oligonucleotide comprises a barcode sequence and is, for example, (1) a forked adapter such as those described in Example 2, FIGs. 15A-15B or Examples 15-16, FIGs. 33A-33C; or (2) a barcoded oligonucleotide such as those described in Examples 9 and 10, FIGs. 29A-29C or Examples 13-14, FIGs. 32A-32C.
  • the second barcoded oligonucleotide comprises a second barcode sequence and a capture sequence, where the capture sequence can be, for example, a poly-T sequence, a random primer sequence (e.g., a random hexamer), or a gene-specific sequence.
  • the single cells are lysed to release template genomic DNA and template RNA (e.g., cytoplasmic mRNA or nuclear mRNA) in a manner that substantially maintains native chromatin organization of the genomic DNA.
  • template RNA e.g., cytoplasmic mRNA or nuclear mRNA
  • partitions e.g., droplets or wells
  • conditions to cause release of barcode oligonucleotide molecules from the solid or semi-solid particle e.g., gel bead
  • Partitions e.g., droplets or wells
  • Partitions are then subjected to conditions to generate a transposase-nucleic acid complex as described in the aforementioned examples.
  • a plurality of pre-formed transposase-nucleic acid complexes are partitioned into the plurality of partitions (e.g., droplets or wells). Partitions (e.g., droplets or wells) are then subjected to conditions such that the transposase-nucleic acid complexes generate double-stranded template genomic DNA fragments.
  • the transposition reaction can take on the structure of any of the aforementioned Examples to generate double-stranded template genomic DNA fragments flanked by a wide variety of functional sequences and suitable for a number of downstream processing steps.
  • the transposition reaction directly integrates the barcode sequence into the template genomic DNA fragments (e.g., Example 1) while, in other
  • the barcode sequence is added to template genomic DNA fragments subsequent to the transposition reaction (such as by ligation, e.g., Example 2). Because the transposase-nucleic acid complex can only act on nucleosome-free DNA, the template genomic DNA fragments are representative of genome-wide areas of accessible chromatin in a single cell or nucleus.
  • the tranposition reaction is performed in intact nuclei, and the nuclei are lysed to release the adapter-flanked template genomic DNA fragments.
  • the transposition reaction is performed in bulk in intact nuclei and a single nucleus comprising template genomic DNA fragments is partitioned and processed as described above.
  • gaps from the transposition reaction are filled in-droplet with a suitable gap-filling enzyme.
  • a gap-filling reaction is performed in bulk after the double-stranded, barcoded adapter-flanked DNA fragments have been released from the partitions.
  • partitions e.g., droplets or wells
  • partitions may be subjected to conditions to capture template RNA (e.g., messenger RNA, mRNA) on second solid or semi-solid particles using a capture sequence of second barcoded oligonucleotides of the plurality of second barcoded oligonucleotides.
  • second barcoded oligonucleotides of the plurality of second barcoded oligonucleotides may be released from the second solid or semi-solid particles (e.g., as described herein) and used to capture template RNA.
  • Captured template RNA may be subsequently processed in bulk after removal from the partitions.
  • partitions may be subjected to conditions to generate single-stranded, barcoded cDNA molecules from the template RNA using the capture sequence from the second barcode oligonucleotide to prime the reverse transcription reaction (e.g., an oligo (dT) sequence).
  • second strand cDNA is produced (e.g., through a template switching oligonucleotide or through random priming) to generate double-stranded, barcoded cDNA molecules.
  • the template switching oligonucleotide also comprises a barcode sequence such that both the 5' and 3 ' end of the cDNA comprise a barcode sequence.
  • the barcode sequence on the 5' and 3 ' end can be the same barcode sequence or the 5 ' end can have a different barcode sequence than the 3 ' end.
  • the plurality of second barcode oligonucleotide molecules are omitted and replaced with plurality of second
  • first strand cDNA molecules are generated using the capture sequence while second strand cDNA is generated through use of a barcoded template switching
  • oligonucleotide to barcode the 5' end of the template RNA.
  • an in- partition e.g., in-droplet or in-well
  • amplification reaction such as linear amplification, is performed on the adapter-flanked DNA fragments, the barcoded cDNA molecules, or both the adapter-flanked DNA fragments and the barcoded cDNA molecules.
  • a barcode oligonucleotide is directly ligated onto the template RNA.
  • cells from a cell population of interest are partitioned into a plurality of partitions (e.g., droplets or wells) such that at least some partitions comprise: (1) a single cell (or a single nucleus) comprising template genomic DNA molecules and template RNA molecules (e.g., mRNA or nuclear pre-mRNA); (2) a solid or semi-solid particle (e.g., bead, such as a gel bead) comprising (i) a plurality of partially double-stranded nucleic acid barcode molecules as shown in FIG. 29B (see also FIG.
  • the solid or semi-solid particle is a bead.
  • the bead is a gel bead.
  • the solid or semi-solid particle (e.g., gel bead) comprises the plurality of partially double-stranded nucleic acid barcode molecules of FIG.
  • the solid or semi-solid particle comprises the plurality of nucleic acid barcode molecules of FIG. 35B attached thereto and a plurality of magnetic particles embedded within the solid or semi-solid particle (e.g., gel bead), wherein the plurality of magnetic particles comprises, attached thereto, the plurality of nucleic acid barcode molecules of FIG. 35A.
  • the barcode sequence in FIG. 35A and the barcode sequence FIG. 35B is the same.
  • the barcode sequence in FIG. 35A and the barcode sequence FIG. 35B comprise one or more barcode segments that are identical.
  • the barcode sequence in FIG. 35A and the barcode sequence FIG. 35B are different.
  • the single cells (or nuclei) are lysed to release template genomic DNA and template RNA ⁇ e.g., cytoplasmic mRNA or nuclear mRNA) in a manner that substantially maintains native chromatin organization of the genomic DNA.
  • template RNA e.g., cytoplasmic mRNA or nuclear mRNA
  • 35B are releasably attached to the solid or semi-solid particle (e.g., bead) and partitions (e.g., droplets or wells) are subjected to conditions to cause release of barcode oligonucleotide molecules from the solid or semi-solid particle (e.g., bead) (e.g., depolymerization or degradation of a bead, for example, using a reducing agent such as DTT). Partitions (e.g., droplets or wells) are then subjected to conditions to generate a transposase-nucleic acid complex as described in the aforementioned examples.
  • partitions e.g., droplets or wells
  • a plurality of pre-formed transposase-nucleic acid complexes are partitioned into the plurality of partitions (e.g., droplets or wells). Partitions are then subjected to conditions such that the transposase-nucleic acid complexes generate double-stranded template genomic DNA fragments.
  • the transposition reaction is performed in bulk in intact nuclei which are partitioned such that at least some partitions (e.g., droplets or wells) comprise (1) a single cell (or a single nucleus) comprising template genomic DNA fragments and template RNA molecules; (2) a solid or semi-solid particle (e.g., a bead, such as a gel bead) comprising (i) a plurality of partially double-stranded nucleic acid barcode molecules as shown in FIG. 29B (see also FIG. 35A), and (ii) a plurality of nucleic acid barcode molecules as shown in FIG. 35B; and (3) a plurality of reverse transcriptase molecules.
  • partitions e.g., droplets or wells
  • a single cell or a single nucleus
  • a solid or semi-solid particle e.g., a bead, such as a gel bead
  • the nucleic acid barcode molecules of FIG. 35A or FIG. 35B are attached to a magnetic particle embedded within a solid or semi-solid particle (e.g., a bead, such as a gel bead), as previously described.
  • a solid or semi-solid particle e.g., a bead, such as a gel bead
  • the single nuclei are lysed to release template genomic DNA fragments and template RNA (e.g., cytoplasmic mRNA or nuclear mRNA) molecules.
  • template genomic DNA fragments are processed generally as outlined in FIG. 29D (or FIG. 29C for bulk tagmentation) by ligating a partially double- stranded nucleic acid barcode molecule as shown in FIG. 29B (see also FIG.
  • template RNA molecules comprising a poly-A tail are processed with the plurality of nucleic acid barcode molecules of FIG. 35B to generate barcoded cDNA molecules as generally described elsewhere herein.
  • cells from a cell population of interest are partitioned into a plurality of partitions (e.g., droplets or wells) such that at least some partitions comprise: (1) a single cell (or a single nucleus) comprising template genomic DNA molecules and template RNA molecules (e.g., mRNA or nuclear pre-mRNA); (2) a solid or semi-solid particle (e.g., bead, such as a gel bead) comprising (i) a plurality of partially double-stranded nucleic acid barcode molecules as shown in FIG. 29B (see also FIG.
  • the solid or semi-solid particle is a bead.
  • the bead is a gel bead.
  • the solid or semi-solid particle comprises the plurality of partially double-stranded nucleic acid barcode molecules of FIG.
  • the solid or semi-solid particle comprises the plurality of nucleic acid barcode molecules of FIG. 35D attached thereto and a plurality of magnetic particles embedded within the solid or semi-solid particle (e.g., gel bead), wherein the plurality of magnetic particles comprises, attached thereto, the plurality of nucleic acid barcode molecules of FIG. 35A.
  • the barcode sequence in FIG. 35A and the barcode sequence FIG.35D is the same.
  • the barcode sequence in FIG. 35A and the barcode sequence FIG.35D comprise one or more barcode segments that are identical.
  • the barcode sequence in FIG. 35A and the barcode sequence FIG.35D are different.
  • the single cells (or nuclei) are lysed to release template genomic DNA and template RNA (e.g., cytoplasmic mRNA or nuclear mRNA) in a manner that substantially maintains native chromatin organization of the genomic DNA.
  • template RNA e.g., cytoplasmic mRNA or nuclear mRNA
  • 35D are releasably attached to the solid or semi-solid particle (e.g., bead, such as a gel bead) and partitions (e.g., droplets or wells) are subjected to conditions to cause release of barcode oligonucleotide molecules from the bead (e.g., depolymerization or degradation of a bead, for example, using a reducing agent such as DTT). Partitions are then subjected to conditions to generate a transposase-nucleic acid complex as described in the aforementioned examples. Alternatively, in some embodiments, a plurality of pre-formed transposase-nucleic acid complexes (e.g., FIG.
  • the transposition reaction is performed in bulk in intact nuclei which are partitioned such that at least some partitions comprise (1) a single cell (or a single nucleus) comprising template genomic DNA fragments and template RNA molecules; (2) a solid or semisolid particle (e.g., a bead, such as a gel bead) comprising (i) a plurality of partially double- stranded nucleic acid barcode molecules as shown in FIG. 29B (see also FIG.
  • nucleic acid barcode molecules of FIG. 35A or FIG. 35D are attached to a magnetic particle embedded within a solid or semi-solid particle (e.g., gel bead), as previously described.
  • a solid or semi-solid particle e.g., gel bead
  • the single nuclei are lysed to release template genomic DNA fragments and template RNA (e.g., cytoplasmic mRNA or nuclear mRNA) molecules.
  • template genomic DNA fragments are processed generally as outlined in FIG. 29D (or FIG.
  • RNA molecules e.g., mRNA molecules
  • a template RNA molecule comprising a poly-A tail e.g., mRNA
  • a nucleic acid molecule comprising a poly-T sequence are processed using the reverse transcriptase to generate a cDNA molecule.
  • an enzyme with terminal transferase activity adds additional nucleotides, (e.g., polyC), to the cDNA in a template independent manner.
  • Switch oligonucleotides or switch oligonucleotide sequences can include sequences complementary to the additional nucleotides, e.g., polyG.
  • the additional nucleotides (e.g., polyC) on the cDNA hybridize to the additional nucleotides (e.g., polyG) on the switch oligo, whereby the switch oligo can be used by the reverse transcriptase as template to further extend the cDNA.
  • the reverse transcriptase comprises terminal transferase activity and generates 5' barcoded cDNA fragments using the switch oligonucleotide sequence in the plurality of nucleic acid barcode molecules of FIG. 35D.
  • cells from a cell population of interest are partitioned into a plurality of partitions (e.g., droplets) such that at least some partitions comprise: (1) a single cell (or a single nucleus) comprising template genomic DNA molecules and template RNA molecules (e.g., mRNA or nuclear pre-mRNA); (2) a solid or semi-solid particle (e.g., a bead, such as a gel bead) comprising (i) a plurality of single-stranded nucleic acid barcode molecules as shown in FIG. 35C, and (ii) a plurality of nucleic acid barcode molecules as shown in FIG.
  • partitions e.g., droplets
  • a single cell or a single nucleus
  • template RNA molecules e.g., mRNA or nuclear pre-mRNA
  • a solid or semi-solid particle e.g., a bead, such as a gel bead
  • the solid or semi-solid particle is a bead.
  • the bead is a gel bead.
  • the solid or semi-solid particle (e.g., gel bead) comprises the plurality of single-stranded nucleic acid barcode molecules of FIG. 35C attached thereto and a plurality of magnetic particles embedded within the solid or semi-solid particle (e.g., gel bead) (see, e.g., FIG.
  • the plurality of magnetic particles comprises, attached thereto, the plurality of nucleic acid barcode molecules of FIG. 35B.
  • the solid or semi-solid particle e.g., gel bead
  • the solid or semi-solid particle comprises the plurality of nucleic acid barcode molecules of FIG. 35B attached thereto and a plurality of magnetic particles embedded within the solid or semi-solid particle (e.g., gel bead), wherein the plurality of magnetic particles comprises, attached thereto, the plurality of nucleic acid barcode molecules of FIG. 35C.
  • the barcode sequence in FIG. 35C and the barcode sequence FIG.35B is the same.
  • FIG.35B comprise one or more barcode segments that are identical.
  • the barcode sequence in FIG. 35C and the barcode sequence FIG.35B are different.
  • the single cells (or nuclei) are lysed to release template genomic DNA and template RNA (e.g., cytoplasmic mRNA or nuclear mRNA) in a manner that substantially maintains native chromatin organization of the genomic DNA.
  • template RNA e.g., cytoplasmic mRNA or nuclear mRNA
  • 35D are releasably attached to the solid or semi-solid particle (e.g., bead, such as a gel bead) and partitions (e.g., droplets or wells) are subjected to conditions to cause release of barcode oligonucleotide molecules from the solid or semi-solid particle (e.g., bead) (e.g., depolymerization or degradation of a bead, for example, using a reducing agent such as DTT). Partitions (e.g., droplets or wells) are then subjected to conditions to generate a transposase- nucleic acid complex as described in the aforementioned examples.
  • partitions e.g., droplets or wells
  • a plurality of pre-formed transposase-nucleic acid complexes are partitioned into the plurality of partitions (e.g., droplets or wells). Partitions are then subjected to conditions such that the transposase-nucleic acid complexes generate double-stranded template genomic DNA fragments.
  • the transposition reaction is performed in bulk in intact nuclei which are partitioned such that at least some partitions (e.g., droplets or wells) comprise (1) a single cell (or a single nucleus) comprising template genomic DNA fragments and template RNA molecules; (2) a solid or semi-solid particle (e.g., bead, such as a gel bead) comprising (i) a plurality of single-stranded nucleic acid barcode molecules as shown in FIG. 35C, and (ii) a plurality of nucleic acid barcode molecules as shown in FIG. 35D; and (3) a plurality of reverse transcriptase molecules.
  • 35D are attached to a magnetic particle embedded within a solid or semi-solid particle (e.g., bead, such as a gel bead), as previously described.
  • a solid or semi-solid particle e.g., bead, such as a gel bead
  • the single nuclei are lysed to release template genomic DNA fragments and template RNA (e.g., cytoplasmic mRNA or nuclear mRNA) molecules.
  • template genomic DNA fragments are processed generally as outlined in FIG. 31 (or FIG. 30B for bulk tagmentation) by performing a linear amplification of template nucleic acid fragments (which in some embodiments, are gap-filled prior to
  • nucleic acid barcode molecules of FIG. 35C see, e.g., Examples 11 and 12.
  • template RNA molecules comprising a poly-A tail e.g., mRNA molecules
  • FIG. 35B barcoded cDNA molecules as generally described elsewhere herein.
  • cells from a cell population of interest are partitioned into a plurality of partitions (e.g., droplets or wells) such that at least some partitions comprise: (1) a single cell (or a single nucleus) comprising template genomic DNA molecules and template RNA molecules (e.g., mRNA or nuclear pre-mRNA); (2) a solid or semi-solid particle (e.g., bead, such as a gel bead) comprising (i) a plurality of single-stranded nucleic acid barcode molecules as shown in FIG. 35C, and (ii) a plurality of nucleic acid barcode molecules as shown in FIG.
  • partitions e.g., droplets or wells
  • a solid or semi-solid particle e.g., bead, such as a gel bead
  • the solid or semi-solid particle is a bead.
  • the bead is a gel bead.
  • the solid or semi-solid particle (e.g., gel bead) comprises the plurality of single- stranded nucleic acid barcode molecules of FIG.
  • the solid or semi-solid particle comprises the plurality of nucleic acid barcode molecules of FIG. 35D attached thereto and a plurality of magnetic particles embedded within the solid or semi-solid particle (e.g., gel bead), wherein the plurality of magnetic particles comprises, attached thereto, the plurality of nucleic acid barcode molecules of FIG. 35C.
  • the solid or semi-solid particle comprises the plurality of nucleic acid barcode molecules of FIG. 35D attached thereto and a plurality of magnetic particles embedded within the solid or semi-solid particle (e.g., gel bead), wherein the plurality of magnetic particles comprises, attached thereto, the plurality of nucleic acid barcode molecules of FIG. 35C.
  • the barcode sequence in FIG. 35C and the barcode sequence FIG. 35D is the same.
  • the barcode sequence in FIG. 35C and the barcode sequence FIG. 35D comprise one or more barcode segments that are identical.
  • the barcode sequence in FIG. 35C and the barcode sequence FIG. 35D are different.
  • the single cells (or nuclei) are lysed to release template genomic DNA and template RNA ⁇ e.g., cytoplasmic mRNA or nuclear mRNA) in a manner that substantially maintains native chromatin organization of the genomic DNA.
  • template RNA e.g., cytoplasmic mRNA or nuclear mRNA
  • 35D are releasably attached to the solid or semi-solid particle (e.g., bead, such as a gel bead) and partitions (e.g., droplets or wells) are subjected to conditions to cause release of barcode oligonucleotide molecules from the solid or semi-solid particle (e.g., bead) (e.g., depolymerization or degradation of a bead, for example, using a reducing agent such as DTT). Partitions (e.g., droplets or wells) are then subjected to conditions to generate a transposase- nucleic acid complex as described in the aforementioned examples.
  • partitions e.g., droplets or wells
  • a plurality of pre-formed transposase-nucleic acid complexes are partitioned into the plurality of partitions (e.g., droplets or wells). Partitions are then subjected to conditions such that the transposase-nucleic acid complexes generate double-stranded template genomic DNA fragments.
  • the transposition reaction is performed in bulk in intact nuclei which are partitioned such that at least some partitions comprise (1) a single cell (or a single nucleus) comprising template genomic DNA fragments and template RNA molecules; (2) a solid or semi-solid particle (e.g., bead, such as a gel bead) comprising (i) a plurality of single-stranded nucleic acid barcode molecules as shown in FIG. 35C, and (ii) a plurality of nucleic acid barcode molecules as shown in FIG. 35D; (3) a plurality of nucleic acid molecules comprising a poly-T sequence; and (4) a plurality of reverse transcriptase molecules.
  • a single cell or a single nucleus
  • a solid or semi-solid particle e.g., bead, such as a gel bead
  • template genomic DNA fragments are processed generally as outlined in FIG. 31 (or FIG. 30B for bulk tagmentation) by performing a linear amplification of template nucleic acid fragments (which in some
  • RNA molecules are processed to generate 5' barcoded cDNA molecules as previously described.
  • a template RNA molecule comprising a poly-A tail e.g., a reverse transcriptase with terminal transferase activity
  • a reverse transcriptase e.g., a reverse transcriptase with terminal transferase activity
  • the additional nucleotides on the cDNA hybridize to the additional nucleotides (e.g., poly-G) on the switch oligo, whereby the switch oligonucleotide sequence in the plurality of nucleic acid barcode molecules of FIG. 35D are used to further extend the cDNA to generate the 5' barcoded cDNA molecules.
  • additional nucleotides e.g., poly-G
  • the barcoded, adapter-flanked DNA fragments and the barcoded cDNA molecules are then released from the partitions (e.g., droplets or wells) to provide a released mixture and processed in bulk to complete library preparation for next generation high throughput sequencing (e.g., subjecting the fragments, or derivatives thereof, to one or more reactions (e.g., nucleic acid amplification) to add functional sequences to facilitate Illumina sequencing).
  • a first portion of the released mixture comprising the adapter-flanked DNA fragments and the barcoded cDNA is taken and processed in bulk to complete library preparation for the barcoded, adapter-flanked
  • a first portion of the partitions e.g., droplets or wells
  • a second portion of the partitions e.g., droplets or wells
  • a second portion of the partitions e.g., droplets or wells
  • the barcoded template molecules e.g., barcoded template DNA fragments or barcoded cDNA molecules, or derivatives thereof
  • the barcoded template molecules can be magnetically separated and further processed to complete library preparation.
  • the fully constructed library or libraries are then sequenced according to a suitable next-generation sequencing protocol (e.g., Illumina sequencing).
  • Nuclei from mice and humans were tagmented and barcoded by ligation (see, e.g., Example 9 and FIGs. 29A-29C) with one of three types of partially double-stranded barcodes, mixed, and subsequently subjected to detection in order to assess the effect of each type of barcode on the ability to distinguish the different types of nuclei.
  • the three types of barcodes included a barcode with a standard Rl sequence (FIG. 37; top), a barcode with a shortened Rl sequence compared to the standard Rl sequence (FIG. 37; middle) and a barcode comprising a uracil in the Rl sequence (FIG. 37; bottom).
  • a plurality of cells is provided in which each cell comprises a template nucleic acid (e.g., nuclear DNA, such as chromatin) and a non-template nucleic acid (e.g., mitochondrial DNA).
  • the plurality of cells is lysed in the presence of a cell lysis agent and a blocking agent (e.g., bovine serum albumin) to generate a plurality of lysed cells.
  • a plurality of nucleic is then separated from the plurality of lysed cells to generate a plurality of biological particles (e.g., nuclei), where a given biological particle of the plurality of biological particles comprises non- template nucleic acid molecules (e.g., mitochondrial DNA molecules) and template nucleic acid molecules.
  • the template nucleic acid molecules may comprise, for example, DNA molecules and RNA molecules.
  • a plurality of template nucleic acid fragments may then be generated in biological particles of the plurality of biological particles with the aid of a transposase-nucleic acid complex comprising a transposase nucleic acid molecule and a transposon end nucleic acid molecule.
  • a plurality of partitions may then be generated, where a given partition comprises (i) a single biological particle comprising the plurality of template nucleic acid fragments and template RNA molecules and (ii) a plurality of first barcode oligonucleotide molecules (e.g., first nucleic acid barcode molecules) comprising a barcode sequence.
  • the partitions may further comprise (iii) a plurality of second barcode oligonucleotide molecules (e.g., second nucleic acid molecules) comprising a barcode sequence and a capture sequence; and (iv) a plurality of reverse transcriptase molecules.
  • the partitions may be, for example, droplets or wells.
  • Barcoded template DNA fragments may then be generated within the partitions using barcode oligonucleotide molecules of the plurality of first barcode oligonucleotide molecules and template nucleic acid fragments of the plurality of template DNA fragments.
  • barcoded cDNA molecules may be generated from the template RNA molecules by reverse transcription using barcode oligonucleotide molecules of the plurality of second barcode oligonucleotide molecules.
  • the biological particles may be nuclei, which may be isolated from lysed cells by, e.g., washing the lysed cells.
  • the method further comprises generating sequencing reads. Application of the method may reduce the fraction of sequencing reads deriving from non-template nucleic acid molecules (e.g., mitochondrial DNA molecules) relative to the total number of sequencing reads generated.
  • a plurality of partitions (e.g., droplets or wells) is provided.
  • a given partition of the plurality of partitions comprises: (i) a single biological particle (e.g., cell) from a plurality of biological particles (e.g., cells), wherein the single biological particle comprises template nucleic acid molecules (e.g., nuclear DNA molecules, such as chromatin) and non-template DNA molecules (e.g., mitochondrial DNA molecules); (ii) a plurality of barcode oligonucleotide molecules (e.g., nucleic acid barcode molecules) comprising a barcode sequence; (iii) a plurality of transposon end oligonucleotide molecules comprising a transposon end sequence; and (iv) a plurality of transposase molecules.
  • template nucleic acid molecules e.g., nuclear DNA molecules, such as chromatin
  • non-template DNA molecules e.g., mitochondrial DNA molecules
  • the given partition may further comprise reverse transcriptases and a plurality of second barcode oligonucleotide molecules (e.g., second nucleic acid barcode molecules) comprising a barcode sequence and a capture sequence.
  • second barcode oligonucleotide molecules e.g., second nucleic acid barcode molecules
  • Barcoded template nucleic acid fragments and barcoded non-template nucleic acid fragments may be generated as described in the preceding examples.
  • One or more non-template nucleic acid fragments of the plurality of non-template DNA fragments, or derivatives thereof may then be cleaved using (i) one or more guide ribonucleic acid molecules (gRNAs) targeted to the one or more non-template nucleic acid fragments, and (ii) a clustered regularly interspaced short palindromic (CRISPR) associated (Cas) nuclease.
  • the method may reduce the amount of fragments and/or barcoded fragments comprising and/or deriving from non-template nucleic acid molecules.
  • the method may reduce the total number of non-template nucleic acid fragments and barcoded non-template nucleic acid fragments, e.g., in a mixture comprising one or more of template nucleic acid fragments, barcoded template nucleic acid fragments, non-template nucleic acid fragments, and barcoded non-template nucleic acid fragments.
  • the endonuclease may be Cas9, such as recombinant Cas9.
  • the non-template nucleic acid fragment may comprise a mitochondrial DNA or RNA fragment.
  • the template nucleic acid fragment may comprise a nuclear DNA fragment.
  • Example 21 Comparison of linear amplification and ligation methods
  • Sample libraries may be generated using any of the methods described in the preceding examples.
  • a library may be generated using a linear amplification method.
  • a library may be generated using a ligation method.
  • a linear amplification method may comprise, within a partition, generating template nucleic acid fragments and performing a gap filling extension process within the partition. Linear amplification may then be performed using, for example, a heat resistant polymerase. Barcodes may be incorporated into sequences comprising template nucleic acid sequences, or
  • the barcoded nucleic acid fragments may then be released from their respective partitions into the bulk for additional processing including, for example, PCR.
  • a ligation method may comprise, within a partition, generating template nucleic acid fragments and ligating barcodes to the fragments with a ligase such as a T4 DNA ligase, thereby generating barcoded nucleic acid fragments.
  • the barcoded nucleic acid fragments may then be released from their respective partitions into the bulk for additional processing including, for example, gap filling and addition of additional sequences.
  • FIG. 40 shows a table comparing sequencing metrics generated from different replicate sample libraries ("A" and "B") generated using either linear amplification or ligation.
  • FIGs. 41A-41B illustrate exemplary amounts of detected mouse or human cells and the inferred doublet rate observed from the analysis of sequencing reads (FIG. 40) from a linear amplification ATAC-seq library (using 75 nM, 150nM, or 250 nM of barcode primer) or ligation-based ATAC-seq library (using the barcode molecules of FIG. 37).
  • FIG. 41A illustrates differences in the number of mouse or human cells detected using either a linear amplification or ligation-based ATAC-seq method.
  • FIG. 41B illustrate differences in inferred doublet rate detected using either a linear amplification or ligation-based ATAC-seq method. As shown in
  • FIG. 41B linear amplification demonstrated a higher doublet rate than ligation.
  • FIG. 42 illustrates a comparison of the sensitivity of sequencing reads obtained from various ATAC-seq libraries as measured by the median fragments per cell barcode.
  • the sensitivity of the linear amplification and ligation methods of library preparation (36k reads/cell) is compared to the methods described in Buenrostro, et al., Nature, 2015 Jul 23;523(7561):486-
  • ligation provides higher sensitivity than linear amplification.
  • a library prepared by ligation sequenced to increased depth (30M reads to 800M reads) demonstrates a significant increase in the sensitivity (as measured by median fragments per cell barcode) and reduced noise (as measured by fraction of non-duplicate wasted reads) relative to the lower depth library.
  • FIG. 48 shows a comparison of exemplary sequencing metrics obtained from linear amplification-based ATAC-seq libraries prepared using different polymerases: a Phusion ® DNA polymerase, a KAPA HiFi DNA polymerase (in combination with betaine), a Deep Vent ® DNA polymerase, as well as a library prepared by ligation.
  • non-duplicate "wasted” reads may be generated while performing the methods described herein.
  • FIG. 44 illustrates an exemplary comparison of the total noise (non-duplicate wasted reads ("Non-dups") and mitochondrial-based reads ("Mito")) in libraries prepared using linear amplification or ligation-based ATAC-seq methods.
  • FIGs. 45A-45B provide an exemplary illustration of the breakdown sequencing reads generated by different library preparation methods.
  • FIG. 45A shows an illustration of the breakdown of reads generated by a linear amplification ATAC-seq library.
  • FIG. 45B shows an illustration of the breakdown of reads generated by a ligation-based ATAC-seq library.
  • reads attributable to mitochondrial nucleic acids may be removed by the use of blocking agents such as bovine serum albumin and/or through the use of Cas9 and targeted gRNAs.
  • FIGs. 46A-46B illustrate an exemplary comparison of read pairs showing the periodicity of nucleosomes generated from ATAC-seq libraries prepared using either a these schemes. Nucleosome free fragments are typically observed below 200bp in length, fragments indicative of a nucleosome periodicity of one are approximately 200bp in length, fragments indicative of a nucleosome periodicity of two are approximately 400bp in length, fragments indicative of a nucleosome periodicity of two are 600bp in length, and so forth. Bulk enrichment
  • linear amplification shows a higher enrichment of transcription start sites (TSS) than ligation due to a bias for shorter insert fragments.
  • TSS transcription start sites
  • CTCF CCCTC-binding factor
  • Example 22 Analysis of nucleic acids in peripheral blood mononuclear cell samples
  • PBMCs Peripheral blood mononuclear cells
  • FIG. 51A shows an exemplary scatterplot produced using t-Distributed Stochastic Neighbor Embedding (tSNE), allowing visualization of RNA transcripts of different
  • FIG. 51B shows an exemplary scatterplot produced using t-Distributed Stochastic Neighbor Embedding (tSNE), allowing visualization of ATAC-seq data of different subpopulations cell types in a peripheral blood mononuclear cell (PBMC) sample.
  • tSNE t-Distributed Stochastic Neighbor Embedding
  • FIG. 50 illustrates protocols for ATAC-seq analyses as described herein compared to data from (1) typical high quality traditional bulk ATAC-seq protocols; (2) Cusanovich, et al, Science, 2015 May 22;348(6237):910-14; (3) Buenrostro, et al., Nature, 2015 Jul

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés et des systèmes pour techniques de préparation d'échantillons qui permettent l'amplification (p. ex., amplification de génome entier) et le séquençage de régions accessibles à la chromatine de cellules uniques. De manière générale, les procédés et les systèmes opèrent par formation ou préparation de cloisonnements (p. ex., gouttelettes ou puits) renfermant une seule particule biologique (p. ex., cellule) et une seule particule solide ou semi-solide (p. ex., bille) comprenant un oligonucléotide à code-barres. La préparation de banques de séquençage de nouvelle génération à code-barres préparées à partir d'une seule cellule est facilitée par la transposition médiée par transposon et la fragmentation d'une séquence d'acide nucléique cible. Les procédés et les systèmes peuvent être conçus pour permettre la mise en œuvre d'un traitement chimique et/ou biochimique à opération unique ou opérations multiples au sein des cloisonnements.
PCT/US2018/034774 2017-05-26 2018-05-25 Analyse de cellule unique de chromatine accessible par transposase Ceased WO2018218226A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SG11201901822QA SG11201901822QA (en) 2017-05-26 2018-05-25 Single cell analysis of transposase accessible chromatin
EP18799660.8A EP3445876B1 (fr) 2017-05-26 2018-05-25 Analyse de la chromatine accessible par une transposase d'une cellule unique
CN201880002912.9A CN109526228B (zh) 2017-05-26 2018-05-25 转座酶可接近性染色质的单细胞分析
EP23168994.4A EP4230746A3 (fr) 2017-05-26 2018-05-25 Analyse de cellule unique de chromatine accessible par transposase
CN202211385845.8A CN116064732A (zh) 2017-05-26 2018-05-25 转座酶可接近性染色质的单细胞分析
US16/419,630 US10927370B2 (en) 2017-05-26 2019-05-22 Single cell analysis of transposase accessible chromatin
US16/841,411 US11155810B2 (en) 2017-05-26 2020-04-06 Single cell analysis of transposase accessible chromatin
US17/492,536 US11773389B2 (en) 2017-05-26 2021-10-01 Single cell analysis of transposase accessible chromatin
US18/355,946 US20240084292A1 (en) 2017-05-26 2023-07-20 Single cell analysis of transposase accessible chromatin

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US201762511905P 2017-05-26 2017-05-26
US62/511,905 2017-05-26
US201762527529P 2017-06-30 2017-06-30
US62/527,529 2017-06-30
US15/842,687 US10400235B2 (en) 2017-05-26 2017-12-14 Single cell analysis of transposase accessible chromatin
US15/842,687 2017-12-14
US15/842,713 US10844372B2 (en) 2017-05-26 2017-12-14 Single cell analysis of transposase accessible chromatin
US15/842,713 2017-12-14
US15/842,550 2017-12-14
US15/842,550 US20180340169A1 (en) 2017-05-26 2017-12-14 Single cell analysis of transposase accessible chromatin
US15/848,714 US20180340172A1 (en) 2017-05-26 2017-12-20 Single cell analysis of transposase accessible chromatin
US15/848,714 2017-12-20
US201862650223P 2018-03-29 2018-03-29
US62/650,223 2018-03-29

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US15/842,687 Continuation-In-Part US10400235B2 (en) 2017-05-26 2017-12-14 Single cell analysis of transposase accessible chromatin
US16/206,168 Continuation-In-Part US11198866B2 (en) 2017-05-26 2018-11-30 Single cell analysis of transposase accessible chromatin
US16/419,555 Continuation-In-Part US20190270983A1 (en) 2017-05-26 2019-05-22 Single cell analysis of transposase accessible chromatin
US16/419,630 Continuation-In-Part US10927370B2 (en) 2017-05-26 2019-05-22 Single cell analysis of transposase accessible chromatin

Publications (1)

Publication Number Publication Date
WO2018218226A1 true WO2018218226A1 (fr) 2018-11-29

Family

ID=64397116

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/034774 Ceased WO2018218226A1 (fr) 2017-05-26 2018-05-25 Analyse de cellule unique de chromatine accessible par transposase

Country Status (1)

Country Link
WO (1) WO2018218226A1 (fr)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019084043A1 (fr) * 2017-10-26 2019-05-02 10X Genomics, Inc. Méthodes et systèmes de préparation d'acide nucléique et d'analyse de chromatine
WO2019152108A1 (fr) 2018-02-05 2019-08-08 The Board Of Trustees Of The Leland Stanford Junior University Systèmes et procédés pour des mesures multiplexées dans des cellules uniques et d'ensemble
WO2020131626A1 (fr) * 2018-12-17 2020-06-25 Illumina, Inc. Procédés et moyens de préparation d'une bibliothèque pour le séquençage
WO2020112604A3 (fr) * 2018-11-30 2020-07-30 Illumina, Inc. Analyse d'analytes multiples à l'aide d'un seul dosage
WO2020168013A1 (fr) 2019-02-12 2020-08-20 10X Genomics, Inc. Procédés de traitement de molécules d'acides nucléiques
WO2020167866A1 (fr) * 2019-02-12 2020-08-20 10X Genomics, Inc. Systèmes et procédés pour le chargement de transposons
WO2020198532A1 (fr) * 2019-03-27 2020-10-01 10X Genomics, Inc. Systèmes et procédés pour le traitement d'arn à partir de cellules
WO2021011433A1 (fr) * 2019-07-12 2021-01-21 New York Genome Center, Inc Procédés et compositions pour des écrans d'arn groupés pouvant être mis à l'échelle avec profilage d'accessibilité de la chromatine monocellulaire
WO2021026228A1 (fr) 2019-08-05 2021-02-11 Mission Bio, Inc. Procédé et appareil d'analyse de cellules uniques pour la détermination d'une trajectoire cellulaire
WO2021163611A1 (fr) 2020-02-13 2021-08-19 10X Genomics, Inc. Procédés de caractérisation de cellules à l'aide de l'expression génique et de l'accessibilité de la chromatine
WO2021188889A1 (fr) * 2020-03-20 2021-09-23 Mission Bio, Inc. Flux de travail unicellulaire pour l'amplification du génome entier
US20210403994A1 (en) * 2019-03-06 2021-12-30 The Trustees Of Columbia University In The City Of New York Methods for rapid dna extraction from tissue and library preparation for nanopore-based sequencing
WO2022010965A1 (fr) * 2020-07-08 2022-01-13 Illumina, Inc. Billes utilisées en tant que supports pour transposomes
US11467153B2 (en) 2019-02-12 2022-10-11 10X Genomics, Inc. Methods for processing nucleic acid molecules
US20220411859A1 (en) * 2017-08-01 2022-12-29 Illumina, Inc. Hydrogel beads for nucleotide sequencing
WO2022271908A1 (fr) 2021-06-23 2022-12-29 10X Genomics, Inc. Procédé de découpage-fixation et dispositif de découpage pour la préparation d'échantillons biologiques
WO2023060270A1 (fr) * 2021-10-08 2023-04-13 Mission Bio, Inc. Analyse de cellules uniques pour établir un profil épigénomique
WO2023099667A1 (fr) * 2021-12-01 2023-06-08 Vilnius University Procédés de traitement et de codage barres d'acides nucléiques
WO2023114203A1 (fr) * 2021-12-13 2023-06-22 Cornell University Génotypage de loci ciblés avec accessibilité à la chromatine mono-cellule
US11773441B2 (en) 2018-05-03 2023-10-03 Becton, Dickinson And Company High throughput multiomics sample analysis
WO2023215765A1 (fr) * 2022-05-03 2023-11-09 Micronoma, Inc. Systèmes et procédés d'enrichissement de molécules d'acides nucléiques microbiens acellulaires
EP3980537A4 (fr) * 2019-06-04 2023-11-22 Universal Sequencing Technology Corporation Procédés de codage d'acide nucléique pour la détection et le séquençage
RU2815513C2 (ru) * 2018-12-17 2024-03-18 Иллюмина, Инк. Способы и средства получения библиотеки для секвенирования
US12049712B2 (en) 2018-02-12 2024-07-30 10X Genomics, Inc. Methods and systems for analysis of chromatin
US12112833B2 (en) 2020-02-04 2024-10-08 10X Genomics, Inc. Systems and methods for index hopping filtering
US12168801B1 (en) 2020-07-02 2024-12-17 10X Genomics, Inc. Hybrid/capture probe designs for full-length cDNA
US12391940B2 (en) 2020-07-31 2025-08-19 Becton, Dickinson And Company Single cell assay for transposase-accessible chromatin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130017978A1 (en) * 2011-07-11 2013-01-17 Finnzymes Oy Methods and transposon nucleic acids for generating a dna library
US20150376609A1 (en) * 2014-06-26 2015-12-31 10X Genomics, Inc. Methods of Analyzing Nucleic Acids from Individual Cells or Cell Populations
WO2016187717A1 (fr) * 2015-05-26 2016-12-01 Exerkine Corporation Exosomes utiles pour l'édition génomique

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130017978A1 (en) * 2011-07-11 2013-01-17 Finnzymes Oy Methods and transposon nucleic acids for generating a dna library
US20150376609A1 (en) * 2014-06-26 2015-12-31 10X Genomics, Inc. Methods of Analyzing Nucleic Acids from Individual Cells or Cell Populations
WO2016187717A1 (fr) * 2015-05-26 2016-12-01 Exerkine Corporation Exosomes utiles pour l'édition génomique

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP3445876A4 *

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220411859A1 (en) * 2017-08-01 2022-12-29 Illumina, Inc. Hydrogel beads for nucleotide sequencing
WO2019084043A1 (fr) * 2017-10-26 2019-05-02 10X Genomics, Inc. Méthodes et systèmes de préparation d'acide nucléique et d'analyse de chromatine
US11725231B2 (en) 2017-10-26 2023-08-15 10X Genomics, Inc. Methods and systems for nucleic acid preparation and chromatin analysis
US12252732B2 (en) 2017-10-26 2025-03-18 10X Genomics, Inc. Methods and systems for nucleic acid preparation and chromatin analysis
WO2019152108A1 (fr) 2018-02-05 2019-08-08 The Board Of Trustees Of The Leland Stanford Junior University Systèmes et procédés pour des mesures multiplexées dans des cellules uniques et d'ensemble
EP4299755A2 (fr) 2018-02-05 2024-01-03 The Board of Trustees of the Leland Stanford Junior University Systèmes et procédés pour des mesures multiplexées dans des cellules uniques et d'ensemble
US12049712B2 (en) 2018-02-12 2024-07-30 10X Genomics, Inc. Methods and systems for analysis of chromatin
US11773441B2 (en) 2018-05-03 2023-10-03 Becton, Dickinson And Company High throughput multiomics sample analysis
CN112867801B (zh) * 2018-11-30 2024-07-12 Illumina公司 使用单一测定分析多种分析物
CN112867801A (zh) * 2018-11-30 2021-05-28 Illumina公司 使用单一测定分析多种分析物
EP4293126A3 (fr) * 2018-11-30 2024-01-17 Illumina, Inc. Analyse d'analytes multiples à l'aide d'un seul dosage
RU2824049C2 (ru) * 2018-11-30 2024-08-01 Иллюмина, Инк. Анализ множества аналитов с использованием одного анализа
IL281538B1 (en) * 2018-11-30 2025-11-01 Illumina Inc Testing multiple analytes using a single probe
JP7574180B2 (ja) 2018-11-30 2024-10-28 イルミナ インコーポレイテッド 単一アッセイを使用した複数の分析物の分析
US12104281B2 (en) 2018-11-30 2024-10-01 Illumina, Inc. Analysis of multiple analytes using a single assay
AU2019390388B2 (en) * 2018-11-30 2025-08-07 Illumina, Inc. Analysis of multiple analytes using a single assay
WO2020112604A3 (fr) * 2018-11-30 2020-07-30 Illumina, Inc. Analyse d'analytes multiples à l'aide d'un seul dosage
JP2022513561A (ja) * 2018-11-30 2022-02-09 イルミナ インコーポレイテッド 単一アッセイを使用した複数の分析物の分析
US12297565B2 (en) 2018-12-17 2025-05-13 Illumina, Inc. Methods and means for preparing a library for sequencing
RU2815513C2 (ru) * 2018-12-17 2024-03-18 Иллюмина, Инк. Способы и средства получения библиотеки для секвенирования
CN112867800A (zh) * 2018-12-17 2021-05-28 Illumina公司 用于制备测序文库的方法和手段
WO2020131626A1 (fr) * 2018-12-17 2020-06-25 Illumina, Inc. Procédés et moyens de préparation d'une bibliothèque pour le séquençage
WO2020168013A1 (fr) 2019-02-12 2020-08-20 10X Genomics, Inc. Procédés de traitement de molécules d'acides nucléiques
US12391975B2 (en) 2019-02-12 2025-08-19 10X Genomics, Inc. Systems and methods for transposon loading
US11584953B2 (en) 2019-02-12 2023-02-21 10X Genomics, Inc. Methods for processing nucleic acid molecules
CN113614245B (zh) * 2019-02-12 2024-08-27 10X基因组学有限公司 用于加工核酸分子的方法
US11467153B2 (en) 2019-02-12 2022-10-11 10X Genomics, Inc. Methods for processing nucleic acid molecules
CN113614245A (zh) * 2019-02-12 2021-11-05 10X基因组学有限公司 用于加工核酸分子的方法
WO2020167866A1 (fr) * 2019-02-12 2020-08-20 10X Genomics, Inc. Systèmes et procédés pour le chargement de transposons
US20210403994A1 (en) * 2019-03-06 2021-12-30 The Trustees Of Columbia University In The City Of New York Methods for rapid dna extraction from tissue and library preparation for nanopore-based sequencing
CN113811619A (zh) * 2019-03-27 2021-12-17 10X基因组学有限公司 用于处理来自细胞的rna的系统和方法
WO2020198532A1 (fr) * 2019-03-27 2020-10-01 10X Genomics, Inc. Systèmes et procédés pour le traitement d'arn à partir de cellules
EP3980537A4 (fr) * 2019-06-04 2023-11-22 Universal Sequencing Technology Corporation Procédés de codage d'acide nucléique pour la détection et le séquençage
US20220267759A1 (en) * 2019-07-12 2022-08-25 New York Genome Center, Inc. Methods and compositions for scalable pooled rna screens with single cell chromatin accessibility profiling
WO2021011433A1 (fr) * 2019-07-12 2021-01-21 New York Genome Center, Inc Procédés et compositions pour des écrans d'arn groupés pouvant être mis à l'échelle avec profilage d'accessibilité de la chromatine monocellulaire
EP4010472A4 (fr) * 2019-08-05 2023-08-16 Mission Bio, Inc. Procédé et appareil d'analyse de cellules uniques pour la détermination d'une trajectoire cellulaire
JP2022543278A (ja) * 2019-08-05 2022-10-11 ミッション バイオ インコーポレイテッド 細胞軌道を測定するためのシングルセル分析のための方法及び装置
WO2021026228A1 (fr) 2019-08-05 2021-02-11 Mission Bio, Inc. Procédé et appareil d'analyse de cellules uniques pour la détermination d'une trajectoire cellulaire
US12112833B2 (en) 2020-02-04 2024-10-08 10X Genomics, Inc. Systems and methods for index hopping filtering
WO2021163611A1 (fr) 2020-02-13 2021-08-19 10X Genomics, Inc. Procédés de caractérisation de cellules à l'aide de l'expression génique et de l'accessibilité de la chromatine
CN115768884A (zh) * 2020-03-20 2023-03-07 使命生物公司 用于全基因组扩增的单细胞工作流程
WO2021188889A1 (fr) * 2020-03-20 2021-09-23 Mission Bio, Inc. Flux de travail unicellulaire pour l'amplification du génome entier
US12168801B1 (en) 2020-07-02 2024-12-17 10X Genomics, Inc. Hybrid/capture probe designs for full-length cDNA
JP2023532905A (ja) * 2020-07-08 2023-08-01 イルミナ インコーポレイテッド トランスポソーム担体としてのビーズ
WO2022010965A1 (fr) * 2020-07-08 2022-01-13 Illumina, Inc. Billes utilisées en tant que supports pour transposomes
US12391940B2 (en) 2020-07-31 2025-08-19 Becton, Dickinson And Company Single cell assay for transposase-accessible chromatin
WO2022271908A1 (fr) 2021-06-23 2022-12-29 10X Genomics, Inc. Procédé de découpage-fixation et dispositif de découpage pour la préparation d'échantillons biologiques
WO2023060270A1 (fr) * 2021-10-08 2023-04-13 Mission Bio, Inc. Analyse de cellules uniques pour établir un profil épigénomique
WO2023099667A1 (fr) * 2021-12-01 2023-06-08 Vilnius University Procédés de traitement et de codage barres d'acides nucléiques
WO2023114203A1 (fr) * 2021-12-13 2023-06-22 Cornell University Génotypage de loci ciblés avec accessibilité à la chromatine mono-cellule
WO2023215765A1 (fr) * 2022-05-03 2023-11-09 Micronoma, Inc. Systèmes et procédés d'enrichissement de molécules d'acides nucléiques microbiens acellulaires

Similar Documents

Publication Publication Date Title
US11155810B2 (en) Single cell analysis of transposase accessible chromatin
US11773389B2 (en) Single cell analysis of transposase accessible chromatin
US20250059588A1 (en) Systems and methods for processing nucleic acid molecules from one or more cells
US11873530B1 (en) Systems and methods for metabolome analysis
US11467153B2 (en) Methods for processing nucleic acid molecules
US20240052397A1 (en) Methods and systems for nucleic acid preparation and chromatin analysis
US11584953B2 (en) Methods for processing nucleic acid molecules
US20220145370A1 (en) Systems and methods for processing rna from cells
WO2018218226A1 (fr) Analyse de cellule unique de chromatine accessible par transposase
US20220025435A1 (en) Methods and systems for enrichment of barcodes
US20210047677A1 (en) Nucleic acid enrichment within partitions
US20240044877A1 (en) Systems and methods for sample analysis
CN111051523A (zh) 功能化凝胶珠
US12188014B1 (en) Compositions and methods for nucleic acid processing using blocking agents
WO2019084328A1 (fr) Procédés de préparation de molécules d'acides nucléiques
US20210270805A1 (en) Systems and methods for metabolome analysis

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2018799660

Country of ref document: EP

Effective date: 20181120

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18799660

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWG Wipo information: grant in national office

Ref document number: 11201901822Q

Country of ref document: SG

WWP Wipo information: published in national office

Ref document number: 11201901822Q

Country of ref document: SG